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GENERAL INTRODUCTION
Fatigue and cancer seem to be inseparable as almost all patients with cancer are confronted 
with fatigue somewhere during their disease trajectory. Cancer-related fatigue is defined as ‘a 
distressing persistent, subjective sense of tiredness or exhaustion related to cancer or cancer 
treatment that is not proportional to recent activity and that interferes with usual functioning’ 1. 
Severe fatigue is an extreme degree of fatigue and should be seen as a clinically relevant symptom 
as it has a profound, debilitating effect on daily quality of life. Some studies, focusing on the time 
just after the cancer diagnosis but before initial treatment with curative intent, reported that 
14 – 28% of patients suffer from severe fatigue 2,3. During treatment for cancer, prevalence rates 
of fatigue up to 99% have been reported 4. In cancer survivors still 20 – 40% experience fatigue, 
even years after completing their treatment 4,5.
 Unfortunately, not all patients with cancer can be cured and overall around 40% of patients 
have to live with incurable disease. When cure is not an option anymore, people enter the so 
called palliative phase. According to the WHO, palliative care is ‘an approach that improves the 
quality of life of patients and their families facing the problem associated with life-threatening 
illness, through the prevention and relief of suffering by means of early identification and 
impeccable assessment and treatment of pain and other problems, physical, psychosocial and 
spiritual care’ (www.who.int./cancer/palliativecare). In contrast to the association in colloquial 
speech on the term palliative care, patients with incurable cancer can have, with all new treat-
ment options nowadays a life expectancy of years. Because of the increased options to treat 
patients in the palliative phase, the term chronic disease is sometimes used to define the stage 
in which cancer patients are treated with (systemic) treatment with life prolonging intent.
 In all patients with advanced, incurable cancer prevalence rates of fatigue up to 99% are 
mentioned 6-10. However, in most studies on fatigue in the palliative phase the data presents 
all patients pooled together, up to the final terminal phase 10-12. When patients are treated with 
systemic therapy, possibly supplemented with local radiotherapy, with the intention to control 
disease and prolong patients’ life, fatigue can be of a different order than fatigue experienced by 
a patient in the terminal phase. Unfortunately there is not much known of fatigue quality and 
severity in the different phases of the palliative trajectory.
Expert Centre Chronic Fatigue
Since 1990 a so called Expert Center Chronic Fatigue in the Radboud university medical center 
is active which firstly focused on chronic fatigue syndrome 13-15. The research focus extended 
during the years to chronic fatigue in several other patients groups 16-19. Since 1996 research 
on fatigue in cancer patients has been conducted, in which predominantly psychologists and 
medical oncologists of the department of Medical Oncology of the Radboud university medical 
center work closely together 20-22. The first studies in oncology explored the natural presence 
and course of fatigue in disease free cancer survivors. It showed that chronic fatigue is a severe 
problem, even years after completing curative treatment, in at least 25% of these survivors 23. 
As no relation was found between fatigue in cancer survivors and their initial disease and treat-
ment characteristics, a model was introduced in which a distinction was made between precip-
itating factors and perpetuating factors of fatigue 20. The precipitating factors are cancer itself 
and its treatment which triggers fatigue in the majority of patients. After successful cancer 
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treatment other none somatic factors, the so-called perpetuating factors, are responsible for 
the persistence of fatigue in a subset of patients 23. To treat fatigue in these survivors a specific 
Cognitive Behavioral Therapy (CBT) was developed. This individually tailored intervention is 
based on the known perpetuating factors found in persisting fatigue. These perpetuating factors 
are: poor or inappropriate coping skills, a heightened fear of disease recurrence, dysfunctional 
fatigue-related cognitions, dysregulatory sleep-wake rhythm, dysregulatory activity patterns, 
insufficient experienced social support and negative interactions.
The CBT for postcancer fatigue was tested in a randomized controlled trial and proved to be 
successful 24. Subsequently a randomized controlled trial was performed in patients during 
their curative treatment. This study aimed to investigate if fatigue shortly after cancer treatment 
could be reduced or even prevented with interventions during the cancer treatment period 
25. This study investigated two interventions for fatigue during treatment and compared them 
to usual care. One intervention was a brief nursing intervention which focused on physical 
activity during the treatment period. The other intervention was CBT which focused on, besides 
physical activity on dysfunctional cognitions about fatigue, distorted sleep-wake rhythm and 
on coping with the consequences of having cancer. Patients of the CBT group were significantly 
Figure 1 The precipitating and perpetuating factors of fatigue
Fatigue
Cancer
itself
Cancer 
treatment
Low social 
support and 
negative 
interactions
Dysregulation 
of activity
Dysregulation 
of sleep
Dysfunctional 
fatigue related 
cogitions
Fear of disease 
reccurence
Poor and/or 
inappropriate 
coping skills
FATIGUE  in  METASTATIC CANCER
12
less fatigued at the two-month post cancer treatment assessment. No significant difference 
however was found between the nursing intervention group and usual care group 26.
 As cancer patients in the palliative phase nowadays tend to live longer a logical next step is 
to investigate fatigue in incurable cancer patients. Firstly we wanted to get more insight in the 
extend and severity of fatigue experience of patients who are still on active cancer treatment 
in the palliative phase. Besides exploring the occurrence and course of fatigue and its severity 
we also wanted to investigate whether the before mentioned model of perpetuating factors of 
the curative setting also is applicable in patients with incurable cancer. Research in this area was 
justified because patients in the palliative phase call fatigue their most distressing symptom, 
and moreover because there are still no effective strategies or interventions to reduce fatigue 
for this group of patients.
 Despite the statement of the WHO in their definition of palliative care that it should improve 
the quality of life of both patients and their families, studies performed in these caregivers are 
scarce. Cancer is par excellence not a disease that afflicts only the individual but has an impact 
on the family as a whole, and therefore we wanted to include the informal caregivers in our 
studies too. With the limited studies focusing on fatigue in informal caregivers we wanted to 
start with exploring their experiences to extend our insight. Therefore in a longitudinal study 
we observed the course of fatigue in both patients and their informal caregivers over a six 
months’ period. Simultaneously, the impact of fatigue of both patients and caregivers on the 
experienced burden of caregivers was investigated.
OUTLINE OF THE DISSERTATION
This dissertation consists of eight chapters. In Chapter 2 a practical overview is presented on 
fatigue in patients with cancer. In this review factors involved in the etiology of fatigue in cancer 
patients, barriers to its effective management, as well as factors involved in the screening, diag-
nosis and treatment of all cancer patients experiencing fatigue are summarized. Additional 
approaches to its management are reviewed. Chapter 3 focuses furthermore specific on 
patients with cancer in the palliative phase and reflects on the state of the art in management 
fatigue in these patients.
 In Chapter 4 results of an explorative analysis on cross-sectional data of a larger longitudinal 
study on fatigue in patients on active treatment in the palliative phase are reported. Besides the 
occurrence of severe fatigue in this group, a probable difference among types of cancer and/or 
treatment modalities was investigated. To investigate a probable cumulative effect of fatigue 
during the palliative phase, a distinction was made between patients at first line and further 
lines of treatment. In Chapter 5 the before mentioned model of fatigue-perpetuating factors, 
known from cancer survivors, was investigated for its applicability in patients with incurable 
cancer.
 To get more insight into the problems caregivers of patients in the palliative phase are facing 
the impact of fatigue in patients and in their informal caregivers was investigated together with 
the experienced burden by these caregivers. Results of this study are reported in Chapter 6. 
To be able to investigate this both in patients and their caregivers, fatigue and its severity was 
measured twice with an interval of six months.
General introduction
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 In Chapter 7 the course of fatigue in patients with incurable cancer on active treatment is 
reported. The course was followed for six months with monthly fatigue assessments. Additional, 
the fatigue-perpetuating factors present at the start of the six month period (Chapter 4) were 
further explored for their probable predictive value of fatigue severity over time.
 Chapter 8 entails a general discussion of this thesis supplemented by learning points and 
suggestions for further research.
FATIGUE  in  METASTATIC CANCER
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ABSTRACT 
Cancer-related fatigue (CRF) is a serious clinical problem and is one of the most common 
symptoms experienced by cancer patients. CRF has deleterious effects on many aspects of 
patient quality of life including their physical, psychological and social well-being. It can also limit 
their ability to function, socialise and participate in previously enjoyable activities. The aetiology 
of CRF is complex and multidimensional, involving many potentially contributing elements. 
These include tumour-related factors and comorbid medical/psychological conditions and also 
side effects associated with anti-cancer therapies or other medications. Barriers to the effective 
management of CRF exist both on the side of physicians and patients, and as a result CRF often 
remains unrecognised and undiscussed in clinical practice. A change of approach is required, 
where fatigue is treated as central to patient management during and after systemic anti-cancer 
treatment. In this review we summarise factors involved in the aetiology of CRF and the barriers 
to its effective management, as well as factors involved in the screening, diagnosis and treatment 
of cancer patients experiencing fatigue. Pharmacological and non-pharmacological approaches 
to its management are also reviewed. We suggest an algorithm for the process of managing 
CRF, guided by our experiences in The Netherlands, which we hope may provide a useful tool to 
healthcare professionals dealing with cancer patients in their daily practice. Although CRF is a 
serious and complex clinical problem, if it is worked through in a structured and comprehensive 
way, effective management has the potential to much improve patient quality of life.
Management of fatigue in patients with cancer
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INTRODUCTION
Cancer-related fatigue (CRF) is a serious and complex clinical problem 1 and is one of the 
most common symptoms experienced by oncology patients 2-4. The proportion of patients 
experiencing CRF varies widely in the literature, but has generally been reported as affecting 
between ~40-100% of those with cancer overall 4-9. The variation in rates is likely due to the fact 
that fatigue is impacted not only by disease stage and status, but also because there is a lack 
of commonly accepted diagnostic criteria and assessment tools. However, rates can still vary 
between studies when the same diagnostic criteria are used, reflecting a lack of consistency in 
how these criteria are applied 10. CRF can occur before, during and even long after anti-cancer 
treatment has been completed 4. Up to 40% of patients report fatigue at diagnosis and virtually 
all patients experience fatigue at some point during cancer therapy 4; reported rates are 80% 
and 90% for patients being treated with chemotherapy or radiotherapy, respectively 4. In the 
post-treatment population, reported CRF rates range from 17-21% when strict ICD-10 criteria 
are applied 11 and from 33%-53% when other criteria are used 12. A further study found that 22% 
of cancer survivors had persistent, severe fatigue in the year following anticancer therapy 13. 
Although there is no universally accepted definition of CRF, the National Comprehensive Cancer 
Network® (NCCN®) defines it as ‘a distressing, persistent, subjective sense of physical, emotional, 
and/or cognitive tiredness or exhaustion related to cancer or cancer treatment, that is not 
proportional to recent activity and interferes with usual functioning’ 9 .
Impact of CRF on patients
In comparison to the fatigue experienced by healthy individuals, CRF is differentiated by its 
severity and the fact that it is often not alleviated by rest or sleep 14. CRF has deleterious effects 
on many aspects of patient quality of life 4, 5, 15, 16. Specifically, it can significantly impact on a 
patient’s physical, psychological, social and spiritual well-being, as well as limiting their ability 
to function, socialise and participate in previously enjoyable activities 16. It is not only a cause of 
stress and anxiety for patients but can also have an impact on their family members/caregivers 17.
The aetiology of CRF
The aetiology of CRF is complex and multidimensional and involves a vast array of potentially 
contributing factors (Figure 1) 14. Anaemia has been linked with poor prognosis and fatigue 18 
and is a condition commonly encountered in cancer patients. Fatigue and anaemia are some-
times used interchangeably in the literature but anaemia is actually only one of many possible 
causes of CRF 14. Other potentially contributing tumour-related factors include electrolyte 
abnormalities, dehydration, cachexia, thrombosis/pulmonary embolism, renal failure, liver 
failure, hypoxia, adrenal insufficiency, neurological deficit, etc. Physical symptoms caused by 
the underlying tumour or its treatment can also have an impact; the symptoms most strongly 
correlated with fatigue are pain and dyspnoea. Loss of appetite commonly occurs in cancer 
patients and can lead to malnutrition and fatigue. This can be exacerbated in patients with more 
advanced disease who may also experience difficulty with swallowing. The possible impact of 
any comorbid medical (e.g. hypothyroidism, diabetes mellitus, chronic obstructive pulmo-
nary disease [COPD], cardiovascular disease, etc) and psychological conditions (e.g., anxiety, 
FATIGUE  in  METASTATIC CANCER
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depression, sleep disorders, etc) also need to be considered. In our opinion, decreased physical 
activity may also be a factor leading to fatigue. Furthermore, anti-cancer treatments such as 
chemotherapy, targeted therapies, radiotherapy or surgery and other commonly prescribed 
medications (e.g., opioids, psychiatric drugs, antihistamines, beta blockers, and corticosteroids) 
are all associated with side effects that may result in fatigue.
As management of CRF is currently sub-optimal, ideally a change of approach is required, where 
fatigue is treated as central to patient management both during and after systemic anti-cancer 
treatment. The ultimate aim would be to develop a management programme including infor-
mation and tools relevant to the screening, diagnosis and potential treatments/interventions 
for CRF, and combine these onto one platform for use by the wider oncology community. 
Various programmes and management tools are already available locally, which could perhaps 
guide best practice more widely. For example, www.oncoline.nl is a website produced by the 
Comprehensive Cancer Centre in The Netherlands (IKNL), which facilitates the development, 
implementation and evaluation of guidelines for oncological and palliative care. This compre-
hensive site includes guidelines on the diagnosis and treatment of patients with various tumour 
types. It also contains guidelines for the diagnosis and treatment of many symptoms and health 
complaints caused by the disease itself or its treatment – including fatigue.
Figure 1 Aetiology of cancer-related fatigue
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Integrated management of CRF
In this section we will overview key factors involved in the screening, diagnosis and treatment of 
cancer patients experiencing fatigue. We also suggest an algorithm for the process of managing 
CRF in clinical practice (Figure 2), which has been guided by our experiences in The Netherlands. 
This includes key stages involved in the screening and diagnosis of fatigue in patients under-
going anti-cancer therapy, as well as some of the potential treatment options. Further details 
relevant to each part of this algorithm are provided below.
Screening and diagnosis
To encourage patients and their families/caregivers to report CRF, education needs to be offered 
to both as soon as possible. This should aim to raise their awareness of the likelihood of fatigue 
developing, its contributing factors, effects on quality of life and the possible treatment options 9. 
NCCN Clinical Practice Guidelines In Oncology (NCCN Guidelines®) recommend that all cancer 
patients should be screened for fatigue at their initial clinical visit, and then regularly during 
and after their anti-cancer treatment has ceased 9. It should be noted, however, that a patient’s 
perception or internal standard for determining their level of fatigue can change as a result of 
receiving radio- or chemotherapy (the so-called ‘response shift’) and this can complicate the 
comparison of fatigue scores over the course of treatment 19. For example, what might have 
Figure 2 Suggested algorithm for managing fatigue in cancer patients
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been perceived as ‘severe fatigue’ before anti-cancer treatment commences might be noted as 
‘slight fatigue’ after the patient has experienced exhaustion during treatment. This has led to 
some investigators advocating the use of ‘then’ ratings, where a patient indicates in retrospect 
after their treatment how they functioned before treatment 20.
 Many screening tools are available for CRF but most are not validated. The Distress 
Thermometer Screening Tool (Figure 3) is a general screening tool included in the NCCN 
Guidelines® for Distress Management 21. It is often used to assess various aspects of physical 
and psychological distress (including fatigue), as well as other practical problems (e.g., fi nan-
cial burden), in oncology patients before, during and after systemic anti-cancer treatment. This 
questionnaire was developed 21 and validated 22 in the USA, before subsequently being adapted 
for use in The Netherlands 23. As this is quite a broad-ranging instrument, it is a good initial 
screening tool, allowing the identifi cation of patients requiring additional psychosocial/medical 
support who may be missed should a more specifi c questionnaire be utilised. Because of their 
close involvement in patient management, it may be useful to train oncology nurses to use 
instruments like the distress thermometer in clinical practice, as is advised in the current Dutch 
guidelines 24.
 If on initial screening a patient is found to have very mild (or no) fatigue, beyond providing 
them with education about CRF and performing regular rescreening, further clinical interven-
tion may not be required. If, however, signifi cant fatigue is found to be present, a quantitative 
Figure 3 An example of a general screening tool for psychosocial, physical and practical issues 
 in cancer patients: the distress thermometer
Management of fatigue in patients with cancer
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or semi-quantitative assessment of its intensity should be performed. This can be done using 
either a uni-dimensional (e.g., the Visual Analogue Fatigue Scale [VAFS] 25 or Brief Fatigue 
Inventory [BFI] 26) or a multi-dimensional tool (e.g., the Multidimensional Fatigue Inventory 
[MFI] 27, Functional Assessment of Cancer Therapy-Fatigue scale [FACT-F] 28 or Checklist Individual 
Strength [CIS] 29, 30). A detailed discussion of the available measures for the assessment of CRF 
is beyond the scope of this article but can be found in Jean-Pierre et al 2007 31. Abbreviated, 
local language versions of these tools, such as the Dutch Fatigue Scale 32 and the short fatigue 
questionnaire 33, 34, are also available, if needed. The short fatigue questionnaire is a validated 
tool developed in The Netherlands that might be particularly useful if lack of time is an issue 
as it consists of just four questions (‘I feel tired’, ‘I am easily tired’, ‘I feel fit’ and ‘I feel physically 
exhausted’), which are rated by the patient using a 7point scale.
Focussed evaluation of likely causes of CRF and options for 
clinical intervention
If moderate or severe fatigue is identified, a more focussed evaluation is required to identify any 
contributing factors and guide potential interventions 9, 17. This should involve taking a thorough 
medical history, including the patient’s current disease status, type and length of treatment, 
their response to such treatment, onset and duration of fatigue, and any changes in fatigue or 
associated factors/symptoms over time. A review of the patient’s current medications is recom-
mended as these may interact or cause side effects that might impact on fatigue levels. The 
patient’s weight should be measured alongside a discussion around their level of appetite and 
diet/nutritional status. A thorough physical examination should also be conducted to determine 
if any symptoms are related to recurrence/progression of the malignancy and a review of the 
body systems may be useful in identifying the systems involved and in directing the specifics of 
the diagnostic work-up.
 During the diagnostic process it is important to identify any potentially treatable factors that 
could have contributed to the development of CRF, such as anaemia, pain, emotional distress, 
sleep disturbance, medication side effects, and comorbidities (Figure 1). Fatigue generally 
increases as the cancer progresses and some causative factors are more likely to be found in 
patients who are close to the end of life 9. For example, at this stage there is an increased likeli-
hood that fatigue is associated with anaemia, medication adverse events, cognitive impairment 
and malnutrition 9.
 Depending on the cause(s) of the fatigue, there are many possible interventions that could 
be used both during and after the patient’s anti-cancer treatment. Both pharmacological 
and non-pharmacological approaches can significantly improve patient quality of life 35-41. 
Consequently, many national and international guidelines have been released regarding the 
management of fatigue and causal factors such as anaemia 9, 24, 42-46. Several CRF guidelines also 
recommend optimising the treatment of accompanying symptoms, however, evidence from 
randomised trials to support this recommendation have been lacking 47. Interestingly, a recent 
randomised trial demonstrated that nurse-led monitoring and protocolised treatment of physical 
symptoms was more effective than usual care in patients with advanced cancer and CRF 47.
 The NCCN Guidelines for CRF 9, state that although the patient’s clinical status (i.e. whether they 
are undergoing active treatment, are post-treatment/receiving no active treatment except for 
hormonal agents, or end of life) will influence CRF management, some more general guidelines 
FATIGUE  in  METASTATIC CANCER
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apply across all clinical categories. As there is a lack of published data on the effectiveness of 
specific CRF interventions in defined clinical settings (e.g., in patients undergoing curative vs 
palliative chemotherapy), interventions that are likely to be useful across a spectrum of patients 
are the focus of this paper. Summaries of the available pharmacological and non-pharmaco-
logical approaches are shown in Tables 1 and 2, respectively. As fatigue is a multifactorial condi-
tion, a combination of approaches is likely to be the best option for most patients.
Options for pharmacological intervention
Potential pharmacological interventions for CRF are likely to include those aiming to correct any 
identified contributing factors impacting on fatigue (Table 1). For example, adjusting the anti-
cancer treatment or dose could be useful if the CRF was thought to be related to the tumour 
itself or its treatment. It could be beneficial to prescribe erythropoiesis-stimulating agents 
(ESAs) for patients with symptomatic anaemia to correct and maintain haemoglobin levels 39, 
48, 49, or for patients to receive blood transfusions to temporarily relieve the symptoms of severe 
anaemia 50. It should be noted, however, that the suitability of ESAs in patients undergoing 
potentially curative anti-cancer therapy is still under discussion in some countries including in 
The Netherlands – with these agents being used more commonly in the palliative setting. Oral/
intravenous iron could also be useful for patients with low iron levels 51. All of these options have 
been shown to positively impact on either fatigue levels or quality or life in cancer patients with 
low haemoglobin levels and/or anaemia 39, 48, 49, 51.
 For other tumour-related factors such as hypercalcaemia 24, 41, hyponatraemia or dehydration 24 
prescribing bisphosphonates or fluids/fluid restriction, respectively, could be the best course of 
action. Megestrol acetate (Par Pharmaceuticals Inc., Spring Valley, NY, USA) or corticosteroids 
can also be considered for patients experiencing any metabolic abnormalities resulting from 
anorexia-cachexia syndrome. The choice between these treatments depends on the life expec-
tancy of the patient (megestrol may be appropriate for those with a life-expectancy of several 
months or more, corticosteroids for those with a life-expectancy less than this) 24.
 Sleep disturbance often occurs in cancer patients and can impact on fatigue levels 52. 
Short-term, short-acting benzodiazepine treatment may be indicated in patients with severe 
sleep disorders or those whose sleep problems are unresponsive to non-pharmacological 
intervention 24. Sedating anti-histamines, antidepressants (e.g. amitriptyline [Actavis UK Ltd 
Barnstaple, Devon, UK]) or antipsychotics may also be useful to this end. Melatonin (RAD Neurim 
Pharmaceuticals EEC Ltd, Reading, Berkshire, UK) or methylphenidate (Novartis Pharma, East 
Hanover, NJ, USA) can also be beneficial if there is a disturbed circadian rhythm 17, 24, 53.
Other potentially useful pharmacological interventions include medications for any specific 
comorbidities that have been identified. This might include prescribing or adjusting treatments 
for hypothyroidism, adrenal insufficiency, diabetes mellitus, cardiovascular disease, COPD, 
etc 9, 24. Depression and fatigue are also often associated in patients with cancer and so antide-
pressants, such as selective serotonin reuptake inhibitors, may be beneficial in some patients 
– although there is little evidence for a direct impact on fatigue levels 41.
 If fatigue persists after all the identified contributing factors amenable to pharmacological 
intervention have been addressed, further action could be indicated to manage symptoms. 
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This could include prescription of non-steroidal anti-inflammatory drugs or opioids for patients 
experiencing pain, and morphine, corticosteroids, bronchodilators or sedatives/anxiolytics 
for those experiencing dyspnoea 24. Psychostimulants (e.g. [dexa]methylphenidate [Novartis 
Pharma, East Hanover, NJ, USA], dexamphetamine [Amedra Pharmaceuticals LLC, Horsham, PA, 
USA] or modafanil [Cephalon Inc., Frazer, PA, USA]) have also shown some efficacy in relieving 
fatigue in randomised and open-label trials 53-55.
Options for non-pharmacological intervention
Several non-pharmacological approaches have been shown to be effective for relieving or 
managing fatigue in patients with cancer (Table 2) and these can be used alongside the phar-
macological interventions described above. Such approaches could also be useful in patients 
Cause of fatigue Possible interventions
Tumour Systemic anti-cancer therapy (e.g., chemotherapy, hormonal therapy or 
targeted therapy)
Anti-cancer treatment Consider reducing/delaying dose or stopping treatment (only if severe)
Other medications Consider reducing dose/withdrawal of potential fatigue-inducing drugs 
(e.g., psychotropic drugs, anti-histamines, beta blockers, etc)
Anaemia If iron, folic acid or vitamin B12 levels are low, use supplements (oral/
intravenous) as appropriate
If haemoglobin levels are low consider erythropoiesis-stimulating agents or 
whole blood/red blood cell transfusion
Electrolyte disorders Hypercalcemia: intravenous sodium chloride and bisphosphonates
Hyponatremia: fl uid restriction and/or salt supplementation (oral/
intravenous)
Dehydration Rehydration with intravenous sodium chloride and depending on cause 
could include for example, discontinuation of diuretics, initiation of 
insulin treatment (if hyperglycemic), and treatments for fever/excessive 
sweating (e.g., clonidine, progestins, selective serotonin reuptake inhibitors, 
gabapentin if related to hot fl ushes)
Weight loss If there are metabolic abnormalities resulting from anorexia-cachexia 
syndrome consider megestrol acetate or corticosteroids (depending on life 
expectancy)
Comorbidity Depends on comorbidity present; check for hypothyroidism, adrenal 
insuffi  ciency, diabetes mellitus, heart failure, cardiovascular disease, COPD, 
infections, etc, and treat according to fi ndings
Depression Consider use of selective serotonin reuptake inhibitors
Sleep disorders Consider short-term short-acting benzodiazepine treatment if severe 
or unresponsive to non-pharmacological intervention. Sedating anti-
histamines, antidepressants or antipsychotics may also be useful. Melatonin 
or methylphenidate may be benefi cial if there is a disturbed day/night-time 
rhythm
Underlying symptoms Pain or dyspnoea can cause fatigue and should be treated appropriately 
(e.g., non-steroidal anti-infl ammatory drugs or opioids for pain, and 
morphine, corticosteroids, bronchodilators or sedatives/anxiolytics for 
dyspnoea)
Unknown Psychostimulants (e.g., dexamphetamine, [dexa-]methylphenidate or 
modafanil) for symptomatic relief
Table 1 Examples of possible pharmacological interventions for use in cancer patients experiencing fatigue
FATIGUE  in  METASTATIC CANCER
26
not benefitting from or amenable to pharmacological treatments, such as those with mild 
symptoms, and those where no treatable causative factors for CRF have been identified. Energy 
conservation can be a useful, common-sense, strategy for all cancer patients, helping them to 
prioritise, pace and delegate activities to prevent energy depletion. Daily self-monitoring of 
fatigue levels may also help patients to find a routine balancing activity and rest, which works 
best for them based on their pattern of fatigue 9.
 If a patient is experiencing difficulties with sleeping, various behavioural techniques can be 
recommended for improving sleep patterns. These include stimulus control (where patients 
are advised to go to bed when sleepy and have routine times for going to bed and rising in 
the morning), sleep restriction (avoidance of long daytime naps and limiting time in bed), and 
sleep hygiene (avoiding caffeine and exercise near bedtime and having comfortable sleep 
surroundings) 17. Complementary therapies may also have a role for improving sleep disor-
ders and other conditions. For example, relaxation techniques and massage may aid sleep and 
decrease distress/anxiety, while yoga, acupuncture and American ginseng have all shown some 
evidence of relieving CRF 9, 17, 56, 57. Some patients experiencing CRF may benefit from additional 
supportive care. Depending on their individual needs, this might include consulting with other 
more specialised healthcare professionals such as dieticians, physiotherapists, or occupational 
therapists 9, 24. It might also be beneficial to assist the patient in gaining additional help at home 
from caregivers, volunteers, or from the use of labour-saving devices.
 It is important to offer psychosocial support to patients showing symptoms of psychological 
burden/distress 14, 58, 59. This could take many forms, for example, stress management techniques, 
use of support groups, counselling/psychotherapy on an individual basis, or spiritual care. The 
use of distraction (i.e. activities such as playing games, music, reading, and socialising, which 
are designed to distract the patient from their condition), may also be helpful 17. Cognitive 
Energy conservation Help patients to fi nd a daily routine that balances activity and rest, which 
works for them based on their pattern of fatigue
Psychosocial support This could include counselling/psychotherapy, cognitive behavioural 
therapy, etc. Can be provided in the form of group therapy as part of 
rehabilitation programmes or individually. Can also be sought through 
professional psychosocial oncology centres or through psychologists, 
counsellors, etc. Inform patient about the possibility of spiritual care. Advise 
distraction (e.g., reading listening to music, walking, gardening, etc), if 
appropriate to patient
Sleep therapy Stimulus control, sleep restriction and sleep hygiene may be benefi cial
Complementary therapies Relaxation therapy, massage, music, herbal remedies (e.g. American 
ginseng), yoga, and acupuncture may also provide relief
Other supportive care Consultation with a dietician, physiotherapist or occupational therapist as 
required
Assist patient in gaining additional help at home from caregivers, 
volunteers, etc
Physical activity Encourage physical activity and provide information on any available 
training and/or rehabilitation programmes (supervised by a physiotherapist 
if fatigue is severe)
Self effi  cacy and self management Encourage positive patient factors such as self effi  cacy, mastery and learned 
resourcefulness
Table 2 Examples of possible non-pharmacological interventions for use in cancer patients experiencing fatigue
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behavioural therapy (CBT) could also have a role to play, as it is not only effective in relieving 
fatigue in patients with cancer 60, 61, but may also lead to a decline in perceived cognitive disability 
and a reduction in concentration problems 62. In line with this, patients reporting concentration 
and memory problems before initiation of anticancer therapy seem to benefit most from CBT, 
with improvements lasting up to 7 months post intervention 63. In the author’s opinion, patients 
should be offered CBT during or in the first 12 months after receiving their anticancer therapy.
 The side effects of anti-cancer therapy can lead to a reduction in the patient’s physical activity 
and performance 9. Conversely, several clinical studies and meta-analyses have shown the bene-
fits of increased physical activity/exercise on CRF, physical/emotional functioning, insomnia 
and overall quality of life 43, 64-66. Benefits have even been observed in patients with advanced 
cancer 65. Exercise may also enhance fitness and minimise the likelihood of the patient deve-
loping fatigue or of it worsening. Interestingly, it has been suggested that CBT offers no addi-
tional benefit over that seen with physical exercise alone 67. However, results have been some-
what conflicting with a second randomised trial unexpectedly reporting that the benefits of CBT 
in patients with CRF were not mediated by increased physical activity 60. At present we cannot 
draw firm conclusions regarding the separate and/or cumulative effects of CBT and physical 
exercise, but trials are ongoing in this area. For instance, the TIRED (Treatment of fatigue duRing 
palliativE care of advanced or metastatic Disease) trial is assessing the benefits of exercise, CBT 
and usual care on fatigue in patients with advanced/metastatic breast or colon cancer 68. Two 
additional randomised trials are assessing the impact of various forms of exercise in patients 
with non-metastatic colon or breast cancer receiving adjuvant chemotherapy. The Physical 
Activity during Cancer Treatment (PACT) trial is comparing fatigue levels between patients 
undergoing an 18week, physiotherapist-supervised physical training/exercise programme 
and control patients not undertaking this programme 69. Whereas, the Physical exercise during 
Adjuvant Chemotherapy Effectiveness Study (PACES) is evaluating the effectiveness of a low/
moderate intensity, home-based, self-managed physical activity programme (Onco-Move) and 
a relatively high-intensity, structured, supervised outpatient exercise programme (OnTrack) 70.
 Although the results of such trials are awaited, it now seems reasonable to encourage 
cancer patients to engage in moderate physical activity during and after anti-cancer treat-
ment 9. The optimum amount or type of activity is yet to be determined but could include 
anything from a general avoidance of inactivity and an increase in activity level in the home, 
to supervised outpatient exercise/training programmes. The type and frequency of exercise 
can be customised to meet the requirements of each patient but exercise should be used 
with caution in those with bone metastases, thrombocytopaenia, anaemia or fever/active 
infection 9. The American College of Sports Medicine has recently published exercise guide-
lines for cancer survivors with specific exercise programming adaptations based on disease 
and treatment-related adverse effects 43.
We should also note that various patient- (and also caregiver-) related factors such as perceived 
self efficacy, mastery, optimism and learned resourcefulness have been reported to influence 
CRF levels 71-76. It is, therefore, important for healthcare providers to recognise and encourage 
such traits to help patients more effectively manage their symptoms. Patient education can help 
improve self efficacy 77 and an ongoing trial (RESTORE) may help identify whether an online or 
leaflet-based approach is most effective 78. The beneficial effects of exercise on CRF may in some 
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part be mediated by self efficacy and mastery 79-82, and conversely, interventions that improve 
self efficacy have also been shown to improve physical activity, and thereby relieve fatigue 83, 84.
Barriers to the effective management of CRF
Despite the existence of multiple treatment guidelines, these are often not followed and in daily 
clinical practice CRF is not optimally dealt with, often remaining unrecognised and untreated 9, 85. 
For example, in a recent study only about half of patients with severe cancer-related anaemia 
and fatigue received treatment with epoetin and/or blood transfusion in accordance with clinical 
practice guidelines 85. Barriers to effective CRF management exist both on the side of the treating 
physician and their patients 86. For example, there may be a lack of awareness by physicians or 
they may feel uncomfortable discussing CRF because they feel they have a lack of knowledge 
in this area or are concerned about the limited treatment options. Furthermore, physicians may 
underestimate the severity or frequency of a patient’s symptoms including fatigue 87 and may 
also fail to appreciate the impact of CRF on a patient’s quality of life 17, 88. Differences can exist 
between the patient’s and their healthcare provider’s estimation of fatigue and overall quality of 
life 89. Many patients regard fatigue as having a greater negative impact on their daily lives than 
many other cancer- or treatment-related complications 18. In contrast, physicians often believe 
that pain adversely affects their cancer patients more than fatigue 90. Furthermore, the patient’s 
family members/caregivers may overestimate the impact of patient symptoms 87.
 System barriers such as time constraints might also exist limiting the opportunity for discus-
sion between physician and patient. For instance, guidance in The Netherlands suggests that 
physicians should ideally spend approximately 15 minutes with each patient at each standard 
follow-up visit after their initial consultation 91. In addition, patients may consider CRF to be an 
unavoidable consequence of their disease or treatment and therefore may avoid mentioning 
it as a symptom because they don’t want to be perceived as complaining. The fear that the 
presence of CRF could mean that the cancer has recurred or progressed or that it might lead to 
a less aggressive form of anti-cancer treatment may also prevent patients from raising this as a 
concern 1, 15, 17, 88. In our experience, patients may also try their best to perform well in front of 
their physician even though they are struggling with fatigue in their daily life, which can make it 
even more difficult for physicians to recognise the scale of the problem.
SUMMARY AND CONCLUSIONS
CRF remains an under-recognised and under-discussed condition, despite its deleterious 
impact on patient quality of life 4, 5, 15, 16. If we are to improve management of this condition, it is 
important to raise awareness about CRF in both healthcare professionals and cancer patients. To 
achieve successful symptom control, there is also a need for close dialogue between the patient, 
their caregivers and the members of the treating multidisciplinary team 87. There are many 
different programmes in The Netherlands and elsewhere focussing on various aspects of CRF 
management (e.g., psychological, social, religious, somatic/physical aspects of this condition, 
etc), but none have been completely validated and their effectiveness remains to be proven. As 
many factors impact on the development of CRF, we believe a multicausal and multidisciplinary 
approach to fatigue management in cancer patients is preferable, where all aspects are assessed 
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and treated together. With this in mind, it is hoped that the suggested algorithm (Figure 2) 
could provide a useful tool to healthcare professionals dealing with cancer patients in their daily 
practice, as it should guide them through the key stages involved in the screening, diagnosis 
and treatment of CRF, and thereby improve its management. Although fatigue is a serious and 
complex clinical problem, it is important to work through it in a structured and comprehensive 
way as effective management has the potential to much improve patient quality of life.
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ABSTRACT
With the currently available treatment options for incurable cancer, a patient’s palliative phase 
may now cover a period of years. The primary purpose when intervening during this phase 
is the improvement of quality of life and secondly, if possible, life extension. One of the main 
complaints of patients in the palliative phase appears to be fatigue with an incidence of 33-99%, 
depending on the definition used, and stage of disease. As well as the influence fatigue may 
have on a patient’s daily life, fatigue also affects the partner and / or caregiver.
 Cancer treatment as explanation for fatigue in the palliative phase certainly plays a role. 
However it is still unclear whether, for instance, the cumulative nature of successive treatments, 
the spread of the disease itself and its consequences, or associated complications contribute to 
fatigue. Pharmacological treatments for fatigue at this stage are not always effective and are of 
limited use because of side effects. Psychosocial interventions employing various approaches 
such as support and coaching have in a limited number of studies been shown to be effec-
tive. Improvements in the options for cancer treatment for this group over the past years have 
resulted in increased attention to quality of life for this group of patients. The importance of 
further research into fatigue and other psychosocial consequences in the palliative phase there-
fore becomes more urgent.
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Palliative phase
Of all cancer patients, approximately 40% are found to be incurable at the start of disease or 
after disease recurrence. When curative treatment is no longer possible, we speak of the pallia-
tive phase, although this definition sometimes includes the terminal phase. In this chapter we 
discuss fatigue during the palliative phase, with the exception of the terminal phase in which 
death is near. 
 Due to the current treatment options there has been a shift in perception of incurable cancer 
as a fatal disease in the short term to a disease that is increasingly becoming a chronic condi-
tion. The palliative phase may thus extend over a period of years. Therefore, in addition to the 
hope of longer life, quality of life in this phase has also increasingly become of importance. 
Initially, interventions are primarily focused on bringing the disease to a standstill and thereby 
prolonging as well as improving the patient’s quality of life. Various treatment options are often 
possible during this period.
 This can partly involve treatments that affect the malignant disease throughout the entire 
body, also known as systemic therapy, but can also partly consist of local therapy if the disease is 
confined to one area of the body or is located in a site which requires more intensive treatment 
(e.g. irradiation of a metastasis). Among the systemic therapy options are hormonal therapy, 
chemotherapy, immunotherapy, and the more recently developed targeted therapies. These 
therapies are used both as mono-therapy and in various combinations of medication. During 
the palliative phase one speaks of different treatment lines. The first treatment in the palliative 
trajectory is referred to as first-line treatment. At progression (or serious adverse events) the 
next line of treatment can be initiated. It is not uncommon nowadays for patients to undergo 
two, three or even more consecutive lines of treatment. 
 In a later stage of the disease process, cancer treatments become less effective, and the balance 
between efficacy and side effects of treatment can become less favorable. Interventions will then 
be more focused on palliation, or ‘lessening’ or ‘relief’ of symptoms associated with progression of 
the disease process. A gradual shift is occurring in oncology whereby, as well as classical parame-
ters of treatment efficacy (disease-free survival and survival), quality of life is also measured. It was 
recently shown for the first time, in lung cancer patients, that the best strategy is to act disease- as 
well as symptom-oriented. This approach even had a positive effect on survival 1.
Prevalence of fatigue in the palliative phase
From the literature it is known that 33% to 99% of patients with advanced or metastatic cancer 
experience fatigue 1-5. This variation is due to the use of different instruments to determine 
fatigue, although the selection of patients also plays a role. It may be that patients from the 
entire palliative trajectory, also including the terminal phase, are included. This makes interpre-
tation and application of these figures in clinical practice difficult. With the previously mentioned 
description of the palliative phase it may be imagined that fatigue during this period may have 
a fluctuating course. It makes a difference whether a patient is still at the beginning of the palli-
ative trajectory, is still being treated with the intent to achieve tumor reduction or is in a period 
of relative rest, for instance because treatment has been terminated on achieving remission.
 Fatigue in cancer has only recently gained a broader interest among researchers and prac-
titioners of cancer therapy. Gradually it is being recognized by professionals as a problem that 
needs to be addressed separately if quality of life during the palliative phase is to improve 1, 3, 5-7.
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Consequences of fatigue
Fatigue is often described as the most distressing symptom of their disease by patients in the 
palliative phase as it has a direct negative impact on daily life and the perceived quality of life 1-8. 
Disease progression (primary non-metastatic, primary metastatic or disease relapse) seems to 
correlate with increased severity of fatigue 8.
Family and caregivers
From the impact fatigue has on the patient’s daily life, it is a short step to the effect that fatigue 
has on the patient’s environment. Previous research has shown that 85% of caregivers mention 
feeling burdened; 40% reported severe overload 9. There is limited research on the role of fatigue 
in this. In their study, Jensen & Given reported excessive fatigue in 25% and severe fatigue in 
28% of caregivers. They found no significant association between the number of hours spent on 
daily care / support and caregivers’ severity of fatigue 10.
 A patient’s fatigue appears to have many consequences on the physical, psychosocial and 
economic sphere of both patient and caregiver 11. It is therefore important for healthcare profes-
sionals to recognize and pay attention to the balance of strength and burden of the caregiver, 
knowing that fatigue may also occur in the caregiver, possibly with as many negative effects as 
in a patient.
Explanations for fatigue
The model of fatigue in curatively treated patients, as described in another chapter, has been 
well studied. A distinction is made between predisposing factors, precipitating factors during 
treatment and factors which sustain the fatigue following treatment. Whether this model also 
sufficiently explains fatigue during the palliative period, and to what extent the previously 
known factors from the curative phase play a role in the palliative phase, is as yet unknown.
 When cancer-directed palliative treatment is given, similar factors which provoke or worsen 
fatigue may be identified. It is less clear to what extent the activity of the malignant disease 
itself causes fatigue, or to what extent fatigue is caused by new complications, nor the extent to 
which progressing disability or lessening of activities causes or maintains fatigue. It seems likely 
that the stage of disease is a predisposing factor 8 and that treatment during this period can also 
be seen as a fatigue-triggering factor.
 However, the possible contribution caused by undergoing successive treatments should not be 
ignored. Is there possibly a cumulative effect on fatigue? As well as ongoing treatment, cognition 
of fatigue, activity patterns and fear regarding the eventual fatal course of the disease can also 
influence the severity and course of fatigue 8. This has hardly been investigated. In unpublished 
own research, we found that in patients with various solid tumors during active cancer treatment 
in the palliative phase, the severity of fatigue increased with the number of consecutive treatment 
lines. No association was found between fatigue and type of (systemic) treatment. Others found, 
in men with locally advanced prostate cancer being treated with hormonal therapy, an increase in 
fatigue during the treatment period 12, or stage of the palliative trajectory 8.
 The palliative trajectory can be clearly distinguished from the treatment period, in which 
the intent of treatment is curative. The possibility to give successive lines of cancer-oriented 
treatment during the palliative phase has increased substantially. Nowadays it is not unusual for 
treatment to continue during the palliative phase up to the final terminal stage. There are hardly 
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any treatment-free periods during which the patient can recover. It is unclear at present, to what 
extent the new treatments contribute to fatigue in positive or negative way.
 In addition, it is conceivable that other factors such as further spread of the disease during 
the palliative phase (increasing tumor load), and increase in the number of symptoms with 
progression of the disease, may affect the severity of fatigue. Further research is needed for the 
development of an effective treatment strategy of fatigue in cancer during the palliative phase 
and on factors that may affect fatigue at this stage.
Treatment options during the palliative phase.
There is not one effective treatment strategy for fatigue in patients with cancer in the palliative 
phase. A great deal of research into the effectiveness of various interventions in this phase is still 
ongoing. The following recommendations are mostly the result of common sense, or based on 
efficacy research of a particular strategy with a known problem. These recommendations are 
included as part of the overall guidelines laid down in the Guidelines on Fatigue in cancer in the 
palliative phase (2.0) (2010) of the Comprehensive Cancer Centers (www.oncoline.nl/vermoeid-
heid ). The present guideline is divided into a number of possible interventions:
 - Provision of information to the patient and caregiver;
 - Integrated approach to fatigue-related issues;
 - If possible, treatment of the underlying cause;
 - Always support with a form of non-drug therapy (find balance in activities, training, 
relaxation therapy, music therapy and psychosocial support)
Treatment
If the patient experiences fatigue and expresses a desire for treatment, the physician will first of 
all need to consider whether treatable conditions are possibly the cause of fatigue. The physi-
cian will assess together with the patient whether treatment is sensible in view of the limited 
prognosis, the time needed before the treatment is effective and the likelihood of success of 
treatment and possibility of unwanted side effects, such as blood transfusion for anaemia or 
erythropoietin and treatment of infection through use of antibiotics. In cases where it is possible 
to successfully give systemic therapy, this may also decrease symptoms of fatigue.
Symptom interventions
When treating specific symptoms it should be borne in mind that these treatments themselves 
can cause fatigue, or worsening it, as a side-effect. When determining the treatment dose, a 
balance between efficacy and side effects should be sought. For each individual complaint, the 
aim should be that the patient has a score of 4 or lower on the Numeric Rating Scale (NRS) 
regarding the appropriate symptom.
 Pharmacological symptom interventions for fatigue have not often been researched 13. Use 
of antidepressants shows no effect on fatigue. Use of corticosteroids may provide improvement 
in fatigue, although its application is limited due to the numerous side effects that are likely to 
occur, and occasionally proximal muscle atrophy may even be the cause of fatigue. Progestins 
and methylphenidate (Ritalin) have been studied in the treatment of fatigue, but they do not 
always appear to be effective and are associated with side effects. The use of these drugs always 
requires attaining a good balance between the desired effect and adverse events 13.
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Psychosocial interventions
A number of randomized trials into psychosocial interventions have shown positive results. The 
effective interventions consisted of multiple components, such as support, coaching, educa-
tion and the provision of information on fatigue. The interventions were carried out by trained 
nurses and/or social workers. These studies have shown that psychosocial interventions specifi-
cally focused on fatigue are more effective than non-specific interventions 14,15.
Physical training programs
Physical training programs for patients in the palliative phase have been developed and 
researched. The approach of these training programs is often maintaining or building physical 
fitness or maintaining independence. The effect on fatigue is questionable 16.
CONCLUSION
There is a strain between the options of keeping patients in the palliative phase alive and the 
possibilities for palliating associated symptoms such as fatigue sufficiently at this stage. There 
is still a limited understanding of the causes of fatigue, possible interventions and effective 
strategies to deal with fatigue in the palliative phase effectively. An important step has been 
made since psychosocial care and support as a treatment of a symptom such as fatigue have 
now been recognized as part of the care to be provided. During the curative trajectory, cogni-
tive behavioural therapy (CBT) appears to be the most effective intervention. CBT specifically 
focused on fatigue during the palliative phase also seems a promising intervention, but this will 
need to be investigated further.
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ABSTRACT
Because of a rise in incidence and more effective treatments, the prevalence of patients with 
metastatic cancer is increasing fast. When palliative treatment is aimed at maintaining or 
improving patients’ quality of life, knowledge about severe fatigue is clinically relevant because 
of its debilitating effect, but at present this information is lacking. This study investigated 
the prevalence of severe fatigue in patients with various incurable cancers, whether severe 
fatigue increased with further treatment lines and differed between various cancers and treat-
ment modalities. In addition a relationship between severe fatigue and other symptoms was 
examined. Patients were asked to fill in the Checklist Individual Strength, EORTC-Quality of Life 
Questionnaire-C30 and the McGill Pain Questionnaire during palliative anticancer treatment 
and HB levels were collected. Of all participating patients (N=137) 47% were severely fatigued. 
Patients who received first line of treatment were significantly less often severely fatigued (40%) 
compared to patients who received further lines (60%). Significantly more severe fatigue was 
observed when patients had more pain, dyspnoea, appetite loss, nausea, vomiting and consti-
pation. During the phase of palliative anticancer treatment fatigue was the most common 
symptom, nearly half of the patients suffered from severe fatigue increasing with further treat-
ment lines. Various treatment-related symptoms were related to more severe fatigue. As severe 
fatigue is significantly related to other symptoms of cancer and its treatment, the screening and 
treatment of these cancer-related symptoms should be more stringent, as they might nega-
tively influence each other.
Severe fatigue during the palliative treatment phase of cancer
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INTRODUCTION
Forty percent of cancer patients will experience a relapse of their disease; some patients have 
incurable cancer from the first diagnosis. Cancer care of patients with incurable disease is 
primarily aimed at prolonging the patients’ life and managing symptoms to maintain or improve 
patients’ quality of life. In recent years, more effective medicines have been developed to treat 
cancer and the symptoms of cancer in all phases of the disease. In some advanced cancers, 
care has led to life prolongation in years 1-3 , but more typically the progress has been gradual 
with an increase in treatment options. Because of the longer survival rates, the prevalence of 
cancer patients with advanced disease is increasing. There are various standard therapies for 
patients with advanced incurable cancer such as chemotherapy, hormonal therapy, radio-
therapy, immuno therapy and targeted therapy given as single agent therapy or in different 
combinations. With the introduction of new oral targeted agents, the treatment adverse effects 
have an impact on patients’ daily quality of life. In contrast to the relatively short, cyclic, and 
sometimes serious adverse effects of antineoplastic drugs, the adverse effects of oral targeted 
agents are continuously present and influencing daily quality of life 4, 5 .
 Fatigue is known to be one of the most distressing symptoms for patients with cancer 
and adversely affects patients’ daily quality of life 6-14. Prevalence rates up to 99% in patients 
with advanced, incurable, cancer are mentioned 8-11, 15. Cancer-related fatigue is defined as ‘a 
distressing persistent, subjective sense of physical, emotional and/or cognitive tiredness or 
exhaustion related to cancer or cancer treatment that is not proportional to recent activity 
and interferes with usual functioning’ 16. Severe fatigue can be considered an extreme degree 
of fatigue with a profound, debilitating effect on daily life and should therefore be seen as a 
clinically relevant symptom.
 Many studies on fatigue in cancer patients have been carried out in patients during treat-
ment with curative intent and in survivors, but there is limited knowledge about the severity 
of fatigue and related factors in patients with advanced cancer. Fatigue is an under-recognized, 
under-assessed and under-treated symptom in this group of patients Some consider fatigue 
an unavoidable symptom, caused by the disease itself or by adverse effects of anticancer treat-
ment. However, studies confirming this are lacking 4, 8, 10, 11, 17, 18 . Therefore we found it important 
to study severe fatigue in patients with advanced cancer in an exploratory way. Moreover, more 
knowledge is warranted to find starting points to develop effective interventions for severe 
fatigue in these patients.
 It is striking that studies of fatigue in patients with incurable cancer pooled the data of all 
patients at different phases of the palliative trajectory up to the terminal phase 15, 19, 20. As a result, 
these studies cannot provide insight to severe fatigue in the various phases of palliative cancer 
treatment trajectory. Several studies involving palliative cancer patients documented that two 
treatments (chemotherapy and radiotherapy) were positively associated with fatigue 15, 21-23. 
Oral targeted therapy as reported in two studies was associated with fatigue in patients with 
advan ced and metastatic renal cell carcinoma 5, 24. In one study involving palliative patients 
with prostate cancer, hormonal therapy showed a relation with fatigue 25. It is unclear whether 
fatigue is more common in certain treatment modalities, whether a cumulative effect exists, or 
whether progression of the disease itself contributes to fatigue.
 Cancer and its treatment as well as other factors can contribute or cause fatigue. For example, 
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hemoglobin level (Hb) has been examined, but mixed findings have been reported in terms of 
it being a causative factor to fatigue 8, 26, 27. In the study of Yennurajalingam et al, a significant 
association with fatigue and several other cancer-related symptoms, such as pain, dyspnea, 
insomnia, anorexia and drowsiness, was described 7. Others have focused on a decrease in the 
quality of life and investigated the experience of other cancer-related symptoms, including 
fatigue in association with quality of life 5, 7, 28, 29.
 The main aim of this study was to investigate the prevalence of severe fatigue in patients 
with advanced incurable cancer. We also aimed to investigate whether certain malignancies, 
treatment modalities, or further line of treatment had a higher occurrence of severe fatigue. 
Furthermore, we examined whether there was a relationship between severe fatigue and other 
cancer- and treatment-related symptoms. The following research questions were formulated:
 - What is the occurrence of severe fatigue in patients with advanced, incurable cancer during 
cancer treatment in the palliative phase?
 - Are patients who are receiving the first treatment line of palliative treatment less likely 
to have severe fatigue as compared to patients receiving subsequent treatment lines of 
palliative treatment?
 - Does the occurrence of severe fatigue differ amongst types of cancers and / or treatment 
modalities?
 - Do severely fatigued cancer patients have more other cancer-related symptoms like: 
dyspnea, pain, loss of appetite, nausea, vomiting, constipation, diarrhea and anemia?
MATERIAL & METHODS
Sample
Patients with advanced, incurable cancer from the Department of Medical Oncology at a 
university medical centre and from a large regional hospital at the Netherlands were invited to 
participate in the study. Potentially eligible participants were identified by the treating physi-
cians. Inclusion criteria were: diagnosis of advanced, incurable solid tumors; eligible for life 
prolonging therapy; and able to complete and return study questionnaires. Eligible participants 
were approached by one investigator (M.P). They were initially informed during a telephone 
contact followed by written information being forwarded to them.
 Participants from the university medical centre were offered the opportunity to complete 
the questionnaires using a computer at the outpatient clinic (in combination with a regular 
visit to the clinic) or a paper-and-pencil version at home. Patients from the regional hospital 
received only the paper-and-pencil version at home. When the questionnaires were sent to the 
participants’ home, an enclosed, addressed return envelope was included. When a mailed ques-
tionnaire was not returned, a study investigator made a maximum of two telephone calls to 
complete the data collection. The study was approved by the ethics committees of both hospi-
tals. All participants gave oral informed consent.
Instruments
Certain demographic and clinical data, including stage of the disease and current treatment 
were obtained from a general questionnaire and were, when necessary, supplemented with 
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data from medical records. Patient-reported fatigue severity was assessed using the fatigue 
subscale of the Checklist Individual Strength (CIS) questionnaire. This subscale consists of eight 
items, and each item is scored on a 7-point Likert scale with higher scores indicating higher 
fatigue. The range (low to high) for fatigue severity is 8 – 56. The validated cut-off score of 35 or 
higher indicated severe fatigue 30, 31. A score of 35 is approximately two times the SD above the 
mean score of healthy controls.
 Symptom subscales of the Quality of Life Questionnaire (QLQ) C30 of the European 
Organization of Research and Treatment of Cancer (EORTC) were used to assess fatigue, 
dyspnea, pain, loss of appetite, nausea, vomiting, constipation and diarrhea. Higher scores on 
the symptom scale indicate more severe symptoms (range 0 – 100) 32. Pain was also assessed 
with the McGill Pain Questionnaire 33. This questionnaire assesses the intensity of pain of three 
time points, using a visual analog scale. Participants were asked to rate the intensity of pain at 
this moment, when they experienced the least pain and when they experienced the most pain. 
Higher scores indicate more pain.
 Hemoglobin levels were obtained from medical records to establish anemia. As all patients 
were on active treatment, the time point of Hb collection was at most two weeks from the 
reported symptoms. According to the Dutch Guideline ‘Fatigue in Cancer During the Palliative 
Stage’, we considered a Hb level below 6 mmol/L to be anemic (both for men and women) 34.
Data analysis
Data were analyzed using Statistical Package for Social Science, version 18 (SPSS Inc, Chicago, 
Illinois). Descriptive statistics were used with the demographic and clinical data. Non-parametric 
tests, such as Chi-square and Mann-Whitney U test, were used to assess for differences in fatigue 
severity between the consecutive treatment lines, cancer types and treatment modalities. 
To examine if symptoms (pain, nausea, vomiting, constipation, diarrhea), HB levels, physical 
functioning and sleep disturbances differed between the severely and non-severely fatigued 
participants, t tests were performed. P < .05 was considered significant.
RESULTS
A total of 208 patients with non-curable advanced cancer was identified by the investigator 
(MP). Eight patients were not considered eligible by their physician. The remaining 200 patients 
were invited to participate in the study, and 162 patients (81%) agreed to participate. Study 
questionnaires were returned by 137 (85%) of 162 participating patients. Only three participants 
preferred to complete study questionnaires on a computer; all others used the paper-and-pencil 
version. Reasons given for not returning the questionnaires (n=25) were that completing the 
questionnaires was too strenuous or the questions were too confronting (n=12). Four patients 
did not give a specific reason but did not want to participate anymore, and seven patients did 
not return the questionnaires despite repeated reminders. Two patients died unexpectedly.
 Not all questionnaires were completed by all patients. The Checklist Individual Strength 
was completed by 136 patients, the EORTC-QLQ-C30 by 122 patients and the McGill Pain 
Questionnaire by 135 patients. Hemoglobin levels were available for all 137 patients.
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Patient characteristics
Of the 137 participants, the mean age was 59 years (range, 30 – 79 years), and 53 patients (39%) 
were male (see table 1). Most patients were married (81%).
 Table 1 also shows some characteristics of the group patients who did not participate in 
this study. Of these 71 patients, the mean age was 60 (range, 22 – 86 years), and 29 of them 
(41%) were male. Nonparticipants and participants did not differ in age (P = .656) or gender 
(P = .767). The majority of the participants had breast cancer or gastrointestinal cancer (both 
30%); non-participants had a prevalence of 24 % of both breast- and gastro-intestinal cancer. 
The distribution of cancer type did not differ significantly between the two groups (P = .476).
 The primary treatment represented was chemotherapy (68%), in combination (with radio-
therapy or targeted therapy) or as single modality therapy. At the time the participants 
completed the study questionnaires, 90 (67%) were receiving their first line of treatment in the 
palliative phase, 28 patients (20%) their second line of treatment, twelve patients (9%) their third 
line, and five patients (4%) were receiving a fourth line of treatment. Two patients completed the 
questionnaires just before starting their first-line palliative treatment.
Occurrence of severe fatigue
Severe fatigue was present in 47% of all participating patients (see table 1). Age did not signifi-
cantly differ between severely fatigued (mean age 58.7 [SD 9.9] years) and not severely fatigued 
patients (mean age 58.9 [SD 10.1] years) (P = .851), but there was a significant difference in 
fatigue severity between genders; 55% of the women were severely fatigued compared to 35% 
of the men (P < .05). When we excluded participants with breast and gynecological cancer, 50% 
of the women (n = 30) were severely fatigued and the difference between men and women was 
no longer significant (P = .175).
Severe fatigue in different treatment lines, various cancers and treatment 
modalities
Of the 92 participants who received first line of treatment, 40% were severely fatigued. This 
percentage was higher (60%) in patients who received further lines of treatment. This difference 
was significant (P < .05) (see Table 1). There were no significant differences between cancer types 
in the occurrence of severe fatigue or between various treatment modalities, even when various 
treatment modalities were combined. In particular, no difference was found in severe fatigue 
between participants treated with chemotherapy, as monotherapy or combination therapy 
(51%) compared to participants not receiving chemotherapy but receiving radiotherapy, 
hormonal treatment or oral targeted therapy (42%) (P = .347).
Do severely fatigued cancer patients have more cancer-related symptoms?
Participants with severe fatigue scored significantly higher than non-severely fatigued patients 
on dyspnea, pain, appetite loss, nausea and vomiting, and constipation (Table 2).
 Mean visual analog scale pain scores of the McGill Pain Questionnaire did not significantly 
differ between severely and non-severely fatigued participants on the three outcomes of the 
McGill Pain Questionnaire: pain at this actual moment, when pain was at its most, and when pain 
was at its least. No significant difference was found in Hb levels (median 7.9 mmol/L) between 
severely and non-severely fatigued patients. Of note, only six participants were anemic at the 
time the questionnaires were completed.
Severe fatigue during the palliative treatment phase of cancer
– an exploratory study
51
C
H
A
P
T
E
R
 4
Characteristics Non-participants
n (%)
Participants
n (%)
Severely Fatigued
n (%)
Sample 71 137 64 (47)
Female gender 42 (59) 84 (61) 46 (55) a
Male gender 29 (41) 53 (39) 18 (35) a
Mean (range) age, y 60 (22 – 86) 59 (30 - 79)
 Female 59 (22 – 86) 58 (32 – 78)
 Male 60 (37 - 81) 61 (30 – 79)
Education level
 Lower education (≤ 4) 89 (65)
 Higher education (>4) 48 (35)
Marital status
 Married 111 (81)
 Other (unmarried, divorced, widowed) 26 (19)
Kind of cancer
 Breast 17 (24) 41 (30) 22 (54)
 Gastro-intestinal 17 (24) 41 (30) 17 (43)
 Urogenital 14 (20) 15 (11) 6 (40)
  Gynaecological 8  (11) 13 (9.5) 9 (69)
 Bone & Soft Tissue 9 (13) 13 (9.5) 5 (38)
 Other 6 (8) 14 (10) 5 (36)
Treatment modalities
 Chemotherapy 72 (53) 40 (59)
 Oral Targeted therapy 21 (15) 10 (48)
 Hormonal therapy 20 (15) 7 (35)
 Chemo-Targeted therapy 19 (14) 6 (19)
 Radiotherapy 2 (1) 1 (-)
 Chemo-radiotherapy 2 (1) 0
 No actual treatment 2 (1) 0
Treatment line
 First line 92 (67) 37 (40) b
 Second line 28 (20)
 Third line 12 (9) 27 (60) b
 Fourth line 5 (4)
Table 1 Sample characteristics (n = 208) and occurrence of severe fatigue in participants
a = Signifi cant diff erence between male and female gender: P = .022 (Chi2)
b = Signifi cant diff erence between 1st line vs further treatment lines: P = .044 (Chi2)
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DISCUSSION
In this study severe fatigue was investigated in patients with advanced incurable cancer during 
palliative treatment. We focused on severe fatigue, because severe fatigue is a clinically rele-
vant symptom, impairing daily functioning and profoundly influencing patients’ quality of life 
negatively 6-14. The current study showed that almost half of the patients (47%) were severely 
fatigued, and the number of patients suffering from severe fatigue increased with treatment 
lines. We found that the occurrence of severe fatigue was lower (40%) in those at the time of 
their first line of treatment during the palliative phase and higher (60%) in those receiving 
further lines of treatment.
 We did not find that severe fatigue was significantly more prevalent in certain types of cancer 
or their treatment. This lack of difference may be because the number of participants in these 
subgroups was too limited to find statistically significant differences, but our results do indi-
cate that the line of treatment was associated with severe fatigue strongly. What exactly the 
explanation is for the increased fatigue is not clear. It might be the treatment of the next line 
itself, the increasing tumor burden, or perhaps a combination or cumulative effect of both. An 
increase in fatigue during the palliative phase has also been found in other studies. Teunissen 
and colleagues reported fatigue in more than 50% of patients with incurable cancer 11. Okuyama 
Symptoms Overall,
Mean (SD)
Severely fatigued,
Mean (SD)
Non severely 
fatigued,
Mean (SD)
P
EORTC –C30
 Fatigue 41 (24,1) 57 (19.8) 26 (16.9) < .001 a
 Dyspnoea 20 (24.5) 25 (26.5) 15 (21.6) .019 a
 Pain 25 (26.4) 35 (29.3) 16 (20.2) < .001 a
 Appetite loss 22 (31.5) 31 (34.5) 13 (26.2) .001 a
 Nausea & Vomiting 12 (17.0) 16 (17.7) 7 (15.2) .003 a
 Constipation 12 (22.2) 17 (24.7) 8 (19.1) .024 a
 Diarrhoea 15 (22.2) 18 (30.4) 11 (20.1) .229
Pain McGill
 Actual 18 (22.2) 20 (23.3) 14 (18.3) .304
 Most 36 (32.0) 40 (31.9) 32 (31.5) .463
 Least 11 (16.8) 12 (15.2) 10 (15.7) .425
HB level 7,8 (1.0) 7,8 (0.9) 7,8 (1.1) .689
Table 2 Mean scores and t-tests of cancer and/or treatment related symptoms and HB-levels 
 in severely and non-severely fatigued patients
EORTC = European Organization of Research and Treatment of Cancer
a = Signifi cant diff erence
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et al identified a percentage of fatigue interfering with daily activities in almost 60% of patients 
with advanced lung cancer 27. Fatigue percentages of 64 to 82% were in patients who were 
terminally ill were identified 35. In all these studies the occurrence of fatigue was higher than in 
the current study, but these studies investigated the presence of fatigue and made no distinc-
tion based on severity of fatigue. The somewhat lower prevalence found in our study might 
be explained by the fact that almost all patients were on active anticancer treatment. Not all 
patients with advanced disease are fit to receive anticancer treatment because of comorbidi-
ties, already existing complications or a low performance status. Therefore our group could be 
considered a better functioning group than palliative patients in general. Also, over 65% of the 
participants were at the beginning of the palliative phase. As performance status is taken into 
account when a decision on treatment is taken, it is surprising that almost half of the partici-
pants suffered from severe fatigue.
 In our study we found that severely fatigued patients had more pain compared to non-severely 
fatigued patients as assessed with the EORTC-QLQ-C30, but not when pain was assessed by 
the McGill Pain Questionnaire. These two questionnaires measure different aspects of pain. 
The EORTC-QLQ-C30 assesses pain occurrence during the last week, whereas the McGill Pain 
Questionnaire consists of a numeric scale that measures the degree of pain at this moment, 
when pain is at its greatest and its least. Laird and colleagues identified pain, fatigue and depres-
sion as a symptom cluster in cachexic cancer patients 36. They calculated thresholds for these 
symptoms of the EORTC-QLQ C-30 for patients with advanced incurable cancer. Although pain 
is experienced by most of our patients, fatigue is the most intense experienced symptom.
 Stepanski and colleagues investigated associations among pain, fatigue, insomnia and 
depressed mood, using data from a self-reported patient care monitor. They found moderate 
to strong associations with fatigue and pain, but also with trouble sleeping and depressed 
mood 37. In addition Yennurajalinga et al found several physical symptoms related to fatigue; 
pain, dyspnea, insomnia, anorexia and drowsiness 7. We found dyspnea, appetite loss, nausea 
& vomiting and constipation related with severe fatigue. That various studies report different 
clusters and associations involving fatigue suggests that symptom clusters in patients with 
advanced cancer may depend largely on the chosen research methods. It is not possible at this 
time to identify one consistent group of factors in relation to fatigue in these patients. Further 
research is needed to learn which factors play an important role in fatigue and the strength of 
their influence. For now, these findings underline the importance of screening for severe fatigue 
and other cancer-related symptoms, especially at crucial moments in the palliative trajectory.
 We found no difference in anemia (Hb levels) between severely and non-severely fatigued 
patients, but the group of anemic patients in our study population was small. This may be 
attributed to our common practice to correct anemia during active cancer treatment. The lack 
of a relationship between Hb level and severe fatigue has been previously reported in studies 
involving a similar population 8, 26, 27. However, Minton and colleagues documented a moderate 
association between Hb level and fatigue in cachexic patients; they suggest that other variables 
are likely more important in the development of fatigue 23.
 As in other studies we did see a significant difference in the incidence of severe fatigue 
between men and women 38, 39. In our group, the highest prevalence of severe fatigue occurred 
in breast and gynecological cancers, both groups with only women involved. Excluding both 
groups from the data, we did not find a significant difference anymore. Therefore we found this 
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difference not meaningful and did not consider this as a clinically relevant finding. It might also 
suggest that type of tumor may play a role.
In this study patients were preselected by their physician. This inclusion method might have 
caused a selection bias. We therefore checked some characteristics of the nonparticipants. No 
significant differences were found between the nonparticipating patients and the participating 
patients on gender, age and type of tumors. However, we do not have any information about 
patients who were not selected by their physicians for our study. It might be patients with a good 
performance status or patients who were already, according to their physician, too fatigued. If 
the latter is the case the problem of fatigue is even larger. So it is possible that we have a biased 
sample, but if so, it is impossible to say in what direction. As we only selected patients on actual 
cancer treatment, we have no information of patients who were physically able to receive a 
further treatment line but refrained from treatment.
 A weakness of our study is its cross-sectional design. Our study found an increase in severe 
fatigue with further treatment lines. Longitudinal studies are necessary to test the current 
findings. Although this study was exploratory in its design, it gives some indication of clinical 
relevant factors that might play a role in fatigue in patients with advanced cancer. Therefore, 
this study contributes to more knowledge about one of the most common and most distressing 
symptoms in these patients.
 Our study includes a relatively large group of patients with bone and soft tissue cancer (10%). 
This can be explained by the fact that our hospital is one of the designated centers for these 
relatively rare tumors in the Netherlands. It is a rare tumor, but type of malignancy was not 
related to severe fatigue in this study. However, it is unknown if and in which direction the 
inclusion of these patients has influenced the results. In our study the majority of patients had 
breast or gastrointestinal cancer, which is in accordance with the cancer incidence rates of the 
Netherlands.
 We investigated only specific cancer- and treatment-related factors for a relation with severe 
fatigue. We could not investigate causality. Probably, not only somatic, but also cognitive and 
behavioral factors, such as physical activity, sleep disturbances, emotional distress, depres-
sive mood, anxiety, low self-efficacy may play a role in severe fatigue in the palliative group 
of patients, as was found in cancer survivors 23, 40-42. Therefore further studies are warranted, to 
determine other relevant factors in this group of patients.
Implications for practice
In conclusion our study confirmed our hypothesis that severe fatigue increases with further treat-
ment lines, and it is the most common symptom in patients with advanced, incurable cancer. 
Severe fatigue is even more often reported than other symptoms such as pain or nausea and 
vomiting. Nowadays, patients are often treated continuously until disease progression or until 
patients experience too much side effects. When this situation arises, a decision on whether to 
start a next treatment line has to be taken. This is mostly a shared decision taken by the patient 
with his/her relatives, physicians, nurses, and other health care providers, in which all kind of 
aspects are discussed and weighted against each other. As health care professionals, we should 
be fully aware of the potential presence of severe fatigue in patients because of its debilitating 
character. Because severe fatigue is significantly related to other symptoms of cancer and its 
treatment, the screening and treatment of these cancer-related symptoms should be more 
stringent, as they might negatively influence each other.
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ABSTRACT
Fatigue is the most frequently occurring and distressing symptom in patients with advanced 
cancer, caused by multiple factors. Neither a specific histological diagnosis of malignancy 
nor type of anti-cancer treatment seem to be strongly related to fatigue, which support the 
idea that other factors may play a role. This study investigated to what extent the model of 
fatigue perpetuating factors that is known for cancer survivors was applicable for patients 
with advanced cancer. Patients on active treatment for various incurable cancers were asked to 
complete the Checklist Individual Strength, subscale fatigue severity and physical activity, the 
Acceptance scale of the Illness Cognition Questionnaire, the Hospital Anxiety and Depression 
Scale, the Fatigue Catastrophizing Scale, the Symptom Checklist subscale sleep, and the van 
Sonderen Social Support List-Discrepancies. The questionnaires were filled in by 137 patients. 
Inappropriate coping, fear of progression, fatigue catastrophizing, discrepancies in social 
support, depressive mood, self reported physical activity and sleeping problems were all related 
to fatigue severity in univariate analyses, of which the latter two were significant in a multi-
variate linear regression analysis. This study tested fatigue-perpetuating factors known to be 
of relevance in cancer survivors, for their relation with fatigue severity in palliative patients. 
We demonstrated that these factors were also relevant for patients on palliative treatment. On 
the basis of our results, we suggest clinicians confronted with palliative patients with serious 
fatigue to address sleeping problems and promote physical activity. In case of persistent fatigue 
personalized cognitive behavioral therapy can be considered.
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BACKGROUND
Fatigue is one of the most frequently occurring symptoms in patients with advanced, incurable 
cancer, with reported prevalence rates from 33% to 99% 1-11. Additionally, patients describe 
fatigue as one of the most distressing symptoms, with a profound effect on their daily quality of 
life 11,12. Fatigue in patients with advanced incurable cancer probably increases with subsequent 
treatment lines and the severity seems to be associated with some types of cancer and 
treatment-related symptoms 12-14. However, in another study, based on data of this group we 
did not find a relation between demographic and clinical characteristics such as tumor type or 
treatment modality and fatigue severity 14.
 In cancer survivors a distinction is made between the etiology of precipitating factors and 
fatigue-perpetuating factors 15. When cancer patients receive treatment, the disease itself 
and its treatment are considered to be fatigue-precipitating factors. But when treatment is 
finished, these factors are no longer present and other factors maintain the fatigue. In cancer 
survivors, there is evidence that fatigue is perpetuated by several behavioral and psychosocial 
factors 15. These factors are poor or inappropriate coping skills, a heightened fear of disease 
recurrence, dysfunctional fatigue-related cognitions, dysregulatory sleep-wake cycles, dys-
regulatory activity patterns, insufficient social support, and negative interactions. This model 
of perpetuating factors was used as the basis for cognitive behavioral therapy for post cancer 
fatigue, which was tested in a randomized controlled trial and proved to be successful 16,17. This 
individually tailored cognitive behavioral therapy intervention in survivors focuses, besides 
avoiding deconditioning, on elements such as coping with the consequences of having cancer, 
changing dysfunctional cognitions about fatigue, and restoring disturbed sleep-wake rhythm. 
After this successful trajectory in the curative setting, we wanted to investigate if such a model 
based on perpetuating factors of fatigue would also be applicable in the palliative setting.
 Until now, no effective strategies or interventions have been developed to reduce fatigue in 
patients with advanced incurable cancer 18. We even do not know which factors are relevant 
for fatigue in palliative cancer patients. In palliative patients the disease and treatment remain 
present over time, which is not the case in survivors. Nevertheless, we can learn from the 
existing knowledge about fatigue in cancer survivors. On the basis of the model of fatigue- 
perpetuating factors in cancer survivors, we explored if the aforementioned factors also 
contributed to fatigue severity in patients with advanced incurable cancer. The following 
rationales for each of these factors can be given.
Poor or inappropriate coping skills
From the curative setting, we know that poor or inappropriate coping skills can have a negative 
impact on quality of life and on the severity of fatigue 16,19. In contrast to the curative setting in 
which patients can remain occupied with the period of cancer treatment, which lays in the past, 
in the palliative setting, the cancer is a fact that will remain. We assume that poor or inappro-
priate coping with having cancer might be of influence on fatigue.
A heightened fear of disease progression
In the palliative phase, the disease will become progressive, as cure is not an option anymore. 
Brown and colleagues concluded in their review that general anxiety, not specific anxiety related 
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to cancer, was significantly correlated with fatigue in 33 of the 35 investigated studies in patients 
with cancer 20. Therefore, we wanted to explore the factor anxiety and a relation with fatigue in 
palliative patients.
Dysfunctional fatigue-related cognitions
Dysfunctional cognitions concerning fatigue appear to maintain fatigue in cancer survivors 16, 21. 
Patients experience a lack of control, feel helpless, or have catastrophic thoughts about their 
fatigue. We assume that these cognitions can also be relevant in palliative patients.
Sleeping Problems
It has been found that sleep-wake rhythm disorders are related to fatigue in patients with 
advanced cancer 22,23. Sleeping problems, such as insomnia, together with distress co-occur with 
fatigue and have been found to be highly prevalent in metastatic breast cancer patients 24.
Dysregulatory activity patterns
A relation between low physical activity and fatigue has been described in several studies in 
cancer patients, also with advanced disease 25,26. A pilot intervention study in patients with 
advanced cancer, solely aimed at increasing physical activity seemed promising in diminishing 
fatigue 26; although the findings were not confirmed in a randomized controlled trial 27. As 
there seems to be a relationship between fatigue and physical activity, we find it relevant to 
investigate its relation and possible contribution to fatigue.
Insufficient social support and interactions
From the curative setting, we have learned that some patients perceive a discrepancy between 
actual support and desired support and sometimes have unrealistic expectations of others. 
These perceptions perpetuate the fatigue 16. A study in 203 patients recently diagnosed with 
advanced cancer showed that social support was the most vital contributor to overall quality 
of life 28. The fact that fatigue has a negative impact on daily quality of life, underlines the 
importance of sufficient social support during this trajectory and legitimates taking this factor 
into account.
Depressive mood
Depressive mood is not a fatigue perpetuating factor in cancer survivors. But this may be 
different in palliative care. Several studies have described an association between fatigue and 
depression in patients with cancer during active treatment 20,22,29,30. Fatigue and depression 
(together with pain or insomnia) frequently co-occur in cancer patients 22,31,32. Therefore we 
wanted to add depressive mood to study its role in fatigue in the palliative phase.
To summarize, we investigated whether all of the seven aforementioned psychosocial factors 
are associated with fatigue in a group of cancer patients on active treatment in the pallia-
tive phase. We also investigated to what extent each factor plays a role and whether some 
factors are of greater or lesser importance in its contribution to fatigue. If the relationship with 
psychosocial factors can be confirmed this would be a basis to develop a fatigue intervention 
in palliative care.
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MATERIAL AND METHODS
Sample
Patients with advanced, incurable cancer from the department of Medical Oncology of a 
university and a regional hospital in the south eastern part of the Netherlands were asked 
to participate in this study in the period between December 2008 and June 2010. Potential 
eligible patients were preselected by the treating physician. Inclusion criteria were diagnosis 
of advanced, incurable cancer; able to receive palliative (symptom reducing or life prolonging) 
therapy; able to fill in and return Dutch questionnaires. Potential participants were approached 
by the investigator (MP). They were informed about the study by telephone, and additional 
written information was sent to them.   
 Participants from the University Medical Centre were offered the opportunity to complete the 
questionnaires using a computer at the outpatient clinic (in combination with a regular visit to the 
clinic) or a paper-and-pencil version at home. Patients from the regional hospital only received 
the paper-and-pencil version at home. The questionnaires that were sent to the patients’ home 
could be returned to the investigator by an enclosed return envelope. When a questionnaire 
was not returned, a maximum of two telephone calls were made by the investigator to complete 
the data. Although this study did not fall under the Medical Research Involving Human Subjects 
Act, we did obtain permission to conduct the study from the institutional review boards of both 
hospitals. All participants gave oral informed consent.
Instruments
General information on demographical characteristics, stage and type of cancer and current 
treatment were obtained from a general questionnaire and if necessary, supplemented with 
data from medical records. Fatigue severity was assessed using the subscale fatigue of the 
Checklist Individual Strength (CIS). This subscale consists of eight items, and each item is scored 
on a 7-point Likert scale. Higher scores indicate more severe fatigue. The range on the fatigue 
subscale is from 8 to 56. The validated cutoff score of 35 or higher was used to determine 
severe fatigue 33,34. This score of 35 is about two times the standard deviation above the mean 
score of healthy controls. The CIS is a well-validated instrument with excellent psychometric 
properties 35,36.
 Poor or inappropriate coping skills were measured by the subscale Acceptance of the Illness 
Cognition Questionnaire for chronic diseases. This subscale consists of six items on a 4-point 
scale from 1 (do not agree) to 4 (completely agree). (e.g. ‘I can handle the problems related to my 
illness’) 37. The Illness Cognition Questionnaire is a self-report instrument with three subscales 
(acceptance, helplessness, and perceived benefits). It has shown good reliability with Cronbach’s 
alpha coefficient range from 0.84 to 0.91 in patients with chronic diseases.
 As a proxy of heightened fear of disease progression the subscale anxiety of the Hospital 
Anxiety and Depression Scale (HADS) was used to measure the level of anxiety 38-40. This subscale 
consists of seven items with a 4-point Likert scale. The HADS is an extensively validated and used 
instrument. A score of 8 or more is used as the cut-off; the subscale anxiety has 78% sensitivity 
and 74% specificity for detecting clinical anxiety 41,42.
 Dysfunctional fatigue-related cognitions were measured with the Fatigue Catastrophizing 
Scale. This scale consists of ten items, measuring the relation of catastrophizing to fatigue on a 
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5-point scale from 1 (never true) to 5 (all of the time true) (e.g. ‘I imagine the fatigue becoming 
even more intense and exhausting’) 21,43. Higher scores are indicative for more fatigue catastro-
phizing. A total score is derived by computing the mean of 10 ratings (Cronbach’s alpha = .85).
 Sleeping problems were measured by the sleep subscale of the Symptom Checklist 44,45. This 
subscale consists of three items on a 5-point scale from 1 (not at all) to 5 (very much) and scores 
range from 3 to 15. Higher scores indicate lower quality of sleep. Patients were asked if they (a) 
slept well (b) had difficulty with falling asleep (c) woke up early in the morning, during the last 
month. This subscale is widely used and has a good reliability with a Cronbach’s alpha of 0.73.
 Level of physical activity was measured by the subscale physical activity of the CIS. This 
subscale consists of three items, and each item is scored on a 7-point Likert scale (e.g. ‘I get little 
done’). Higher scores are indicative for a lower level of physical activity 35,36,46. The Cronbach’s 
alpha for this subscale is 0.87 33.
 Insufficient social support and interactions were measured by the van Sonderen Social 
Support List- Discrepancies (SSL-D) 47,48. The subscale SSL-D consists of eight items on a 4-point 
scale and measures discrepancies between the amount of received social support and desired 
amount of social support (e.g. ’What is your opinion about the extent to which people: Stand 
by you?’. Scores for the SSL-D range from 8 to 32. Higher scores are indicative for a higher 
discrepancy. This instrument has a good reliability with a Cronbach’s alpha of 0.95 48.
 Depressive mood was measured with the subscale depression of the HADS 38,39. This subscale 
consists of seven items with a 4-point Likert scale. The HADS is a well validated instrument 49. 
When using a cut-off score of 8 or more, this subscale has 82% sensitivity and 74% specificity for 
detecting major depressive disorder 41,42.
Statistical methods
We analyzed our data using SPSS software version 20 (SPSS Inc, Chicago, IL, USA). For sample 
characteristics, descriptive statistics and frequencies were generated. To explore the association 
between fatigue severity and the seven psychosocial factors of fatigue, Pearson correlations 
were performed. To further explore the contribution of the different factors of fatigue to its 
severity, we performed a linear regression analysis, enter-method. For all analyses, a p value of 
< 0.05 was considered statistically significant.
RESULTS
Two-hundred patients with advanced cancer were approached for this study. One hundred and 
sixty-two patients agreed to participate. One hundred and thirty-seven patients (69%) filled in 
the questionnaires. Only three of them completed the questionnaires on the computer at the 
hospital, all others preferred the paper-and-pencil version at home. Non-participants (N = 63) 
did not differ from the participants with regard to gender, age and cancer diagnosis as has been 
reported elsewhere 14. Table 1 gives additional demographical and cancer-related information of 
the participants. This table shows that almost 30% of all participants were retired and that 20% 
still participated in regular labor. Another 10% was involved in voluntary work. The mean score 
of fatigue was 32 (13.2). Sixty-four of all participants (47%) were severely fatigued.
 The mean scores of seven psychosocial factors are shown in table 2. This table also shows that 
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Characteristics Participants n (%)
Participants 137
Female gender 84 (61)
Male gender 53 (39)
Mean Age, years (range) 59 (30 - 79)
  Female 58 (32 – 78)
  Male 61 (30 – 79)
Education Level
  Lower education (≤ 4) 89 (65)
  Higher education (>4) 48 (35)
Marital Status
  Married 111 (81)
  Single (unmarried, divorced, widowed) 26 (19)
Employment status
  Work outside home 27 (20)
  Voluntary work 14 (10)
  Disablement insurance act 25 (18)
  Partial disablement insurance act 6 (4)
  Sick leave 30 (22)
  Retired 39 (29)
Type of Cancer
  Breast 41 (30)
  Gastro-intestinal 41 (30)
  Urogenital 15 (11)
  Gynaecological 13 (9.5)
  Bone & Soft Tissue 13 (9.5)
  Other 14 (10)
Treatment Modalities
  Chemotherapy 72 (53)
  Oral Targeted therapy 21 (15)
  Hormonal therapy 20 (15)
  Chemo-Targeted therapy 19 (14)
  Radiotherapy 2 (1)
  Chemo-Radiotherapy 1 (1)
  No actual treatment 2 (1)
Treatment Line
  First-line 92 (67)
  Second-line 28 (20)
  Third-line 12 (9)
  Fourth-line 5 (4)
Table 1 Demographical  and cancer-related characteristics (n = 137)
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all seven psychosocial factors correlated significantly with fatigue severity. The linear regression 
(see table 3) shows that the seven investigated psychosocial factors together predicted 64% of 
the variance on fatigue severity. The factors sleeping problems and physical activity each had a 
significant contribution to fatigue (beta .244 and .676 respectively).
DISCUSSION
In this study, seven plausible psychosocial factors, identified by their effect on fatigue in cured 
cancer patients or by literature, were explored for their potential relationship with fatigue 
severity in patients with advanced incurable cancer. All seven factors correlated significantly 
with fatigue. A linear regression showed that fatigue severity was most strongly associated with 
sleeping problems and self-reported low physical activity. Six of the seven psychosocial factors 
were chosen as they were components of an effective fatigue intervention in cancer survivors 16. 
The current study demonstrated that such a model may be relevant for advanced cancer patients 
Factors Mean score
(SD)
Min Max Pearson 
correlation
p value
Poor or inappropriate coping skills
  Acceptance (ICQ) 17 (4.3) 7 24 -.309 <.001
Anxiety 
  Anxiety (HADS) 6 (4.3) 0 18 .359 <.001
Dysfunctional fatigue related cognitions
  Catastrophizing (FCS) 18 (17.3) 10 40 .433 <001
Sleeping problems 
  Sleep quality (SCL-90) 6 (2.9) 3 15 .356 <.001
Level of  physical activity 
  Physical activity (CIS) 13 (5.6) 3 21 .735 <.001
Insuffi  cient social support 
  Discrepancies (SSL-D) 9 (2.4) 8 24 .187 .030
Depressive mood
  Depression (HADS) 4 (3.6) 0 19 .455 <.001
Table 2 Mean scores and correlations between fatigue severity and seven psychosocial factors
All correlations are signifi cant  
SD = Standard deviation
ICQ = Illness Cognition Questionnaire
HADS = Hospital Anxiety and Depression Scale
FCS = Fatigue Catastrophizing Scale
SCL-90 = Symptom Checklist
CIS = Checklist Individual Strength
SSL_D = Van Sonderen Social Support List-Discrepancies
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too. However, some critical remarks should be made. Although we found significant relations, 
only two factors showed independent correlation by linear regression. This might be due to 
the instruments we used to operationalize the seven psychosocial factors. Some of them were 
more generic in nature and not always directly related to the experience of having advanced 
incurable cancer or experiencing fatigue. For example the factor anxiety: As a proxy we used the 
subscale anxiety of the HADS. This subscale measured anxiety as a mood disorder but gives no 
information on fear related to the disease which we intended to measure. To our knowledge, at 
that time there was no specific questionnaire available in Dutch to measure specifically anxiety 
for progression. Such a questionnaire which recently has been validated, would have probably 
been more suitable 50. Furthermore, we measured sleeping problems with the subscale sleep of 
the Symptom Checklist. Some studies have reported that an irregular sleep-wake cycle is related 
to fatigue 22-24. We did not take this into account.
 Fatigue catastrophizing had a borderline significance in the multivariate analyses. As over 
50% of our patients did not experience severe fatigue, this might have resulted in an under-
estimation here. Although in our group as a whole, not all factors contributed significantly to 
fatigue; they should not be precluded in advance in an individual patient. Clinical experience in 
cancer survivors showed us that at individual level, each factor can play a unique role. We have 
no reason to assume that this is different in the palliative phase.
Independent variables
Dependent variable: CIS-fatigue
95% Confi dence Interval for B
Beta Lower bound Upper bound P-value
Poor or inappropriate coping skills  
  Acceptance (ICQ) .073 -.265 .747 .347
Anxiety 
  Anxiety (HADS) -.026 -.646 .472 .759
Dysfunctional fatigue related 
cognitions
  Catastrophizing (FCS) .154 -.004 .577 .054
Sleeping problems
  Sleep quality (SCL-90) .244 .587 1.749 <.001
Level of physical activity  
  Physical activity (CIS) .676 1.285 1.900 <.001
Insuffi  cient social support 
  Discrepancies (SSL_D) -.050 -1.226 .493 .400
Depressive mood
  Depression (HADS) -.066 -.324 .831 .386
Table 3 Linear regression to predict fatigue severity
Adjusted R2 = 0.642
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 We explored seven factors in the current study, but this does not preclude other psychosocial 
factors from contributing to fatigue in patients with advanced cancer. Moreover, it is difficult 
to extrapolate our results to an individual patient. In severely fatigued cancer survivors, not 
all fatigue-perpetuating factors are present in each patient, and this may also be the case in 
fatigued patients with advanced cancer 16. Additionally the advanced cancer and its treatment 
cannot be ruled out as a precipitating factor combined with perpetuating factors for fatigue in 
this palliative setting.
 A limitation of our study is its cross-sectional design. In this study, we included patients at one 
time point, but at various moments in their palliative trajectory. Most participants in this study 
were at the beginning of the palliative phase, as 67% of them received first-line treatment. Also, 
the fact that 20% were still active in regular labor could be seen as an indication that our group 
of participants could be considered as a relatively fit group. In another study based on data of 
this group of patients we found a significant difference in fatigue severity between patients at 
first treatment line and patients at further treatment line 14. Also other studies reported that 
most cancer-related symptoms increase when the disease progresses, and a cumulative effect 
of several treatment lines cannot be precluded 13,51-53.
 This study is to our knowledge the first in which a specific model of perpetuating psychosocial 
factors of fatigue in cancer survivors was investigated for its applicability in the palliative phase. 
Although we did not test this model, our results confirmed the correlations of seven factors 
with fatigue severity in the patients with advanced incurable cancer. This study could therefore 
be considered a step forwards in getting more insight in the multifactorial symptom fatigue in 
the palliative phase and the development of an intervention. However, new studies, preferably 
longitudinal, are warranted to confirm our findings. Such an intervention should probably be 
individually tailored because at individual level, each factor may play a unique role such as in 
cured cancer patients. For now, for health care professionals in daily practice, it seems advisable 
to focus on sleeping problems and physical activity as options to reduce fatigue.
CONCLUSION
The main aim of this study was to explore the extent to which seven psychosocial factors 
contributed to fatigue and its severity. Though all investigated factors were significantly 
correlated to fatigue severity, only sleeping problems and low physical activity level contributed 
independently. Our finding that the investigated psychosocial factors together explained 
64% of the variance in fatigue severity, gives support to the suggestion that a model of 
fatigue-perpetuating factors is also relevant in the palliative setting. Such a model could lead 
to a starting point for developing a cognitive behaviorally oriented intervention for fatigue. 
Currently, in daily practice, health care professionals could focus on sleeping problems and 
physical activity as options to reduce fatigue, as they seem to be the most common and relevant 
aspects related to fatigue in patients with advanced cancer.
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ABSTRACT
Although fatigue is the most frequently occurring symptom in patients with cancer, hardly 
anything is known about fatigue of their informal caregivers and the impact fatigue might have 
on perceived burden with providing care. We investigated the presence of fatigue in caregivers, 
its course and the relation of fatigue severity between caregivers and patients. Furthermore, we 
explored in caregivers whether fatigue severity was correlated to experienced burden. Informal 
caregivers and patients on cancer treatment in the palliative phase completed questionnaires at 
baseline and follow-up (6 months later). To measure fatigue severity, both groups completed the 
Checklist Individual Strength. Additionally, caregivers completed the Caregivers Strain Index to 
assess experienced burden with providing care. Descriptive analyses, paired T-tests, Chi2 -tests, 
Pearson correlations and regression analysis were performed. At baseline 111 couples (patients 
and caregivers) participated, at follow-up 75 couples. At both time points 23% of caregivers 
was severely fatigued. There was no significant correlation between patients and caregivers on 
fatigue. Higher fatigue in both patients and caregivers was correlated with higher burden in 
caregivers and over 30% of burden could be explained by fatigue. Almost a quarter of caregivers 
of patients on active palliative treatment were severely fatigued, which figure remained stable 
over time. Fatigue in both patients and caregivers was related to caregivers’ burden. This obser-
vation should be taken into account with the growing demand on caregivers and the increase 
in cancer treatment options in the palliative setting.
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BACKGROUND
With all new treatment options available, the number of cancer patients treated with palliative 
intent has increased during the last decade 1-3. Also the duration of the palliative active treatment 
phase has increased significantly for quite a number of malignancies. In line with this observa-
tion, the number of informal caregivers who support these patients in their disease trajectory is 
augmenting and the duration of care giving is increasing. Together with the trend to discharge 
patients earlier and to give more treatment in an ambulatory setting, a more prominent role 
is given to the informal caregiver 4. This shift may influence the needs and problems of care-
givers. Several studies have reported a negative impact of care giving on quality of life and 
mental health in informal caregivers of cancer patients in the palliative phase 5-7. Williams and 
McCorkle stated in their review that caregivers in the palliative (and hospice and bereavement) 
phase are at an increased risk for physical and mental morbidity as a direct consequence of their 
care giving role 8. This is endorsed in daily practice were we are sometimes confronted with 
caregivers who are overwhelmed by their care giving tasks and therefore their well-being is a 
growing point of concern 9,10.
 Knowing the profound effect fatigue has on patients’ quality of life, fatigue may also have its 
impact on the quality of life of their informal caregivers. Fatigue in cancer patients is described 
as ‘a distressing, persistent, subjective sense of physical, emotional, and/or cognitive tiredness or 
exhaustion related to cancer or cancer treatment that is not proportional to recent activity and 
interferes with usual functioning’, as stated in the NCCN guideline Cancer–Related Fatigue. This 
definition gives evidence to the suggestion that fatigue in cancer patients is complex and multi-
dimensional and cancer and cancer treatment plays an eminent role. For caregivers the defini-
tion of fatigue in the Oxford dictionaries seems more applicable: ‘fatigue is an extreme tired-
ness resulting from mental or physical exertion or illness’. This definition suggests that fatigue in 
caregivers is also of a multidimensional concept. For caregivers of cancer patients it is very likely 
that their role in supporting and assisting the patient might influence their fatigue. As a conse-
quence this might also affect their experienced burden, together with their concerns regarding 
the situation of their patient 1. Studies on fatigue and its impact on caregivers of patients 
with advanced incurable cancer on active treatment in the palliative phase are scarce. In four 
published reports we could only retrieve some prospective research. Two pilot studies investi-
gated fatigue and experienced burden in caregivers of cancer patients admitted at a palliative 
care unit. One study in 56 couples found a high prevalence of fatigue in relatives of admitted 
cancer patients 11. Another pilot study in 25 partners of fatigued cancer patients with anemia 
found a relevant impact of the level of patients’ fatigue on experienced burden in caregivers 12. 
They also performed a one-month follow-up assessment and found that caregivers with higher 
fatigue levels at baseline reported higher levels of experienced burden. A significant relation 
between impact of care on the daily schedule of caregivers and fatigue has been described 
in another study 13. This study, in 248 caregivers of cancer patients in a homecare setting, was 
performed over 20 years ago and showed that the more burdensome the care giver’s schedule 
is, the greater their fatigue will be. One more recent study investigated fatigue in 131 caregivers 
of fatigued palliative patients receiving radiotherapy. This study was a secondary analysis of a 
randomized controlled trial to investigate the efficacy of an intervention to maintain the quality 
of life of patients with advanced cancer. In several intervention sessions the caregivers were 
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involved 14. Though they found relatively low and stable fatigue scores in caregivers over a 
six-month period, they reported that the greatest symptom burden of caregivers came from 
fatigue. In summary, these four studies support the suggestion that fatigue might affect the 
caregivers’ burden of patients during palliative treatment. However, in the last decade much has 
changed for cancer patients during palliative treatment. For many patients nowadays the pallia-
tive phase is not equal to the terminal phase, but a treatment phase, in which the intention is to 
prolong patients’ life and / or to relieve symptoms, turning advanced cancer to a chronic disease. 
This means that caregivers are struggling between the continuation of their former personal 
tasks and duties, and the care giving of their patients.
 As informal caregivers of cancer patients fulfill an important role during the palliative cancer 
treatment of the patients, we first wanted to investigate the prevalence and severity of fatigue in 
this group of patients and their informal caregivers and observe its course over time. Secondly, 
we studied the relation between fatigue of patients and their caregivers and thirdly we explored 
the relation between fatigue and experienced burden by caregivers. Further insight in fatigue 
of caregivers could lead to a better understanding of problems caregivers are facing. Ultimately, 
this could lead to the development of interventions or strategies to better support caregivers.
MATERIAL AND METHODS
The patient sample consisted of patients with advanced incurable solid tumors who visited the 
departments of Medical Oncology of the Radboud university medical center and of the Jeroen 
Bosch Hospital, a large regional hospital, both in the Netherlands, to receive anti-cancer treat-
ment, between December 2008 and June 2010. Inclusion criteria for patients were: diagnosis 
of advanced, incurable cancer; able to receive systemic therapy and able to fill in and return 
questionnaires. Patients who were about to start and who actually received palliative cancer 
treatment were eligible, regardless of the line of, or time on treatment in the palliative setting.
 Potential eligible patients were preselected by the treating physician (according to the 
eligibility criteria). Eligible patients were subsequently approached by the investigator (MP) 
and asked about their interest to participate. They were informed by telephone and addi-
tional written information was sent to them. After consenting, the participating patients were 
requested to identify their principal informal caregiver (i.e. partner or other close relative) poten-
tially willing to participate in this trial. The identified informal caregivers were approached by MP 
by telephone, asked to participate and were also sent written information. Both patients and 
informal caregivers twice received a paper-and-pencil version of the questionnaires at home, 
together with an enclosed return envelope. The interval of sending out these questionnaires 
was six months. When a questionnaire was not returned, a maximum of two telephone calls 
were made by MP to complete the data. Where a patient had died within the study period or no 
longer wanted to participate, their caregivers did not receive a follow-up questionnaire. Those 
who only participated at base line are called ‘group BLO’ and those who also participated at 
follow-up are called ‘group FU’ in this study. In the Netherlands, observational studies like this 
one, in which only questionnaires are used, do not fall under the Medical Research Involving 
Human Subjects Act. Nevertheless we requested and obtained permission to conduct the study 
by the institutional review boards of both hospitals. All participants gave oral informed consent.
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Instruments
General information on demographic data of all participants and for patients supplemented 
with information about stage, type of cancer and current treatment were obtained from a 
general questionnaire and if necessary, supplemented with data from medical records.
 The subscale fatigue of the Checklist Individual Strength (CIS) was used, both in patients 
and their caregivers, to assess fatigue severity. This subscale consists of eight items, and each 
item is scored on a 7-point Likert scale (i.e. ‘Physically I feel exhausted’). Higher scores indicate 
higher levels of fatigue 15-17. The range (low to high) for fatigue severity is 8 – 56. The validated 
cut-off score of 35 or higher was used to determine severe fatigue. This score of 35 is about 
two times the standard deviation (sd) above the mean score of healthy controls 18. The CIS is 
a well-validated instrument with excellent psychometric properties, Cronbach’s alpha for the 
fatigue subscale is 0.88 17,19.
 Caregivers’ burden was operationalized by using the Caregiver Strain Index (CSI). This is a 
questionnaire containing 13 statements of yes/no answers about strain experienced by care-
givers (i.e. ‘It is confining’). Scores range from 0 to 13 and a score of 7 or more positive items is 
indicative for high burden. The internal consistency of the scale is good (Cronbach’s α=.86) 20.
Statistical methods
To determine sample characteristics of patients and their caregivers, and the courses of fatigue, 
descriptive statistics and frequencies were generated. Paired sample t-tests were used to explore 
the differences between baseline and follow-up measurements. The non-parametric Chi2 was 
used to test for differences in percentages of severely fatigued patients and caregivers. Cases 
with only a baseline measurement were compared with cases with a baseline and follow-up 
measurement at six months.
 Pearson’s correlations were performed to test the associations between fatigue severity in 
patients and their caregivers, between fatigue severity in patients and the experienced burden 
in caregivers and also between fatigue severity in caregivers and their experienced burden. A 
linear regression analysis (enter-method) was performed to further explore the contribution of 
patients’ and caregivers’ fatigue to the burden experienced by caregivers. SPSS software (version 
20) was used to analyze our data (SPSS Inc, Chicago, IL. USA).
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RESULTS
Of the 142 potential patients with an identified caregiver, 131 couples (patient and their informal 
caregiver) agreed to participate (see study flow-chart in figure 1). At baseline 111 couples 
(85%) responded and at follow-up 75 couples (‘group FU’) still participated The percentage of 
questionnaires returned at follow-up was 68% of the initial participating group.
 In table 1 baseline characteristics of the patients and their informal caregivers are represented. It 
shows that the mean age in both groups was 60 years. Fifty-eight percent of the patients was female 
and 50% of the caregivers. In both groups 93% of patients were married and 89% of the caregivers 
were the partner of the patient. At baseline measurement 17% of the patients still worked outside 
the home, in the caregivers this was the case in 45%. In patients 22% was on sick leave which was 
also the case in 4% of the caregivers. Of the group of patients described here, more specific results 
of their own fatigue, cancer diagnosis and treatment have been published elsewhere21.
Fatigue in patients and caregivers
Table 2 shows the mean fatigue scores of all 111 patients and their caregivers at baseline, 
including the mean scores of the group FU and the group BLO. The mean scores of fatigue in 
patients varied from 32 to 35 of which the latter score is just at the cut-off score of severe fatigue. 
In caregivers the mean scores varied from 23 to 26. No significant correlations between patients’ 
Figure 1 Study fl owdiagram of patients and their caregivers
Patients: approached for study (n = 200) 
Patients: Agreed to participate (n=162)
Caregivers: approached for study (n = 142)
Patients and caregivers = Couples 
Agreed to participate (n = 131)
Couples: returned questionnaires baseline (n = 111) 
Couples: returned questionnaires follow-up ( n = 75)
     Withdrew (n = 1)
     Reason unknown (n = 16)
Declined to participate (n=38)
No main caregiver ( n = 20)
Declined to participate (n = 11)
No FU sent out:
  Withdrew (n = 4)
Died (n = 15)
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Characteristics Patients (n = %) Caregivers (n = %)
Participants 111 111
  Female gender 64 (58) 55 (50)
  Male gender 47 (42) 56 (50)
Mean Age, years (range) 60 (30 – 79) 60 (27 – 80)
  Age, females 58 (32 – 78) 61 (32 – 80)
  Age, males 61 (30 – 79) 59 (27 – 74)
Education Level
  Lower education (≤4) 72 (64) 73 (66)
  Higher education (>4) 39 (36) 38 (34)
Marital Status
  Married 103 (93) 103 (93)
  Single (unmarried, divorced,  widowed) 8   (7) 8 (7)
Relation to patient
  Partner 100 (89)
  Parent 1
  Son (in law) / daughter (in law) 6 (5)
  Other 4 (4)
Employment
  Work outside home 19 (17) 50 (45)
  Voluntary work 12 (11) 6 (5)
  Disablement insurance act 20 (18) 3 (3)
  Partial disablement insurance act 6 (5) 4 (4)
  Sick leave 24 (22) 4 (4)
  Retired 35 (32) 38 (34)
Kind of cancer
  Breast 29 (26)
  Gastrointestinal 34 (30)
  Urogenital 13 (12)
  Gynecologic 10 (9)
  Bone and soft tissue 11 (10)
  Other 14 (13)
Treatment modalities at start of study
  Chemotherapy 58 (52)
  Oral targeted therapy 20 (18)
  Hormonal therapy 13 (12)
  Chemo-antibodies therapy 15 (13)
  Radiotherapy 2 (2)
  Chemo-radiotherapy 1 (1)
  No actual treatment 2 (2)
Treatment line in palliative phase
  Just before fi rst line 2 (2)
  First-line 74 (66)
  Second-line 22 (20)
  Third-line 11 (10)
  Fourth-line 2 (2)
Table 1 Baseline characteristics of all patients and their caregivers
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and caregivers’ fatigue scores were found (table 3).
 Of all patients 45% suffered from severe fatigue at baseline. In the patient group FU, the 
percentages ‘severely fatigued’ varied from 39% at baseline to 41% at follow-up. In the group 
BLO the percentage ‘severely fatigued’ proved to be 58%, which difference was, compared with 
the group FU at baseline, close to significance (p = .069).
 Of all caregivers 24% was severely fatigued at baseline. In the group FU 23% was severely 
fatigued at baseline and 21% at follow-up. In the group BLO 28% was severely fatigued at 
baseline which difference was not statistically significant in comparison with the group FU at 
baseline (p = .235).
The influence of fatigue severity on burden experienced by caregivers
The mean score of the CSI in the baseline group of 111 informal caregivers was 3.1 (2.0). In the 
Caregivers Baseline fatigue Follow-up 
fatigue
Baseline strain Follow-up strain
Patients
Baseline fatigue .057 .334*
Follow-up 
fatigue
.162 .293**
Table 3 Pearson correlations with fatigue in patients and fatigue in caregivers and experienced burden 
 at baseline and follow-up (n = 75)
* = P-value < .05
** = P-value ≤ .001
Baseline Follow-up
Mean score
 (sd)
95% 
confi dence 
Interval
% severely 
fatigued (n)
Mean score
 (sd)
95% 
confi dence 
Interval
% severely 
fatigued (n)
All patients
(n = 111)
32 (12.9) 29,6 – 34,5 45 (50)
group BLO
(n = 36)
35 (12.0) 30,9 – 39,7 58 (21)
group FU
(n = 75)
31 (13.2) 27.5 – 33.7 29 (29) 32 (14.1) 28.3 – 34.8 41 (31)
All caregivers
(n=111)
24 (13.2) 21,6 – 26,6 24 (27)
group BLO
(n = 36)
26 (12.9) 21,9 – 30,6 28 (10)
group FU
(n = 75)
23 (13.1) 20,0 – 26,1 23 (17) 23 (13.5) 19.8 – 25.9 21 (16)
Table 2 Mean fatigue scores and percentages severe fatigue in patients and their caregivers
group BLO = Group baseLine only
group FO = Group follow-up
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group FU the mean CSI was 2.8 (1.9) at both time points (sd 1.9 and 2.1 respectively). In the 
group BLO the mean score was 3.8 (2.1) which was a significant difference with the baseline CSI 
of the group FU (p = .016).
 At baseline seven caregivers (6%) had a score of 7 or higher, which is indicative for high 
burden. Of the group FU two (3%) had a score of ≥ 7 at baseline and three (4%) at follow-up. In 
the group BLO 14% (5 /36) had a score of 7 or higher. The difference with high burden between 
the groups BLO and FU was significant (p = .028).
 A significant correlation was found between fatigue of patients and the experienced burden 
of the informal caregivers both at baseline and at follow-up as can be seen in table 3. A linear 
regression analysis with gender, age, treatment line of patient as covariates, showed that at 
Independent variables
Dependent variable: CIS – experienced burden
95% Confi dence Interval for B
Beta Lower bound Upper bound P-value
Fatigue in patients .260 .012 .069 .006
Fatigue in caregivers .461 .043 .096 .000
Age patients -.083 -.078 .041 .539
Age caregivers .079 -.038 .071 .552
Gender patients .143 -.837 2.000 .418
Gender caregivers .058 -1.259 1.723 .758
Treatment line patient
  First vs further lines .049 -.556 .979 .585
Table 4 Linear regression to predict experienced burden by caregivers – at baseline (n = 111)
Adjusted R2 = 0.325
Independent variables
Dependent variable: CIS – experienced burden
95% Confi dence Interval for B
Beta Lower bound Upper bound P-value
Fatigue in patients .210 -.002 .064 .067
Fatigue in caregivers .357 .018 .092 .004
Age patients -.322 -.147 .008 .076
Age caregivers .134 -.036 .090 .393
Gender patients .271 -.886 3.116 .269
Gender caregivers .342 -.663 3.457 .180
Table 5 Linear regression to predict experienced burden by caregivers – at follow-up (n = 75)
Adjusted R2 = 0.352
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baseline 33% and at follow–up 35% of the variation in caregivers’ strain could be explained by 
fatigue in both patient and caregivers (see table 4 and 5). At both time points fatigue of care-
givers and patients contributed significantly to the burden of the caregiver
DISCUSSION
In this unique longitudinal study of patients on anti-cancer treatment for incurable cancer we 
focused on the prevalence, course over time and impact on burden of fatigue in both informal 
caregivers and their patients.
 Though the mean fatigue scores of 23 - 26 in our group informal caregivers are well below 
the cut-off score of 35 for severe fatigue, the norm score of the used questionnaire is 19.9 (sd 
9.4) for healthy controls. Therefore we can conclude that the level of fatigue in the informal 
caregivers in this study was raised 19,22. This is in line with a study in care giving elderly with a 
spouse suffering from Alzheimer’s disease, Parkinson’s disease or cancer, which reported more 
fatigue in the group of caregivers compared with age-related non-care giving controls 23. The 
researchers of this study suggested that fatigue might be related to the informal caregiver role, 
possibly combined with their own personal and professional role. However our finding is not 
in concordance with the study of Clark et al who found strikingly low fatigue scores in informal 
caregivers of cancer patients 14. This could be explained by a different group of patients and 
informal caregivers studies, as they included only fatigued patients which was not the case in 
our study.
 About fatigue over time we found that fatigue scores at both time points were stable. This 
seems to be in line with another study in caregivers where stable levels on quality of life over 
time were found 24. The authors of this study suggested that with a stable condition of the 
patient during a longer period their caregivers adjust to their role. Probably our patients sample 
also consisted of patients with a stable stage of cancer. This is supported by the percentages of 
severe fatigue we found. In all participating patients, 45% was severely fatigued at baseline, and 
in the group FU, the percentage was 39%. In the group BLO this percentage was 58%. Knowing 
that most patients withdrew because of deterioration of their health status, higher fatigue levels 
at baseline seems in line with that suggestion. Also the informal caregivers of those deterio-
rating patients could not have been approached during the episode of deterioration. Another 
study design should provide a more specific insight in the mechanism of change over time in 
perceived fatigue of the cancer patient and his informal caregiver at the pivotal events during 
treatment and development of this illness.
 We found no significant relation between fatigue severity of caregivers and fatigue severity of 
patients, neither at baseline nor at follow-up. With the knowledge that fatigue has a profound 
impact on quality of life and the suggestion that quality of life of a patient is likely to influence 
the experience of the caregiver 25, we had expected to find some relationship. Possibly so many 
factors may influence the perceived fatigue in patient and their caregiver independently so that 
a potential relationship could not be determined. Interestingly we found that fatigue of both 
patients and caregivers correlated significantly with the experienced burden by caregivers, 
which was also described in a pilot study of spouses of fatigued cancer patients 12. Although 
they also found a relation with fatigue and experienced burden, our mean scores on the CSI 
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(from 2.8 to 3.8) were lower compared to their group of 25 couples with scores of 4.8 at baseline 
and 3.9 at one month follow-up 12. This difference could be explained by the fact that patients 
in the study of Passik and Kirsh suffered from chemotherapy-induced fatigue and anemia which 
might be of influence on their caregivers. In our group of patients, which is a subgroup of a 
larger cohort of 137 patients, only 6 patients were anemic at baseline assessment 21.
Although this study is to our knowledge the first in which the course of fatigue was longitu-
dinally observed both in patients on active anti-cancer treatment and their caregivers, it has 
some limitations. Patients and their caregivers were followed during six months, a period in 
which patients were actively treated for advanced cancer. The patients who are still on active 
treatment at follow-up might be part of a relatively fit group, who probably benefitted most 
from their treatment. Of the patients who were lost to follow up, 14% had died during the 
study period and another 5% did not want to participate any further. Unfortunately we have 
no further data of caregivers of those who had withdrawn. This would probably have given us 
some interesting findings as these patients might had progressive disease or were closer to the 
terminal phase at study entry. The fact that both patients and caregivers who only participated 
at baseline had higher fatigue levels and these caregivers experienced higher burden supports 
this suggestion. We have also assumed that our caregivers were ‘healthy controls’. Unfortunately 
we have no information on their health status. In a further study on fatigue and experienced 
burden by caregivers, this should be taken into account.
 Another limitation lies in the procedure of selecting patients. Patients were preselected 
by their physician and therefore some selection-bias might have occurred. As except for two 
patients, all other patients were somewhere within their treatment trajectory, varying from 
1st to 4th treatment line it is possible that a physician postponed the moment of introducing 
the study, based on patients’ actual situation. The fact that our patients were at various points 
during their treatment phase in the palliative trajectory, makes it on one hand difficult to gener-
alize our results to all patients in the palliative phase. On the other hand this reflects the day to 
day broad spectrum of patients oncologists are faced with.
 In conclusion, this study is a contribution to further knowledge and insight into problems 
informal caregivers are facing in their role. The fact that almost a quarter of the caregivers was 
severely fatigued, legitimates attention from all health care professionals towards this symptom. 
As fatigue contributed more than 30% to the caregivers’ experienced strain, we can cautiously 
conclude that, besides fatigue, other factors are also likely to be involved. Therefore other 
studies are warranted to expand insight and knowledge about factors involved in fatigue and 
caregivers burden. With the growing pressure on caregivers, and the increasing number and 
duration of medical treatment options in the palliative phase, insight into the specific needs of 
caregivers in this situation is needed to support them optimally in the daily home setting.
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ABSTRACT
Fatigue is a frequently reported symptom by patients with advanced cancer, but hardly any 
prospective information is available about fatigue while on treatment in the palliative setting. 
In a previous cross-sectional study we found several factors contributing to fatigue in these 
patients. In this study we investigated the course of fatigue over time and if psychosocial factors 
contributed to fatigue over time. Patients on cancer treatment for incurable solid tumors were 
observed during six months. Patients filled in the Checklist Individual Strength monthly to 
measure the course of fatigue. Baseline questionnaires were used to measure: disease accep-
tance, anxiety, depressive mood, fatigue catastrophizing, sleeping problems, discrepancies 
in social support, and self-reported physical activity for their relation with fatigue over time. 
At baseline 137 patients and after six months 89 patients participated. The mean duration of 
participation was 4.9 months. At most time points fatigue scores differed significantly between 
the group drop-outs and the group participating six months (completers). Overall fatigue 
levels remained stable over time for the majority of participants. In the completers 42% never 
experienced severe fatigue, 29% persisted being severely fatigued and others had either 
an increasing or decreasing level. Of the investigated factors low reported physical activity 
and non-acceptance of cancer contributed significantly to fatigue. A substantial number of 
participants never experienced severe fatigue and fatigue levels remained stable over time. For 
those who do experience severe fatigue non-acceptance of having incurable cancer and low 
self-reported physical activity are probably fatigue perpetuating factors.
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INTRODUCTION
The main aim of cancer treatment in patients with advanced incurable cancer is prolonging 
patients’ life while ideally maintaining patients’ quality of life. Patients with advanced cancer 
described fatigue to be their most distressing symptom limiting their quality of life 1,2. Although 
the knowledge of prevalence of fatigue, its course and related factors in cancer survivors is 
extensive 3-6 the literature in patients with advanced cancer is scarce and prospective research in 
patients on active palliative cancer treatment is even more limited.
 With all new treatment options nowadays, the palliative phase for patients with advanced 
cancer can last for years 7-9 and has been compared with a chronic illness 10. When we are able to 
prolong patients’ life for years in the palliative phase, attention towards fatigue in this trajectory 
is relevant. In patients with advanced cancer prevalence rates of fatigue of 33 – 90% have been 
reported 11-14. Some researchers have suggested that fatigue will increase when a patient moves 
further in his palliative trajectory, in particular when being on active treatment 14-16. Regrettably, 
most studies in patients within the palliative trajectory, pooled data of patients at different 
phases of their disease trajectory up to the final, terminal phase 14-16. Also the majority of studies 
that report on fatigue in patients receiving palliative chemotherapy had not been designed to 
investigate fatigue as a primary research question. Some studies investigated fatigue in patients 
with advanced cancer when admitted to a palliative care unit or hospital for serious health 
deterio ration 13,17-20. These patients were mostly at a late palliative stage, or terminal phase and 
did not receive anti-cancer treatment. In an observational study aimed at fatigue during anti-
cancer therapy in 99 patients with different stages of disease, fatigue levels remained stable over 
two months 21. We reported in a cross-sectional study severe fatigue in 47% of palliative patients 
on anticancer treatment, with higher fatigue scores in patients who were receiving further lines 
of treatment 22. A longitudinal study is needed to determine whether fatigue increases during 
palliative cancer treatment.
 In cancer survivors a model was developed to explain persistent severe fatigue not related 
to somatic factors 23 and additional a successful therapy, based on this model was developed 
24,25. In the above mentioned cross-sectional study in patients with advanced cancer we found 
several non-somatic factors related to fatigue similar to those in cancer survivors 26. The psycho-
social factors: non acceptance of having advanced cancer, anxiety, depressive mood, fatigue 
catastrophizing cognitions towards fatigue, sleeping problems, discrepancy in (expected and 
experienced) social support and low perceived physical activity were all related to fatigue. In the 
current longitudinal study we wanted to investigate these factors prospectively for their contri-
bution to fatigue over time in advanced cancer patients while on treatment. Our hypothesis was 
that the same psychosocial factors are related to fatigue over time and contribute to fatigue 
over time independently.
 Exploring the factors related to the course of fatigue prospectively might bring us a step 
forward to the development of a treatment model, on which interventions for fatigue can be 
developed also in the palliative phase of cancer treatment.
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PATIENTS AND METHODS
Between December 2008 and June 2010, patients on or about to start with treatment for 
advanced, incurable cancer from the departments of Medical Oncology of a university and a 
regional hospital in the south eastern part of the Netherlands were asked to participate in this 
study. Physicians preselected potentially eligible patients based on the following inclusion criteria: 
diagnosis of advanced, incurable cancer; able to receive palliative (symptom reducing and/or life 
prolonging) cancer treatment; able to fill in and return questionnaires in Dutch. The main investi-
gator (MP) approached potential participants by telephone. She informed them about the study 
and additional written information was sent to those who were interested in the study.
 Participants from the university medical center had the opportunity to either complete 
the baseline questionnaires using a computer at the outpatient clinic (in combination with a 
regular visit to the clinic) or fill in a paper-and-pencil version at home. Patients from the regional 
hospital all received the paper-and-pencil version at home. After the baseline investigation, the 
fatigue questionnaire Checklist Individual Strength was sent every month for six months. Six 
month after inclusion a final set of follow-up questionnaires were sent. A maximum of two tele-
phone calls were made by the investigator to complete the baseline and follow-up data . For the 
monthly sent out fatigue questionnaires, no additional attempts were made to complete these. 
Permission to conduct the study was obtained from both institutional review boards of the 
participating hospitals, although this study did not fall under the Medical Research Involving 
Human Subjects Act. All participants provided verbal consent.
Instruments
General information on demographical characteristics, stage and type of cancer and current 
treatment was obtained from a general questionnaire, eventually supplemented with data 
from medical records. Fatigue severity was assessed with the subscale fatigue of the Checklist 
Individual Strength (CIS). This subscale consists of eight items asking for fatigue severity over 
the last two weeks; each item is scored on a 7-point Likert scale; range is from 8 to 56; higher 
scores indicate more severe fatigue. The validated cut-off score of 35 or higher was used to 
determine severe fatigue 27,28. This score of 35 is about two times the standard deviation (sd) 
above the mean score of healthy controls. The subscale physical activity, consisting of three 
items on a 7-point Likert scale was used to measure self-reported physical activity. Higher scores 
are indicative for lower self-reported physical activity 29,30. The CIS is a well-validated instrument 
with excellent psychometric properties 27,29,30.
 Inappropriate coping with disease was measured with the subscale Acceptance of the Illness 
Cognition Questionnaire for chronic diseases (ICQ). This subscale measures the degree of 
acceptance of having cancer and consists of six items on a 4-point scale from 1 (do not agree) to 
4 (completely agree) 31. It has shown good reliability with Cronbach’s alpha coefficients ranging 
from 0.84 to 0.91 in patients with chronic diseases 32.
 Anxiety was measured with subscale anxiety of the Hospital Anxiety and Depression Scale 
(HADS) 33-35. To assess depressive mood the subscale depression of the HADS was used 33,34. Both 
subscales consist of seven items on a 4-point Likert scale. The HADS is an extensively used and 
validated instrument 36.
 Fatigue catastrophizing was measured by the Fatigue Catastrophizing Scale (FCS), consisting 
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of ten items on a 5-point scale from 1 (never true) to 5 (all of the time true) 37,38. Higher scores 
are indicative for more fatigue catastrophizing. A total score is derived by computing the mean 
of ten ratings. This subscale has a good reliability with a Cronbach’s alpha of 0.85 37.
 Sleeping problems were measured by the sleep subscale of the Symptom Checklist (SCL-90) 39, 
consisting of three items on a 5-point scale from 1 (not at all) to 5 (very much). Higher scores 
indicate lower quality of sleep. Patients were asked if they, during the last month a) slept well 
b) had difficulty with falling asleep c) woke up early in the morning. This subscale has a good 
reliability with a Cronbach’s alpha of 0.73 39.
 Discrepancy between the received and desired amount of social support was measured by 
the van Sonderen Social Support List- Discrepancies (SSL-D) 40, consisting of eight items on a 
4-point scale. Scores for the SSL-D range from 8 to 32. Higher scores are indicative for a higher 
discrepancy. This instrument has a good reliability with a Cronbach’s alpha of 0.95 41.
Statistical methods
Descriptive statistics and frequencies were generated to determine the sample characteristics 
and the course of fatigue. To give insight into the course of fatigue, we also differentiated 
between a group who dropped out (group DO) and a group that still participated at six-months 
(completers). The non-parametric Mann-Whitney test was used to investigate differences in 
fatigue scores between the groups DO and completers. A linear regression analysis (enter-
method) was performed to assess the contribution of psychosocial factors at baseline to fatigue 
over time. SPSS software (version 20) was used to analyze our data (SPSS Inc, Chicago, IL. USA).
RESULTS
Two hundred patients with advanced cancer receiving treatment were approached for this 
study. One hundred and sixty-two patients agreed to participate and 137 of them (69%) filled 
in the baseline questionnaires. Non-participants (n=63) did not differ from the participants with 
regard to sex, age and cancer diagnosis as has been reported elsewhere 22.
 Figure 1 shows the number of participants at the different time points. The mean duration of 
follow-up for all participants (AP) in the study, including drop outs, was 4.9 months. During the 
whole period of six months participated 89 patients (completers), the remaining 48 patients 
were considered as the group DO and they participated for a mean period of 2.7 months (range 
1 – 5 months). Twelve of them only filled in the baseline measurements. Reasons for drop-out 
were: no longer being able to fill in questionnaires (n = 7), died during the study (n=20) and 
not wanting to participate anymore (n=4). Of 17 patients there is no reason for drop-out. 
Demographic, cancer- and treatment-related characteristics of all participants at baseline are 
shown in table 1.
The mean fatigue scores and percentages severely fatigued patients at the different time points 
of AP, of the group DO and the group FU patients are shown in table 2. The mean fatigue scores 
in all three groups remained stable over time. At time points T1, T2, T3 and T4 the mean fatigue 
scores between the groups DO and the completers, differed significantly. Also the percentage 
severely fatigued remained quite stable over time within the group AP. The group DO showed 
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an increase in percentages severely fatigued patients during the first two months, and the 
completers showed the opposite. After the third month the percentage severely fatigued stabi-
lized in both sub groups.
 In the completers 42% (37/89) never experienced severe fatigue and 29% (26/89) experienced 
severe fatigue at all time points. Thirteen patients became severely fatigued (15%) and in twelve 
patients (14%) it decreased in the six months follow-up from severe to not severely fatigued. 
The linear regression analysis within the completers showed that 51% of the variance on fatigue 
severity could be explained by the psychosocial factors, of which the factors non-acceptance 
of having cancer and self-reported physical activity contributed significantly to the severity of 
fatigue over the six month period (see table 3).
Figure 1 Flowchart participants
200 patients were approached
162 patients agreed to participate 
Baseline T0: 137 patients returned the questionnaires
At 1 month: T1: returned n = 116 (CIS)
At 2 months: T2: returned n = 119 (CIS)
At 3 months: T3: returned n = 108 (CIS)
At 4 months: T4: returned n = 103 (CIS)
At 5 months: T5: returned n = 103 (CIS)
At 6 months T6: returned n = 89
(CIS & Follow-up questionnaires)
38 refused to participate 
25 did not return the questionnaires 
Questionnaire sent n =137
Questionnaire sent n = 132
Questionnaire sent n = 127
Questionnaire sent n = 121
Questionnaire sent n = 115
Questionnaires sent n = 106
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Characteristics Participants 
n (%)
Participants 137
Female gender 84 (61)
Male gender 53 (39)
Mean Age, years (range) 59 (30 - 79)
Marital Status
  Married 111 (81)
  Single (unmarried, divorced, widowed) 26 (19)
Type of Cancer
  Breast 41 (30)
  Gastro-intestinal 41 (30)
  Urogenital 5 (11)
  Gynaecological 13 (9.5)
  Bone & Soft Tissue 13 (9.5)
  Other 14 (10)
Treatment Modalities
  Chemotherapy 72 (53)
  Oral Targeted therapy 21 (15)
  Hormonal therapy 20 (15)
  Chemo-Targeted therapy 19 (14)
  Radiotherapy 2 (1)
  Chemo-Radiotherapy 1 (1)
  No actual treatment* 2 (1)
Treatment Line 
  First-line 92 (67)
  Second-line 28 (20)
  Third-line 12 (9)
  Fourth-line 5 (4)
Table 1 Baseline demographical, cancer- and treatment related characteristics
* Two patients were about to start with their fi rst-line treatment.
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All participants
n = 137
Group drop-out
n = 48
Completers
n = 89
Diﬀ erences in 
mean fatigue 
scores
Group DO and 
completers
P-value
Mean 
fatigue 
(sd)
Severe 
fatigue
% (n /N)
Mean 
fatigue 
(sd)
Severe 
fatigue
% (n /N)
Mean 
fatigue 
(sd)
Severe 
fatigue
% (n/N)
Baseline / T0 32 (13.2) 47 (64/136) 35 (13.1) 54 (26/48) 31 (13.1) 43 (38/89) .187
T1 32 (12.9) 46 (53/116) 38 (11.7) 67 (20/30) 30 (12.8) 38 (33/86) .007
T2 32 (12.8) 40 (48/119) 38 (12.9) 59 (19/32) 29 (11.9) 33 (29/87) .001
T3 32 (13.8) 45 (49/108) 38 (14.2) 57 (12/21) 31 (13.4) 43 (37/84) .045
T4 31 (13.9) 44 (45/103) 39 (13.6) 58 (11/19) 30 (13.1) 41 (34/84) .017
T5 31 (13.8) 44 (45/103) 38 (13.0) 50 (7/14) 31 (13.4) 43 (38/89) .082
T6 32 (13.9) 44 (39/89) 32 (13.9) 44 (39/89)
Table 2 Mean fatigue scores and percentages severe fatigue during six months
Dependent variable:
mean CIS fatigue of all follow-up assessments
95% CI for B
Independent variables at baseline Beta Lower bound Upper bound P value
Acceptance (n=89) -.263 -1.366 -.045 .037
Catastrophizing (n=87) .049 -.322 .474 .704
Depressive mood (n=86) .204 -.169 1.635 .110
Anxiety (n=86) -.672 -.998 .495 .504
Sleep quality (n=79) -.009 -.870 .800 .933
Discrepancies social support (n-89) -.079 -1.702 .739 .434
Self- reported physical activity (n=88) .504 .580 1.406 .000
Table 3 Linear regression to predict fatigue severity over six months follow-up
R2 = 0.514
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DISCUSSION
In this study we investigated the course of fatigue over a period of six months in patients with 
advanced cancer receiving palliative cancer treatment. Additionally, we prospectively explored 
which psychosocial factors contributed to the severity of fatigue over this period. To our know-
ledge this is the first study in which the severity of fatigue is longitudinally observed in cancer 
patients on active treatment in the palliative phase.
 Patients who were able to participate during the total period of six months 42% were not 
severely fatigued and did not become so during this period. About a quarter of these patients 
was severely fatigued and remained severely fatigued. In 15% a decrease from severe fatigue to 
non-severe fatigue occurred and in 12% of patients fatigue level increased from non-severe to 
severe fatigue. Interestingly, in two thirds of the patients the fatigue level did not change during 
the course of the study and the mean score was rather stable for the whole group participants 
during the 6 months period. However, patients who dropped out somewhere during the study 
often had a significant higher fatigue level at the various time-points compared to the patients 
who remained in the study.
 Although fatigue is the most often reported symptom in patients with incurable cancer, 13,15,17 
we demonstrated for the first time that not every patient suffers from severe fatigue. In the 
group of patients who remained in the study the percentage severely fatigued patients was 
lower compared with patients who dropped out. This might suggest that the patients who still 
participated after six months are part of a relative fit group. This suggestion is supported by the 
finding of higher fatigue scores at baseline in the group who dropped out, and by the finding 
that the main reason for drop-out was deterioration of the health status or death. Moreover, 
the percentage of patients that changed levels of fatigue severity in the group that continued 
follow-up was rather low (29%), suggesting that several factors perpetuate the fatigue during 
this observation period of six months.
 Two of the investigated fatigue-perpetuating factors were related to the course of fatigue (the 
mean fatigue score during the follow-up period), namely a low level of self-reported physical 
activity and difficulties in acceptance of having incurable cancer. This implicates that influencing 
and addressing these factors might reduce fatigue and may have an improvement on the 
quality of life in these patients. A few studies already addressed the issue of physical activity and 
focused on exercise training to tackle fatigue but did not reach clinically relevant reductions in 
fatigue 42. Other studies had small samples and mainly investigated the feasibility of exercise 
programs in patients in the palliative phase 43-45. It is important to remark that in our study we did 
not measure actual physical activity, for example by actimetry, but assessed the self-reported 
level of physical activity.
 To reflect on the difficulties of acceptance of having incurable cancer relating to fatigue, we 
only found in literature that acceptance of having incurable cancer can be a specific factor for 
palliative patients. It has been described as a psychological process that evolves throughout the 
course of a disease trajectory 46. To our awareness, however, this is the first study that found a 
relation with problems of acceptance with having incurable cancer and fatigue.
 For five other postulated perpetuating factors we could not prove a relation with the course of 
fatigue in the palliative phase. There might be two reasons why we did not find such a relation. 
First, it could be explained by individual differences in relevance of these factors, an observation 
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which has also been made in fatigue in cancer survivors 25,26. Second, it could be that we inves-
tigated the wrong factors. This would mean that other factors than postulated in our study may 
contribute to the course of fatigue. It is however, difficult to state which factors we could have 
missed because literature on this topic is very scarce.
 There are several limitations to be acknowledged. Although all participants had advanced 
cancer at baseline, the patients were not at the same point in their disease trajectory. At baseline 
two patients were just about to start with their first line treatment, while all others participants 
were somewhere within their disease trajectory varying from 1st to 4th treatment line. Regrettably, 
we have no information, whether patients still received treatment at six months follow-up and 
if so, the kind of treatment or treatment-line they were receiving at the final assessment, nor the 
effect on oncologic parameters.
 Another limitation might be the questionnaires we used. We used the subscale anxiety of the 
HADS as a proxy for heightened fear of disease progression. We wanted to get more insight into 
fear related to having an incurable disease. At the time of study such a validated questionnaire 
was not available in Dutch. Recently such a questionnaire, the ‘fear of progression questionnaire’ 
has been validated and this one could have been more suitable 47.
 To summarize, an important conclusion from this study is that not all patients who continue 
active treatment within the palliative trajectory suffer from severe fatigue and only a minority 
change fatigue level over time. For those who do experience severe fatigue, non-acceptance of 
having incurable cancer and low perceived physical activity seem to be fatigue-perpetuating 
factors. Fatigue interventions might therefore be directed at helping palliative patients to 
accept the cancer and improving their level of (subjective) physical activity.
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SUMMARY
In this final chapter a summary of the main findings of the studies are presented and additionally 
they are discussed in a wider, more practical perspective and recommendations for future 
research directions are suggested.
In Chapter 1 a general introduction to the problem of fatigue in patients with cancer is given. 
The current situation is that cancer related fatigue (CRF) is one of the most common symptoms in 
patients with cancer. Unfortunately, in daily practice in the Netherlands fatigue is still unrecognized 
and underreported. Chapter 2 presents an overview about CRF at all stages of cancer. CRF is 
a complex and multidimensional phenomenon in which many potentially contributing factors 
are involved, like tumor- and treatment-related factors and complications, comorbid condi-
tions, psychological and behavioral factors. There is some evidence for effective management of 
CRF at several stages within the disease trajectory, which can roughly be divided into pharma-
cological and non-pharmacological treatment options. Unfortunately in daily practice barriers 
exist for structural effective management of CRF. Barriers exist on sides of the physician and the 
patient: a physician might feel uncomfortable discussing fatigue due to a lack of awareness, an 
under estimating of the severity of CRF and its impact on the patients’ quality of life, and a lack of 
knowledge of management strategies. A time constraint during a consultation might be another 
barrier. On the other side, patients may avoid mentioning CRF because either they consider it 
unavoidable and do not want to complain, or they might think that it could mean that the cancer 
has recurred or progressed. Not mentioning fatigue by patients makes it difficult for physicians to 
recognize the problem. In this chapter an algorithm is presented which could be of help in daily 
practice. It actually guides the healthcare professional through the different stages of screening, 
diagnosis and treatment of CRF and aims to improve its management.
 While in chapter 2 CRF in all stages is paramount, Chapter 3 focuses specifically on the current 
knowledge of fatigue in patients during the palliative phase. Of all patients with cancer around 
40% of them are, either from diagnosis or at a later stage, confronted with incurable cancer. In 
literature prevalence rates of fatigue in the palliative phase ranges from 33 to 99%. This wide 
range can be explained by the use of different questionnaires, by the variety of actual palliative 
treatments and by the phase of the disease. In most research on patients during the palliative 
phase, data of various phases up till the final terminal phase, is pooled together. However, nowa-
days palliative treatment doesn’t necessarily mean support in the terminal phase only. Palliative 
treatment either aims on life prolongation or maintaining quality of life. At the present time there 
are various standard therapies to prolong life for patients in the palliative phase such as chemo-
therapy, hormonal therapy, radiotherapy, immune- and targeted therapy, given as a single-
agent or in different combinations. Due to these new treatment options the life expectancy of 
patients in the palliative phase has increased and probably will further increase. Therefore the 
term chronic phase of cancer seems to be more in place. Maintaining quality of life has been 
investigated less extensively, nevertheless experience based guidelines on supportive care in 
the palliative phase have been published. Fatigue has been shown the most constant single 
symptom with a major negative impact on quality of life. According to the Dutch guideline in 
palliative care: ‘practice guidelines - fatigue in cancer patients’ (2010), the current treatment 
strategies for fatigue in palliative patients consist of the following interventions; education; 
integral treatment of fatigue-related problems; treating tumor- and treatment related factors, 
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support with non-pharmacological interventions (www.oncoline.nl). This diversity of options 
makes clear that there is no consensus or one transcending intervention or strategy to alleviate 
fatigue specifically. As fatigue has impairing effects on patients’ daily functioning it is a short 
step to realize that fatigue might also have impact on their informal caregivers. In conclusion, 
we can say that in daily practice we have to deal with a field of tension in patients with incurable 
cancer with all options to prolong their life and potentialities to palliate concomitant symptoms, 
like fatigue. Additional knowledge and insight into fatigue during palliative cancer treatment is 
requisite in order to have a basis on which effective strategies or interventions can be developed 
to support patients and their caregivers in managing fatigue.
 To get more insight and knowledge about fatigue, its severity and course over time in 
patients with incurable cancer while on cancer treatment, we performed a study in patients 
with incurable solid tumors. Patients could participate if they were aged 18 years or older, were 
about to start or were actually receiving anti-cancer therapy with life-prolonging intent. The 
potential participating patients were requested to identify their principal informal caregiver for 
participating too.
 In Chapter 4 the results of an exploratory analysis on the cross-sectional baseline data of 
this study are reported. We found that severe fatigue occurred in 64 of the 137 participating 
patients (47%). Zooming in on the current treatment line we found a higher percentage severely 
fatigued patients while on further treatment line (2nd – 4th) compared with patients on first 
treatment line which difference was significant. We found no differences in fatigue severity 
between different kind of cancers nor between the various treatment modalities. Initially we 
found significant differences in fatigue severity between men and women. When we excluded 
the groups with only women involved (breast and gynecologic cancers) from the data, there was 
no significant difference between gender anymore. Furthermore we found that patients with 
severe fatigue also experienced significantly more other cancer related symptoms: dyspnea, 
pain, appetite loss, nausea and vomiting, and constipation.
 A next step was to investigate these cross sectional data for probable fatigue contributing 
factors. Therefore in Chapter 5 we used the model of precipitating and perpetuating factors of 
fatigue, known from cancer survivors. We wanted to investigate the applicability of this model 
to the palliative setting, but there are some substantial differences between those two settings. 
First, in the palliative phase, the cancer itself and its treatment remain present over time and their 
impacts on fatigue cannot be ruled out. Considering the perpetuating psychosocial factors of 
the curative setting we adapted them for the palliative phase into: poor or inappropriate coping 
skills towards having a chronic illness; a heightened fear of disease progression; dysfunctional 
fatigue-related cognitions; sleeping problems; dysregulatory activity patterns; discrepancy 
in (expected and experienced) social support. Based on literature we also analyzed whether 
depressive mood was a contributing factor. So in conclusion, seven psycho-social factors were 
investigated for their probable fatigue contributing role in patients on cancer treatment in 
the palliative phase. We found that all seven investigated factors were significantly correlated 
with fatigue. A linear regression analysis showed that these seven factors predicted 64% of 
the variance of fatigue severity. The factors ‘level of physical activity’ and ‘sleeping problems’ 
contributed significantly and ‘dysfunctional fatigue related cognitions’ was close to significance. 
This finding supports the suggestion that psychosocial factors do play an eminent role in fatigue 
and are relevant for developing an intervention or strategy for fatigue in the group patients with 
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incurable cancer receiving cancer treatment .
 As stated in the general introduction palliative care aims to improve quality of life both of 
patients and their families. Therefore the experience of informal caregivers should concern 
healthcare professionals who take care of patients with incurable cancer. The limited existing 
literature showed us that as a direct consequence of giving care to a relative during the palliative 
stage and beyond (hospice and bereavement phase), informal caregivers are at an increased 
risk for physical and mental morbidity. In Chapter 6 we reported the observed course of fatigue 
in both patients and their informal caregivers over a six months’ period in which the patients 
were receiving cancer treatment, together with the impact fatigue of both patients and care-
givers had on the experienced burden of caregivers. We found that the mean scores of the 
patients at both time points were significantly higher in comparison to their caregivers. Though 
the caregivers scored lower, their mean scores were higher compared with norm-score for 
healthy controls. Fatigue of patients and caregivers proved not to be correlated, but there was 
a significant correlation between fatigue in patients as well as in caregivers with experienced 
burden by caregivers. With the increase in treatment options for patients with cancer in the 
palliative setting together with the growing demand we put on informal caregivers nowadays, 
this finding is of societal importance.
 In Chapter 7 we looked at the course of fatigue in patients over time. Therefore we used 
monthly sent out questionnaires on fatigue in the same group as reported in chapter 4. We 
made a distinction in participants in a group who dropped-out earlier (n =48) and a group that 
participated till the final assessment at six months (n =89). Though in both groups, fatigue levels 
remained quite stable, the group drop-outs had significantly higher fatigue scores compared 
with the group follow-up at most time-points. Looking more in detail within the group that 
participated for six months, we were able to separate four groups: a small majority of patients 
(42%) never experiencing severe fatigue, a group patients (29%) who was and remained severely 
fatigued, and a smaller subset of patients who showed a change in fatigue level over time: from 
severely fatigued to not severely fatigued (14%) or the opposite (15%). Investigating the seven 
psychosocial factors of chapter 5 for their contribution to fatigue over time, we found that 51% 
of the variance of fatigue at follow-up could be explained by these factors. The factors self 
reported physical activity and disease acceptance contributed significantly to fatigue over time. 
So in conclusion, though almost 30% of the participating patients experienced severe fatigue at 
all time points, over 40% did not experience severe fatigue during six months and overall fatigue 
levels remained quite stable over time. For patients within the palliative trajectory who do expe-
rience severe fatigue, interventions to alleviate fatigue might be directed at helping them to 
accept the cancer and improving level of (subjective) physical activity.
GENERAL DISCUSSION
Fatigue is the most constant negative factor impairing daily functioning in patients with cancer. 
In literature prevalence rates up to 99% of fatigue are mentioned in mixed groups within the 
palliative phase 1-6. Most studies within the palliative phase however show the results of pooled 
data of patients in the whole palliative trajectory, including the final terminal phase. Therefore, 
the versatility of fatigue level over time will be lost as well as the chance to elucidate related 
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factors at certain stages within the palliative trajectory. With all new treatment options available 
for patients in the palliative phase of cancer nowadays, this period can last for years 7.
 Trajkovic-Vidakovic et al. differentiate between three stages within the palliative trajectory for 
symptom assessment to predict survival in patients with advanced cancer 8: a first stage with 
disease-directed treatment, a second stage with symptom oriented palliation and a third final 
terminal phase. Such a distinction seems useful as at each stage specific support seems desirable. 
However in daily practice these phases cannot always be distinguished precisely in individual 
patients. This is underlined by our results as at baseline participants could be considered being 
within the first stage, although retrospectively many patients were more close to their terminal 
phase than expected upfront.
 The results from this thesis should be viewed in light of the first palliative stage (the disease 
directed treatment phase), as we included only palliative patients on treatment with life 
prolonging intent. Our research has not shed light on the fatigue problem and related factors in 
other stages when support is more at stake than cancer treatment.
 Although literature suggests otherwise, we found in our longitudinally study that not yet half 
of the participating patients on active palliative cancer treatment experienced severe fatigue. 
Additional, during life prolonging palliative therapy directed against cancer, the fatigue level 
did not change in 2/3 of patients during six months follow up. Only a minority experienced 
either a decrease or increase in fatigue levels. Despite the relative stable course of fatigue over 
time during treatment we found in a cross-sectional study, that fatigue levels were higher for 
the patient group on further lines of treatment This finding is in concordance with other studies 
suggesting that fatigue will increase when a patient moves further in his palliative trajectory  5, 9-12. 
Two findings of our study also underline this suggestion: firstly, the main reason for patients to 
drop out early was due to progression of the disease and secondly those patients proved to 
have a higher fatigue level on inclusion.
Fatigue in daily clinical practice
Unfortunately, while fatigue is the most common symptom in patients during the palliative phase, 
it often still remains unrecognized and untreated in daily practice 13, 14. The presented algorithm 
for managing fatigue in cancer patients (chapter 2) could be of help in daily practice. However, 
one of the main points of our concern remains. With the increasing numbers of cancer patients 
and their expanding treatment options, it is unlikely that physicians can take into account all 
aspects of fatigue into the decision making of starting a next line of systemic treatment. In the 
thesis of De Raaf (2013), who also focused on fatigue in the palliative stage, it is suggested that to 
consider and manage a problem like fatigue, a rearrangement of tasks between physicians and 
nurses seems inevitable 15. We assume that oncology nurses within the hospitals, on the ward, the 
day care unit and out-patient clinic, are able and keen to screen for and further explore symptoms 
like fatigue. Because oncology nurses are the most easy accessible healthcare professionals for 
patients, they could play such an integral role. This has also been demonstrated by De Leeuw 
et al., in a study during the follow-up care of patients with head and neck cancer 16,17. With the 
general and specialized training of oncology nurses, they could also have a more prominent role 
in decision making concerning treatment options. Though in many studies nurse-led care in the 
curative setting was investigated, we think that oncology nurses are competent to play such a 
role within the palliative phase too. Oncology nurses are already involved in psychosocial care 
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by screening patients with the distress thermometer on a regular basis (http://www.oncoline.
nl/detecteren-behoefte-psychosociale-zorg). One of the items on the distress thermometer is 
fatigue. Although the current Dutch guideline is meant for patients during a curative trajectory 
with follow-up assessments, we want to suggest also regular screening within the palliative 
trajectory. Ideally, the first screening should take place before actual cancer treatment within the 
palliative phase has started. This gives the opportunity to treat somatic causes for fatigue. For 
patients on cancer treatment with life-prolonging intent, screening could be repeated at time 
points when a decision on whether or not to continue (current) treatment needs to be taken. 
Such a decision is made together with the patient, their informal caregivers and the members of 
the healthcare team. Together they balance quality of life and/or life prolongation while taking 
into account the role of fatigue and its contributing factors.
 If at screening a patient is not experiencing fatigue, and we learned from this thesis that this 
is the case for about half of all patients, no further action is required for the mean time. If a 
patient does experience severe fatigue this should be further explored for its impact on daily 
functioning. It might be that there are treatable somatic causes for fatigue like anemia, an infec-
tion, burdensome cancer related symptoms or side-effects of the current cancer treatment. In all 
these cases the oncologists are the designated professionals to manage these causes. If there are 
no treatable-somatic causes, it is useful for the oncology nurses to explore the fatigue further. 
Figure 1 Investigated contributing factors of fatigue in the palliative phase
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For cured cancer patients a clear model exists explaining the multidimensional base of fatigue. 
Based on this model effective treatment strategies have been developed. In our study we found 
that in line with the model of fatigue in cancer survivors, in the palliative phase psychosocial 
fatigue maintaining factors are involved as well. (see figure 1).
 All the investigated psychosocial factors were significantly related to fatigue in the palliative 
phase. We found that both at baseline and at follow-up, level of self reported physical activity 
contributed significantly to fatigue severity. This could be a starting point to support patients 
experiencing fatigue. However, results of exercise intervention-studies in patients with advanced 
cancer have been quite disappointing, so far. Oldervoll and colleagues developed an exercise 
intervention for patients with advanced cancer to alleviate fatigue 18,19. Though in a pilot study 
their intervention seemed promising, in their randomized controlled trial it did not prove to be 
successful. More recently another pilot study investigated the feasibility and potential effects 
of a walking exercise program to reduce fatigue in patients with advanced cancer, and found 
a trend towards less fatigue 20. According to our results low self-reported physical activity can 
be a fatigue perpetuating factor. Therefore, it seems obvious that an intervention directed 
at managing fatigue, can be aimed at physical activity. For clinical practice now, promoting 
physical activity seems relevant. The study of Goedendorp et al. proved, that a nurse-led inter-
vention aiming at physical exercise is feasible in patients on cancer treatment 21.
 At baseline sleeping problems was also a factor contributing significantly to fatigue. In a 
recent review of Davis et al. an association with sleeping disorders and fatigue in patients with 
advanced cancer is described too 22. Though several interventions are suggested such as sleep 
hygiene instructions, light therapy and yoga, they conclude that overall evidence for inter-
ventions to tackle sleeping problems in this patient group is weak. Our finding that sleeping 
problems was a fatigue-perpetuating factor, supports the suggestion that oncology nurses 
should also explore sleeping habits when a patients experiences fatigue. One suggestion could 
be to educate both patients and their informal caregivers on the importance of regular sleep-
wake habits as a first attempt to manage fatigue.
 Additionally acceptance of having incurable cancer contributed significantly to fatigue over 
time. This factor seems to be specific for palliative patients with cancer 23. Thompson et al. 
described this to be a psychological process that evolves throughout the course of a disease 
trajectory like incurable cancer. But to our knowledge this is the first study that found a relation 
with problems of acceptance with having incurable cancer and fatigue. According to the Cancer 
Nursing Curriculum of the European Oncology Nursing Society (EONS) oncology nurses have the 
skills and competencies to support patients and their relatives while managing with the impact 
of cancer and provide them advice 24. Oncology nurses can stimulate patients to discuss their 
struggle with acceptance with others, like their informal caregivers. Recognizing and discussing 
the problem can be a first step, which can be evaluated by the oncology nurses. If the problem 
remains or even increases, a referral to a more specialized professional like a psychologist or a 
therapist, should be the next step.
 As there is still is not one exceeding strategy or transcending intervention to alleviate fatigue 
in patients with incurable cancer and their informal caregivers, further research into this area is 
warranted. In our study not all postulated factors contributed significantly to fatigue over time. 
This might imply that other factors also play an important fatigue perpetuating role 25. Research 
to discover more factors associated with fatigue in the palliative phase is essential. Therefore 
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larger samples sizes are needed to investigate this. When further elucidating the fatigue main-
taining model in palliative patients, the next step will be to formulate treatment strategies 
for the fatigue perpetuating factors. Randomized controlled trials are necessary to prove the 
potential effect of interventions on fatigue in palliative patients on cancer treatment. Results of 
this thesis, identifying somatic and psychosocial factors associated with fatigue could act as a 
starting point for the recommended further research. Within this research the applicability for 
more nurse-led services within the healthcare team could certainly be one of the topics. Despite 
the lack of evidence for interventions yet, the knowledge described in this thesis can be taken 
into account when discussing fatigue with patients in the setting of metastatic cancer.
Role of the informal caregiver
We found in our study that almost a quarter of the informal caregivers suffered from severe 
fatigue, and the mean fatigue score of this group was higher when compared to a healthy 
reference group. Additionally it is noteworthy that fatigue of both caregivers and patients 
contributed significantly to the experienced burden by caregivers. It has been described that 
45% of informal caregivers are overstrained at the end of the palliative trajectory 26,27. Other 
studies have demonstrated that caregivers in the hospice and bereavement phase are at an 
increased risk for physical and mental morbidity 28. Now knowing that our participating care-
givers had increased levels of fatigue, these findings should make all healthcare providers alert 
to this symptom. With the current trend to discharge patients earlier and a shift to treat patients 
more often in the ambulatory setting, caregivers are confronted with an increasing demand on 
their role. Healthcare professionals should pay better attention to the specific needs related to 
the tasks we put in front of the caregivers. Obviously, further research is warranted focusing on 
the specific needs of caregivers and probable risk-factors of fatigue and experienced burden. 
For now, paying attention to fatigue severity in caregivers, verifying which tasks they are willing 
to do for their patient and verifying if they feel themselves capable for these tasks, can be a 
first step. Communicating this with the caregiver and patient might ultimately contribute to a 
decreasing risk of physical and mental morbidity of these caregivers.
FINAL CONCLUSION
If we want to tackle fatigue in both patients in the palliative setting and their informal caregivers, 
a more structured approach of fatigue seems inevitable. In such an approach each healthcare 
professional has his responsibility, regarding screening and managing fatigue both in patients 
and their informal caregivers. To make this approach realistic in daily practice, future research is 
necessary aiming at the development of effective interventions or strategies to alleviate fatigue. 
In our view screening for fatigue on a regular basis by oncology nurses, in both patients with 
cancer in the palliative trajectory and their informal caregivers, is essential. For oncology nurses 
it is important to discuss the fatigue perpetuating factors we found in our study with patients 
and verifying with the informal caregivers the tasks where they are confronted with. Additionally 
evaluating these proposed suggestions on a regular basis, is a first step to improve support for 
those experiencing fatigue, having metastatic cancer or being an informal caregiver.
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SAMENVATTING
In dit hoofdstuk wordt een samenvatting van de belangrijkste bevindingen van het onderzoek 
gepresenteerd. Tevens worden deze in een breder, meer praktisch perspectief geplaatst en 
worden aanbevelingen voor toekomstige onderzoeksrichtingen voorgesteld.
 Hoofdstuk 1 geeft een algemene inleiding tot het probleem van vermoeidheid bij patiënten 
met kanker. Vermoeidheid is een van de meest voorkomende klachten van patiënten met 
kanker. Helaas, wordt deze vermoeidheid in de dagelijkse praktijk in Nederland nog niet altijd 
herkend en gerapporteerd. Hoofdstuk 2 geeft een overzicht van vermoeidheid in alle stadia van 
kanker. Het laat zien dat kankergerelateerde vermoeidheid een complex en veelzijdig fenomeen 
is, waarbij een groot aantal potentieel bijdragende factoren betrokken zijn, zoals de tumor zelf; 
de aan behandeling gerelateerde klachten en complicaties; comorbiditeiten; psychologische en 
gedragsfactoren. Adviezen voor de behandeling van kanker gerelateerde vermoeidheid in de 
verschillende stadia zijn grofweg te verdelen in farmacologische en niet-farmacologische inter-
venties. Helaas blijken er in de dagelijkse praktijk belemmeringen te zijn voor een structurele 
aanpak van deze vermoeidheid. De belemmeringen kunnen zowel aan de zijde van de arts als 
van de patiënt liggen. Een arts voelt zich wellicht ongemakkelijk om het onderwerp vermoeid-
heid ter sprake te brengen door een gebrek aan bewustzijn of een onderschatting van de ernst 
van de vermoeidheid en de impact hiervan op de kwaliteit van leven van de patiënt. Daarnaast 
speelt mogelijk een gebrek aan kennis over methoden om het probleem aan te pakken. Ook 
tijdsdruk tijdens een spreekuur kan eventueel een belemmering zijn. Aan de andere kant, 
kunnen patiënten het onderwerp vermoeidheid vermijden omdat zij niet willen klagen, of 
denken dat de vermoeidheid zou kunnen betekenen dat de kanker is teruggekeerd of opnieuw 
actief is. Het niet vermelden van vermoeidheid door de patiënten maakt het moeilijk voor artsen 
om het probleem te herkennen. In Hoofdstuk 2 wordt een algoritme voorgesteld dat in de 
dagelijkse praktijk behulpzaam kan zijn. Het leidt de zorgverlener door de verschillende stadia 
van screening, diagnose en behandeling van kankergerelateerde vermoeidheid en streeft naar 
verbetering van de aanpak ervan.
 Terwijl in Hoofdstuk 2 kankergerelateerde vermoeidheid in alle stadia wordt besproken, richt 
Hoofdstuk 3 zich specifiek op de huidige kennis van vermoeidheid bij patiënten in de palliatieve 
fase. Van alle patiënten met kanker zal ongeveer 40%, ofwel op moment van diagnose of later 
geconfronteerd worden met ongeneeslijke kanker, de palliatieve fase. In de literatuur varieert 
de prevalentie van vermoeidheid in de palliatieve fase van 33-99%. Deze brede variatie kan 
verklaard worden door het gebruik van verschillende vragenlijsten, door een verschil als gevolg 
van diverse actuele behandelingen en door de fase van de ziekte. In de meeste onderzoeken bij 
patiënten met kanker in de palliatieve periode, zijn de gegevens van de verschillende fasen tot 
en met de laatste terminale fase, samengevoegd. Tegenwoordig betekent een palliatieve behan-
deling echter niet altijd dat de patiënt al in de terminale fase zit. Een palliatieve behandeling 
richt zich op levensverlenging of op het behouden van de kwaliteit van leven. Momenteel zijn 
er diverse standaard therapieën om het leven te verlengen voor patiënten in de palliatieve fase, 
zoals chemotherapie, hormonale therapie, radiotherapie, immuun- en doelgerichte therapie, 
allen te geven als monotherapie of in verschillende combinaties. Door al deze behandel- 
mogelijkheden is de levensverwachting van de patiënten in de palliatieve fase toegenomen en 
zal deze waarschijnlijk in de toekomst nog verder toenemen. Daarom lijkt de term chronische fase 
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van kanker in deze periode verdedigbaar. Ondanks dat het behouden van de kwaliteit van leven 
minder uitgebreid is onderzocht, zijn er richtlijnen gepubliceerd voor ondersteunende zorg in 
de palliatieve fase. Hierbij is gebleken dat vermoeidheid het meest voorkomende symptoom 
is met een grote negatieve invloed op de kwaliteit van leven. Volgens de Nederlandse richt-
lijn ‘Vermoeidheid bij kanker in de palliatieve fase’ (2010), bestaan de huidige behandelings- 
strategieën voor vermoeidheid bij palliatieve patiënten uit de volgende interventies; infor-
matie verstrekking aan patiënt en mantelzorger; integrale benadering van met de vermoeid-
heid samenhangende problematiek; zo mogelijk behandeling van de onderliggende oorzaak; 
altijd ondersteuning met een vorm van niet-medicamenteuze behandeling (www.oncoline.nl). 
Deze diversiteit aan opties maakt duidelijk dat er geen consensus of één overstijgende inter-
ventie of strategie is om specifiek vermoeidheid aan te pakken. Met de negatieve invloed die 
vermoeidheid heeft op het dagelijks functioneren van patiënten is het een kleine stap naar het 
besef dat vermoeidheid wellicht ook invloed heeft op de mantelzorgers. Concluderend kunnen 
we zeggen dat we in de dagelijkse praktijk bij patiënten met ongeneeslijke kanker te maken 
hebben met een spanningsveld gezien alle opties om hun leven te verlengen en beperkte 
mogelijkheden om een bijkomend symptoom als vermoeidheid aan te pakken. Extra kennis 
en inzicht in de vermoeidheid tijdens de palliatieve behandeling van kanker is dus vereist om 
een basis te vinden waarop effectieve strategieën en interventies kunnen worden ontwikkeld 
die patiënten en hun mantelzorgers tot steun kunnen zijn bij het aanpakken en omgaan met 
vermoeidheid.
 Om meer inzicht en kennis te verkrijgen over vermoeidheid, de ernst en het verloop ervan 
bij patiënten met ongeneeslijke kanker die actief behandeld worden voor kanker, hebben we 
een onderzoek uitgevoerd bij patiënten met ongeneeslijke solide tumoren. Patiënten konden 
deelnemen indien zij 18 jaar of ouder waren, bezig waren met een behandeling voor kanker 
met levensverlengende intentie of op het punt stonden hiermee te beginnen. De potentiële 
kandidaten (patiënten) werden gevraagd of zij een voor hen belangrijke mantelzorger konden 
aanwijzen die wellicht ook bereid was deel te nemen.
 In Hoofdstuk 4 worden de resultaten van een explorerende analyse beschreven bij de 
aanvang van de studie. We vonden dat 64 van de 137 deelnemende patiënten (47%) ernstig 
vermoeid was. Verder kijkend naar de actuele behandellijn vonden we een hoger percentage 
ernstig vermoeide patiënten bij volgende behandellijnen (2e – 4e) vergeleken met patiënten 
tijdens de 1e behandellijn. Dit verschil was significant. We vonden geen verschillen in ernst van 
vermoeidheid tussen verschillende soorten kankers, noch tussen de verschillende behandel-
vormen. In eerste instantie vonden we significante verschillen in ernst van vermoeidheid tussen 
mannen en vrouwen. Echter toen we de kwaadaardige aandoeningen die alleen bij vrouwen 
voorkomen uitsloten van de analyse (borst- en gynaecologische kanker) was er geen significant 
verschil meer. Verder vonden we dat patiënten die ernstig vermoeid waren meer andere kanker-
gerelateerde klachten hadden zoals: kortademigheid, pijn, verlies van eetlust, misselijkheid en 
braken en constipatie.
 Een volgende stap was om te kijken naar mogelijke aan vermoeidheid bijdragende factoren. 
Daarvoor gebruikte we een in Hoofdstuk 5 beschreven model van uitlokkende en instand-
houdende factoren van vermoeidheid, dat bekend is uit onderzoek naar vermoeidheid bij 
patiënten die genezen zijn van kanker. We wilden de toepasbaarheid van dit model in de 
palliatieve setting onderzoeken, waarbij opgemerkt dient te worden dat er enkele belangrijke 
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verschillen zijn tussen de palliatieve en curatieve fase. Allereerst zullen in de palliatieve fase, de 
kanker zelf en de behandeling aanwezig zijn en blijven, waarbij de invloed hiervan op vermoeid-
heid niet kan worden uitgesloten. We hebben eveneens de instandhoudende psychosociale 
factoren vanuit de curatieve setting enigszins aangepast naar de palliatieve fase: verwerkings-
problemen met het hebben van een chronische ziekte; een verhoogde angst voor progressie 
van de ziekte; niet helpende vermoeidheid gerelateerde cognities; slaapproblemen; ontregeld 
activiteiten patroon en discrepantie in (verwachte en ervaren) sociale steun. Op basis van 
de literatuur hebben we ook gekeken of depressieve gevoelens een bijdragende factor was. 
Concluderend hebben we dus zeven psychosociale factoren onderzocht op hun mogelijke 
bijdrage aan vermoeidheid bij patiënten tijdens behandeling voor kanker in de palliatieve fase. 
Wij vonden dat alle zeven onderzochte factoren significant gecorreleerd waren met vermoeid-
heid. Uit een lineaire regressie bleek dat deze zeven factoren 64% van de variantie in voor-
komen van vermoeidheid verklaarde. Het ‘niveau van zelf gerapporteerde lichamelijke activiteit’ 
en ‘slaapproblemen’ waren de factoren die een significante bijdrage leverde en ‘niet helpende 
vermoeidheid gerelateerde cognities’ droeg net niet significant bij. Deze bevinding onder-
steunt de suggestie dat psychosociale factoren ook bij patiënten die behandeld worden in het 
palliatieve traject een aanzienlijke rol spelen bij vermoeidheid en dus meegenomen dienen te 
worden bij het ontwikkelen van een interventie of strategie om de vermoeidheid in deze groep 
patiënten aan te pakken.
 Zoals in de algemene inleiding beschreven, heeft palliatieve zorg als doel om de kwaliteit van 
leven van zowel patiënten als ook hun naasten te verbeteren. Daarom is de ervaring van mantel-
zorgers van groot belang voor alle professionals die betrokken zijn bij de zorg voor patiënten 
met ongeneeslijke kanker. De beperkt beschikbare literatuur geeft aan dat mantelzorgers, als 
direct gevolg van het geven van zorg aan een familielid tijdens de palliatieve fase en daarna 
(terminale- en rouw fase) een verhoogd risico op lichamelijke en psychische problemen hebben. 
In Hoofdstuk 6 is het verloop van de vermoeidheid bij zowel patiënten als hun mantelzorgers 
over een periode van zes maanden beschreven, samen met de impact die de vermoeidheid van 
zowel de patiënten als de mantelzorgers zelf had op de ervaren druk van de mantelzorgers. 
We zagen dat de gemiddelde scores van vermoeidheid van de patiënten op beide tijdstippen 
significant hoger waren in vergelijking met hun mantelzorgers. Hoewel de mantelzorgers lager 
scoorden, waren hun gemiddelde scores hoger in vergelijking met normscores van een gezonde 
controle groep. Vermoeidheid van patiënten en mantelzorgers was niet gecorreleerd, maar wel 
bleek een significante correlatie tussen vermoeidheid van zowel patiënten als mantelzorgers 
met de ervaren druk van de mantelzorgers. Met de uitbreiding van behandelmogelijkheden 
voor patiënten met kanker in de palliatieve fase en het toenemende beroep dat we tegen-
woordig op de mantelzorgers doen, zijn deze bevindingen van maatschappelijk belang.
 In Hoofdstuk 7 hebben we gekeken naar het verloop van vermoeidheid bij patiënten in 
een palliatief behandeltraject over een langere periode. Daarvoor hebben we maandelijks een 
vragenlijst naar de deelnemende patiënten gestuurd. Wij hebben voor de analyse onderscheid 
gemaakt tussen de groep deelnemers die uitvielen tijdens de studie periode (n = 48) en een 
groep die deelnam tot en met de laatste meting na zes maanden (n = 89). Hoewel in beide 
groepen de niveaus van vermoeidheid vrij stabiel bleven, had de groep die voortijdig uitviel 
significant hogere scores op de meeste meetmomenten in vergelijking met de groep die de 
gehele studie periode deelnam. Meer in detail kijkend naar de groep die zes maanden deelnam, 
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konden we vier groepen onderscheiden: een kleine meerderheid van patiënten (42%) had nooit 
last van ernstige vermoeidheid, een groep patiënten (29%) was en bleef ernstig vermoeid, en 
een kleinere subgroep die een verandering in ernst van vermoeidheid vertoonde: van ernstig 
vermoeid naar niet ernstig vermoeid (14%) of andersom (15%). Bij het nader onderzoeken van 
de eerder genoemde zeven psychosociale factoren op hun bijdrage aan vermoeidheid over 
de tijd, vonden we dat bij de laatste meting 51% van de variantie verklaard kon worden door 
deze factoren. De factoren ‘niveau van zelf gerapporteerde lichamelijke activiteit’ en ‘acceptatie 
van het hebben van een ongeneeslijke ziekte’, droegen significant bij. Hoewel dus bijna 30% 
van de deelnemende patiënten ernstig vermoeid was op alle tijdstippen, bleek ruim 40% geen 
ernstige vermoeidheid te ervaren tijdens de zes maanden van de studieperiode en bleef over 
het algemeen de ernst van vermoeidheid vrij stabiel. Voor patiënten in het palliatieve traject 
die ernstige vermoeidheid ervaren, zouden interventies voor het aanpakken van vermoeid-
heid gericht dienen te zijn op het helpen met de acceptatie van het hebben van ongeneeslijke 
kanker en het verbeteren van het niveau van de (subjectieve) fysieke activiteit.
DISCUSSIE
Vermoeidheid is de meest constante negatieve factor die afbreuk doet aan het dagelijks 
functioneren bij patiënten met kanker. In de literatuur worden prevalenties tot 99% van 
vermoeidheid vermeld in gemengde groepen binnen de palliatieve fase. De meeste studies in 
de palliatieve fase blijken echter de resultaten van het gehele palliatieve traject, inclusief de 
laatste terminale fase, bijeen te voegen. Daarmee gaat het zicht op mogelijke spreiding van de 
mate van vermoeidheid over de tijd verloren evenals de kans om verwante factoren in bepaalde 
fasen binnen het palliatieve traject helder te krijgen. Met alle nieuwe behandelopties die tegen-
woordig beschikbaar zijn voor patiënten in de palliatieve fase van kanker, kan deze periode een 
tijdsbestek van jaren beslaan.
 Trajkovic-Vidakovic et al. onderscheiden drie fasen binnen het palliatieve traject. Een eerste 
fase met ziektegerichte behandeling, een tweede fase met een symptoom gerichte behandeling 
(palliatie) en een derde laatste terminale fase. Een dergelijk onderscheid is in de praktijk van 
belang gezien de specifieke steun die in de verschillende fasen wenselijk is. In de praktijk zijn 
deze fasen echter niet altijd even nauwkeurig te onderscheiden bij een individuele patiënt. 
Dit wordt onderstreept door onze resultaten: bij aanvang beschouwde wij de deelnemende 
patiënten in de eerste fase gezien hun ziektegerichte behandeling, echter achteraf gezien 
bleken een aantal van hen dichter bij de terminale fase dan van te voren ingeschat.
 De resultaten van dit onderzoek dienen gezien te worden in het licht van de eerste fase in 
het palliatieve traject (de ziekte gerichte behandelingsfase), daar wij ons gericht hebben op 
patiënten die met levensverlengende intentie behandeld werden. Ons onderzoek heeft geen 
betrekking op de vermoeidheid en mogelijke samenhang met factoren in de andere fasen, 
wanneer de intentie van het behandelen meer klachtgericht is (palliatie).
 Hoewel de literatuur anders doet vermoeden, vonden we in ons longitudinaal onderzoek 
dat nog niet de helft van de deelnemende patiënten tijdens actieve behandeling voor kanker 
ernstig vermoeid was. Daarnaast bleek dat tijdens levensverlengende palliatieve behandeling 
voor kanker, het niveau van vermoeidheid bij twee-derde van de patiënten niet veranderde 
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gedurende zes maanden follow-up. Slechts bij een minderheid trad ofwel een afname ofwel 
een toename van vermoeidheid op. Ondanks het relatief stabiele verloop van de vermoeidheid 
tijdens de behandeling vonden we bij het cross-sectionele deel van de studie wel dat vermoeid-
heid hoger was bij patiënten in een verdere behandellijn. Deze bevinding is in overeenstem-
ming met andere onderzoeken die suggereren dat vermoeidheid zal toenemen wanneer een 
patiënt verder in zijn palliatieve traject komt. Twee bevindingen uit onze studie onderstrepen 
deze suggestie ook: allereerst bleek de belangrijkste reden voor patiënten om af te zien van 
verdere deelname progressie van de ziekte te zijn en daarnaast bleken deze patiënten bij 
inclusie al een hoger vermoeidheidsniveau te hebben.
Vermoeidheid in de dagelijkse klinische praktijk
Terwijl vermoeidheid het meest voorkomende symptoom is bij patiënten tijdens de palliatieve 
fase wordt het helaas in de praktijk nog niet altijd herkend en blijft het daarmee onbehandeld. 
Het voorgestelde algoritme voor het omgaan met vermoeidheid bij kanker (hoofdstuk 2) kan 
behulpzaam zijn in de dagelijkse praktijk. Echter, hiermee blijft een van de belangrijkste punten 
van zorg bestaan. Met de toename van het aantal patiënten met kanker en de uitbreiding van 
behandel opties, is het onwaarschijnlijk dat artsen bij het nemen van een besluit over het al dan 
niet starten met een volgende behandellijn, steeds rekening zullen houden met alle aspecten 
van vermoeidheid. In het proefschrift van De Raaf (2013), dat eveneens gericht is op vermoeid-
heid in de palliatieve fase, wordt een herschikking van taken tussen artsen en verpleegkundigen 
voorgesteld om een probleem zoals vermoeidheid aan te pakken. Wij achten oncologiever-
pleegkundigen binnen de ziekenhuizen, zowel op de afdeling, de dagbehandeling en polikli-
niek, eveneens in staat en bereid om patiënten te screenen op voorkomende symptomen zoals 
vermoeidheid en deze, indien nodig verder te exploreren. Mede omdat oncologieverpleegkun-
digen voor patiënten laagdrempelig te benaderen beroepsbeoefenaren zijn, zijn zij in staat een 
dergelijke integrale rol te spelen. Dit is ook aangetoond door De Leeuw et al., in een studie tijdens 
de follow-up voor patiënten met hoofd en halskanker. Het huidige opleidingsniveau, aange-
vuld met de gespecialiseerde opleiding tot oncologieverpleegkundige, maakt dat oncologie- 
verpleegkundigen de competenties hebben om een meer prominente rol te spelen in het besluit-
vormingsproces rondom de verschillende behandel opties. Hoewel de meeste studies met deze 
door verpleegkundigen geleide zorg in de curatieve setting hebben plaatsgevonden, denken 
wij dat ook in de palliatieve setting de oncologieverpleegkundigen in staat zijn een dergelijke 
rol op zich te nemen. Oncologieverpleegkundigen hebben reeds een structurele rol toebedeeld 
gekregen bij het geven van psychosociale ondersteuning aan patiënten, door op regelmatige 
tijden de lastmeter af te nemen (http://www.oncoline.nl/detecteren-behoefte-psychosocia-
le-zorg ). Een van de items op de lastmeter is vermoeidheid. Hoewel de huidige Nederlandse 
richtlijn met name toegepast wordt bij patiënten tijdens een curatief traject met follow-up 
evaluaties, willen we hier voorstellen ook regelmatig te screening binnen het palliatieve traject. 
Idealiter dient de eerste screening plaats te vinden vóór start van de eigenlijke behandeling 
van kanker in de palliatieve fase. Dit geeft de mogelijkheid om eventuele lichamelijke oorzaken 
voor vermoeidheid eerst te behandelen. Bij patiënten die behandeld worden met levensverlen-
gende intentie, kan screening vervolgens herhaald worden rond tijdstippen waarop een beslis-
sing over het al dan niet continueren van de (huidige) behandeling genomen dient te worden. 
Een dergelijk besluit wordt samen met de patiënt, zijn mantelzorger(s) en overige leden van 
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het zorgteam genomen. Samen kan dan de balans opgemaakt worden met in achtneming 
van de kwaliteit van leven en / of wens tot levensverlengende behandeling, waarbij de rol van 
vermoeidheid en bijdragende factoren meegenomen kan worden.
 Indien een patiënt bij screening geen vermoeidheid ervaart, en vanuit dit proefschrift 
is gebleken dat dit het geval is bij ongeveer de helft van de patiënten, is geen verdere actie 
vereist. Als een patiënt wel ernstig vermoeid is, dient dit verder geëxploreerd te worden om 
hiermee zicht te krijgen op de impact hiervan op het dagelijks functioneren. Het kan zijn dat er 
behandelbare somatische oorzaken van vermoeidheid zijn zoals anemie, een infectie, kanker-
gerelateerde symptomen of bijwerkingen van de huidige behandeling. In al die gevallen is 
de oncoloog (behandelaar) de aangewezen persoon om deze oorzaken te behandelen. Als er 
geen behandelbare somatische oorzaken zijn, is het zinvol dat de oncologieverpleegkundige 
samen met de patiënt, de vermoeidheid verder exploreert. Voor genezen patiënten bestaat 
een duidelijk model dat de multidimensionale basis van vermoeidheid weergeeft. Op basis van 
dit model zijn effectieve behandelstrategieën ontwikkeld. In ons onderzoek hebben we vast - 
gesteld dat in overeenstemming met het hiervoor genoemde model van vermoeidheid 
bij kanker in de curatieve setting, ook in de palliatieve fase psychosociale instandhoudende 
factoren van vermoeidheid betrokken zijn.
Figuur 1 Onderzochte factoren van vermoeidheid in de palliatieve fase
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 Alle onderzochte psychosociale factoren waren significant gerelateerd aan vermoeidheid 
in de palliatieve fase. We vonden dat zowel bij aanvang als bij follow-up, het niveau van zelf 
gerapporteerde lichamelijke activiteit in belangrijke mate bijdroeg aan de ernst van vermoeid-
heid. Dit kan een uitgangspunt zijn voor het ondersteunen van patiënten die vermoeid zijn. 
Echter, tot nu toe zijn resultaten van studies met op beweging gerichte interventies bij patiënten 
met uitgebreide kanker teleurstellend. Oldervoll en collega’s ontwikkelden een op beweging 
gerichte interventie voor patiënten met gevorderde kanker om vermoeidheid te verminderen. 
Hoewel in een pilotstudie hun interventie veelbelovend leek, bleek deze in het gerandomi-
seerde onderzoek niet succesvol. Ook recent is in een andere pilotstudie de haalbaarheid en de 
mogelijke effecten van een wandel / oefen programma om vermoeidheid te verminderen bij 
patiënten met gevorderde kanker onderzocht, en vond men een trend naar minder vermoeid-
heid. Volgens onze resultaten kan lage zelfgerapporteerde fysieke activiteit een instand- 
houdende factor van vermoeidheid zijn. Daarom lijkt het voor de hand te liggen dat een inter-
ventie die zich richt op vermoeidheid, ook lichamelijke activiteit meeneemt. Voor de klinische 
praktijk nu, lijkt het stimuleren tot lichamelijke activiteit relevant. De studie van Goedendorp et 
al. liet zien dat een door verpleegkundigen geleide interventie gericht op lichamelijke oefening 
haalbaar is bij patiënten tijdens behandeling voor kanker.
 Bij baseline bleken ook slaapproblemen een factor die significant bijdroeg aan vermoeidheid. 
In een recente review van Davis et al. is een associatie tussen slaapstoornissen en vermoeidheid 
bij patiënten met vergevorderde kanker beschreven. Hoewel een aantal interventies worden 
voorgesteld zoals instructies rondom slaaphygiëne, lichttherapie en yoga, concluderen zij dat 
er maar zwak bewijs is voor deze interventies om slaapproblemen bij deze groep patiënten aan 
te pakken. Onze bevinding dat slaapproblemen een instandhoudende factor van vermoeidheid 
kunnen zijn, maakt wel dat het zinvol dat door de oncologieverpleegkundige bij een patiënt 
die ernstig vermoeid is, de slaapgewoonten verder geëxploreerd worden. Een suggestie zou 
kunnen zijn om het belang van een regelmatig slaap-waak ritme voor zowel patiënten als zijn 
mantelzorger te benoemen als een eerste poging om vermoeidheid te bestrijden.
 Ook het gebrek aan acceptatie van het hebben van ongeneeslijke kanker bleek aanzienlijk bij 
te dragen aan vermoeidheid. Deze factor lijkt specifiek te zijn voor patiënten met kanker in het 
palliatieve traject. Thompson et al. beschrijven dit als een psychologisch proces dat zich in de 
loop van een ziektetraject zoals ongeneeslijke kanker ontwikkelt. Echter, bij ons weten is dit de 
eerste studie die een verband heeft gevonden met problemen van aanvaarding van ongenees-
lijke kanker en vermoeidheid. Volgens het Curriculum van de oncologieverpleegkundige van de 
Europese Oncology Nursing Society (EONS) hebben oncologieverpleegkundigen de vaardig-
heden en competenties om patiënten en hun familie te ondersteunen en te adviseren bij het 
leren omgaan met de gevolgen van kanker. Oncologieverpleegkundigen kunnen patiënten en 
hun mantelzorgers stimuleren tot het bespreekbaar maken van de problemen die zij ervaren 
bij de acceptatie. Het herkennen en bespreekbaar maken van het probleem kan een eerste stap 
zijn, die door de oncologieverpleegkundigen vervolgd kan worden door er regelmatig naar te 
blijven vragen. Als het probleem blijft bestaan of zelfs toeneemt, kan een verwijzing naar een 
meer gespecialiseerde professional zoals een psycholoog of therapeut, een volgende stap zijn.
 Aangezien er nog steeds niet één heldere strategie of interventie is om vermoeidheid te 
verminderen bij zowel patiënten met ongeneeslijke kanker als hun mantelzorgers, is verder 
onderzoek gerechtvaardigd. In onze studie bleken niet alle onderzochte factoren een 
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significante bijdrage te leveren aan vermoeidheid over tijd. Dit zou kunnen betekenen dat 
ook andere factoren een belangrijke instandhoudende rol kunnen hebben. Onderzoek naar 
andere factoren die samenhangen met vermoeidheid in de palliatieve fase is essentieel. Om 
dit goed te kunnen onderzoeken zijn studies met grotere patiëntenaantallen nodig. Indien het 
model van instandhoudende factoren bij palliatieve patiënten verder uitgebouwd is, zal de 
volgende stap zijn om behandelstrategieën te ontwikkelen gericht op deze factoren. Hierna 
zijn gerandomiseerde gecontroleerde studies nodig, om bewijs te leveren voor het effect van 
dergelijke interventies die gericht zijn op vermoeidheid bij patiënten tijdens behandeling voor 
ongeneeslijke kanker. Resultaten van dit proefschrift, waarbij een aantal somatische en psycho-
sociale factoren geïdentificeerd zijn die samenhangen met vermoeidheid, kunnen fungeren als 
uitgangspunt voor verder onderzoek. Binnen dit onderzoek dient zeker de toepasbaarheid van 
verpleegkundig geleide zorg, als onderdeel van de totale zorg, aan bod te komen. Ondanks 
het momenteel ontbreken van bewijs voor effectieve interventies, kan de in dit proefschrift 
beschreven kennis toegepast worden bij het bespreken van vermoeidheid bij patiënten met 
ongeneeslijke kanker.
Rol van de mantelzorger
In onze studie vonden we dat bijna een kwart van de mantelzorgers ernstig vermoeid was, en dat 
de gemiddelde vermoeidheidscore van deze groep hoger was in vergelijking met een gezonde 
controle groep. Daarnaast is het opmerkelijk dat de vermoeidheid van zowel de mantelzorgers 
zelf als de patiënten aanzienlijk bijdroegen aan de ervaren belasting door de mantelzorgers. Er 
is beschreven dat 45% van de mantelzorgers overbelast zijn aan het einde van het palliatieve 
traject. Andere studies hebben laten zien dat mantelzorgers in de fases van hospice zorg en 
rouw een verhoogd risico op lichamelijke en psychische ziekten hebben. De wetenschap dat 
onze deelnemende mantelzorgers verhoogde niveaus van vermoeidheid hadden, zouden 
alle zorgverleners hier alert op moeten maken. Met de huidige trend om patiënten eerder 
vanuit het ziekenhuis te ontslaan en de verschuiving van behandelingen naar een ambulante 
setting, worden mantelzorgers geconfronteerd met een toenemende aanspraak op hun rol. 
Beroepsbeoefenaren in de gezondheidszorg zouden meer alert moeten zijn op de specifieke 
behoeften van de mantelzorgers vanwege de taken waarvan wij verwachten dat zij die op zich 
nemen. Uiteraard is ook hier verder onderzoek gerechtvaardigd dat gericht is op de specifieke 
behoeften van mantelzorgers en mogelijke risicofactoren voor vermoeidheid en de door hen 
ervaren last. Voor nu kan als een eerste stap gezien worden dat er structureel aandacht is voor 
eventuele vermoeidheid bij de mantelzorger. Er dient geverifieerd te worden welke taken zij 
bereid zijn op zich te nemen en gecontroleerd te worden of zij zichzelf ook in staat achten 
deze taken op zich te nemen. Het open communiceren met de mantelzorger en de patiënt kan 
uiteindelijk bijdragen aan een afnemend risico van lichamelijke en psychische morbiditeit van 
de mantelzorgers.
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Als we vermoeidheid echt aan willen pakken bij zowel patiënten in de palliatieve setting als hun 
mantelzorgers, lijkt een meer gestructureerde aanpak van vermoeidheid onvermijdelijk. In een 
dergelijke benadering heeft elke zorgverlener zijn eigen verantwoordelijkheid ten aanzien van 
screening en het behandelen van vermoeidheid bij zowel patiënten als mantelzorgers. Om deze 
aanpak werkelijkheid te laten worden in de dagelijkse praktijk, is onderzoek noodzakelijk waarbij 
gekeken dient te worden naar het ontwikkelen van effectieve interventies of strategieën om 
vermoeidheid te verminderen. Naar onze mening is het regelmatig screenen door oncologie - 
verpleegkundigen op vermoeidheid, bij zowel patiënten met kanker in het palliatieve traject 
als hun mantelzorgers, hierbij cruciaal. Voor oncologieverpleegkundigen is het belangrijk om 
de instandhoudende factoren van vermoeidheid die we in deze studie gevonden hebben met 
patiënten te bespreken en met de mantelzorgers de taken waarvoor ze geplaatst worden, te 
verifiëren. Daarnaast is het regelmatig evalueren van de voorgestelde suggesties om ernstige 
vermoeidheid te verminderen een eerste stap om nog betere ondersteuning te kunnen bieden 
aan hen die ernstig vermoeid zijn, ongeacht of het de patiënt of de mantelzorger betreft.
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Van alle patiënten die de diagnose kanker krijgen zal zo’n 40% vroeger of later geconfronteerd 
worden met het gegeven dat de ziekte niet meer te genezen is. Als genezing niet meer mogelijk 
is gaat de patiënt over naar de palliatieve fase. Echter, met de huidige behandelmogelijkheden 
voor patiënten met ongeneeslijke kanker kan deze periode een tijdsbestek van jaren beslaan. 
Naast verlenging van leven is een belangrijke insteek van de behandeling het behouden of 
vergroten van een goede kwaliteit van leven. Een van de belangrijkste klachten van patiënten 
in de palliatieve fase is echter vermoeidheid, wat een negatieve invloed heeft op de kwaliteit 
van leven. In de bestaande literatuur worden percentages tot 99% genoemd als het gaat om 
het voorkomen van vermoeidheid tijdens de palliatieve fase. In het palliatieve traject kan er 
evenwel onderscheid gemaakt worden in een eerste periode waarin behandeling gericht is op 
het aanpakken van de ziekte met als doel deze terug te dringen of tot stilstand te brengen, 
zodat verlenging van leven bereikt wordt. Na deze levensverlengende periode komt er vaak een 
periode waarin de verschillende symptomen / klachten als gevolg van voortschrijdende ziekte 
meer op de voorgrond staan. Het doel van de behandeling is dan gericht op het verbeteren 
van deze klachten en/of symptomen. Uiteindelijk zal de laatste, terminale fase zijn intrede doen 
waarbij behandeling gericht is op een goede kwaliteit van het sterven. De eerder genoemde 
percentages komen uit studies waarin patiënten opgenomen waren zonder onderscheid te 
maken in de fase waarin zij zich bevonden binnen het palliatieve traject. Ook het gebruik van 
verschillende meetinstrumenten bij deze studies maakt het lastig deze cijfers op juiste wijze te 
interpreteren.
 In dit proefschrift is allereerst het probleem van kanker gerelateerde vermoeidheid geschetst 
binnen het gehele spectrum van de ziekte kanker. Hierin komt naar voren dat ondanks dat 
vermoeidheid een van de meest voorkomende symptomen is bij patiënten met kanker, het in 
de dagelijkse praktijk niet altijd goed herkend en erkend wordt. Een aantal barrières worden 
beschreven waarom vermoeidheid niet altijd goed (h)erkend wordt. Deze barrières kunnen zowel 
bij de zorgprofessional als bij de patiënt zelf liggen. Een arts kan door ongemak rondom vermoe-
idheid, het onderwerp vermijden. Deels mogelijk door onbekendheid met het probleem of een 
onderschatting van de ernst ervan maar mogelijk ook door onbekendheid met behandelmog-
elijkheden voor vermoeidheid. Tevens kan ook het tijdsaspect in de spreekkamer een rol spelen. 
Aan de andere kant kunnen patiënten het als een onvermijdelijk symptoom beschouwen en het 
daarom niet benoemen. Het niet willen klagen bij de arts draagt hier mogelijk ook aan bij. Ook 
kan het zijn dat patiënten het onderwerp uit de weg gaan omdat ze bang zijn dat het een signaal 
is dat de ziekte teruggekeerd is of dat er sprake is van progressie. Als een patiënt het onder-
werp niet ter sprake brengt, wordt het ook lastiger voor de zorgprofessional het probleem te (h)
erkennen. In dit eerste hoofdstuk wordt een praktisch algoritme voorgesteld dat behulpzaam 
kan zijn in het beter (h)erkennen van vermoeidheid in de dagelijkse oncologische praktijk met 
de verschillende behandelmogelijkheden. Meer specifiek over het voorkomen van vermoeid- 
heid in het palliatieve traject variëren de percentages van 33 tot 99%. Deze ruime variatie komt, 
als gezegd, deels door de verschillende manieren waarop vermoeidheid gemeten is, en doordat 
geen onderscheid is gemaakt in de eerder genoemde verschillende fases binnen het palliatieve 
traject. Door de toename aan behandelmogelijkheden voor patiënten met gemetastaseerde 
kanker zijn er stemmen die ervoor pleiten om de fase waarin nog actief behandeld wordt met 
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levensverlenging als inzet, de chronische fase van kanker te noemen.
 Denkend vanuit de impact die vermoeidheid op de patiënt kan hebben, is het een kleine stap 
naar de suggestie dat deze vermoeidheid ook zijn weerslag heeft op naasten. De wereld gezond-
heidsorganisatie (WHO) hanteert de volgende definitie voor palliatieve zorg: ‘Palliatieve zorg is 
een benadering die de kwaliteit van het leven verbetert van patiënten en hun naasten die te 
maken hebben met een levensbedreigende aandoening, door het voorkomen en verlichten van 
lijden, door middel van vroegtijdige signalering en zorgvuldige beoordeling en behandeling 
van pijn en andere problemen van lichamelijke, psychosociale en spirituele aard’. Van hieruit is 
het logisch om ook naasten mee te nemen in een onderzoek naar vermoeidheid bij patiënten 
met kanker in het palliatieve traject.
 Om meer zicht en kennis te verkrijgen over de ernst en het verloop van vermoeidheid bij 
een groep patiënten met ongeneeslijke kanker hebben we de volgende observationele studie 
uitgevoerd. We hebben gedurende een half jaar patiënten en naasten op verschillende tijd-
stippen vragenlijsten voorgelegd. We hebben gekeken naar de ernst van de ervaren vermoeid-
heid, eventuele andere klachten/symptomen en een aantal psychosociale factoren. Specifiek 
bij de naasten waren we ook geïnteresseerd in de ervaren druk als zijnde een mantelzorger. 
Patiënten konden deelnemen als zij 18 jaar of ouder waren, behandeld werden voor onge-
neeslijke kanker of op het punt stonden hiermee te beginnen. Het doel van de behandeling was 
verlenging van leven. Aan de patiënten die mee wilde doen werd gevraagd of zij een naaste 
hadden die eventueel ook bereid was deel te nemen.
 In hoofdstuk 4 worden de resultaten beschreven van de eerste meting bij de 137 patiënten 
die aanvankelijk deelnamen aan de studie. Hier bleek dat 64 van hen ernstig vermoeid waren 
(47%). We vonden ook dat mensen die al meerdere behandelingslijnen in het palliatieve traject 
hadden gehad, meer vermoeid waren dan mensen die aan het begin van het palliatieve traject 
stonden. Er werd geen verschil gevonden in vermoeidheid tussen mensen met verschillende 
soorten kanker, evenmin tussen de verschillende behandelvormen. We vonden wel dat mensen 
met ernstige vermoeidheid significant meer andere kanker gerelateerde symptomen rappor-
teerde zoals kortademigheid, pijn, verminderde eetlust.
 Het volgende hoofdstuk gaat in op de eventuele samenhang van een aantal psychosociale 
factoren en vermoeidheid. Vanuit eerder onderzoek bij patiënten die genezen zijn van kanker 
weten we dat zo’n 25 – 30% van hen, ernstige vermoeidheid kan blijven ervaren. Zij zijn dus 
ernstig vermoeid, zonder dat daar nog een lichamelijke verklaring voor is. Er wordt vanuit 
gegaan dat de kanker en de behandeling hiervoor, vermoeidheid hebben uitgelokt. Zij worden 
wel de uitlokkende factoren van vermoeidheid genoemd. Er spelen echter een aantal psycho-
sociale factoren een rol bij het aanhouden van de vermoeidheid. Deze factoren worden wel de 
instandhoudende factoren van vermoeidheid genoemd. Deze factoren zijn: een verwerkings- 
probleem; angst voor terugkeer van kanker; niet-helpende gedachten rondom vermoeid-
heid; een onregelmatig slaap-waak ritme; een verstoord activiteitenpatroon; niet-realistische 
verwachtingen van de omgeving. Uiteindelijk is er vanuit deze kennis een effectieve cognitieve 
gedragstherapie ontwikkeld voor patiënten die na genezing van kanker ernstig vermoeid 
blijven. Vanuit deze gedachtegang waren we benieuwd of deze factoren mogelijk ook een rol 
spelen bij vermoeidheid bij patiënten in het palliatieve traject.
 Naast voornoemde factoren hebben we hieraan, op basis van literatuur, de factor depressie 
toegevoegd. Ons onderzoek liet zien dat alle zeven factoren gecorreleerd waren met 
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vermoeidheid. Een meer specifieke analyse liet zien dat het grootste deel van de vermoeid-
heid verklaard kon worden vanuit deze factoren waarbij met name een lager nivo van fysiek 
actief zijn en slaapproblemen een grote rol speelde. We hebben ook gekeken of de psycho-
sociale factoren over de tijd een rol speelde bij vermoeidheid. We vonden dat de vermoeidheid 
zes maanden later ook grotendeels verklaard kon worden uit deze factoren. Wederom droeg 
minder fysieke activiteit belangrijk bij aan de ernst van vermoeidheid, maar ook moeite met het 
feit dat men een ongeneeslijke ziekte heeft, bleek een grote rol te spelen. Hoofdstuk 7 beschrijft 
het verloop van de vermoeidheid bij de patiënten over de maanden heen. We hebben hiervoor 
maandelijks verstuurde vermoeidheidsvragenlijsten gebruikt. Bij het analyseren hebben we een 
verdeling gemaakt tussen de groep van 48 patiënten die tijdens de studie periode uit de studie 
zijn gegaan (de uitvallers) en de groep van 89 patiënten die ook na een half jaar nog deelnamen. 
We zagen dat de groep uitvallers aanmerkelijk meer vermoeid was op de verschillende tijd-
stippen. Van de groep die gedurende de gehele studieperiode meedeed, bleek 42% geen enkele 
keer ernstig vermoeid te zijn en was er een groep van 29% die ernstig vermoeid was en bleef. 
De overige patiënten bleken een wisselend beloop te hebben: 14% veranderde over tijd van 
ernstig vermoeid naar niet ernstig vermoeid en bij de overige 13% was het beloop andersom.
 Zoals eerder gezegd, hebben we ook naasten van de patiënt meegenomen in het onder-
zoek. Hoofdstuk 6 beschrijft de vermoeidheid van zowel de mantelzorger als de patiënt met zes 
maanden interval en de invloed die de vermoeidheid had op de ervaren druk van de mantel-
zorger. We vonden dat de patiënten op beide meetmomenten meer vermoeid waren dan de 
mantelzorger. Hoewel lager dan de patiënten, bleek de vermoeidheid van de mantelzorgers 
overall hoger in vergelijk met normgegevens van een gezonde controlegroep. De vermoeid-
heid van de patiënten en naasten hing niet met elkaar samen. Wel was er samenhang tussen de 
vermoeidheid van zowel patiënten als de mantelzorgers zelf, en de ervaren druk van de mantel-
zorger. Met de toenemende behandelopties en de huidige verschuiving van zorg naar de thuis-
situatie is dit een belangrijke en relevante bevinding.
DISCUSSIE
De bevindingen zoals beschreven in dit proefschrift maken duidelijk dat vermoeidheid in de 
dagelijkse praktijk, nog lang niet altijd (h)erkend wordt. Met het groeiend aantal patiënten 
met kanker, de toenemende mogelijkheden van behandelen ook in het palliatieve traject en 
grotere roep vanuit de overheid om meer efficiëntie in de zorg, lijkt het herrangschikken van 
taken tussen de medische en verpleegkundige discipline onvermijdelijk. Met name voor de 
(oncologie)verpleegkundigen ligt hier een enorme kans en uitdaging. Vanuit het curriculum 
van de opleiding tot oncologieverpleegkundige behoort het herkennen, nader inventariseren 
van symptomen als vermoeidheid tot hun competenties. Daarnaast is het een groot voordeel 
dat (oncologie)verpleegkundigen door zowel patiënten als hun naasten als laagdrempelig te 
benaderen zorgprofessionals gezien worden. Door voorafgaand aan de behandeling, en op 
regel matige tijdstippen nadien, bij de patiënt te inventariseren of een symptoom als vermoeid-
heid een rol speelt, wordt ook belangrijke informatie verkregen. Deze informatie kan gebruikt 
worden bij beslissingen die genomen moeten worden omtrent het al dan niet voortzetten van 
een behandeling. Door ook de direct naasten (mantelzorgers) van de patiënt hierbij te betrekken 
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kan helder worden of zij nog in staat zijn om de aan hen toevertrouwde zorg en ondersteuning 
te geven. Indien hier problemen mee zijn, kunnen door de verpleegkundigen gerichte acties 
ingezet worden om hier ondersteuning in te bieden.
 Dit proefschrift heeft ook laten zien dat een ruim 40% van de patiënten tijdens behandeling 
voor uitgebreide kanker geen ernstige vermoeidheid ervaart. Ook werd helder dat er weinig 
fluctuaties zijn in de ervaren vermoeidheid. Dit betekent dat niet bij alle patiënten interventies 
voor vermoeidheid geïndiceerd zijn. Voor hen die echter wel ernstige vermoeidheid ervaren 
blijft onverlet dat er nader onderzoek gewenst is om effectieve behandelingen te ontwikkelen. 
Vooralsnog zijn de meeste interventies momenteel gericht op het aanpakken van eventueel 
achterliggende somatische problemen zoals bloedarmoede of een infectie. Om als verpleeg-
kundige optimaal de patiënt en zijn naaste bij te kunnen staan in het palliatieve traject, dienen 
zij betrokken te worden bij het ontwikkelen van effectieve interventies voor vermoeidheid.
 Concluderend kan gezegd worden dat om het probleem vermoeidheid bij zowel patiënten 
als hun mantelzorgers aan te pakken, een meer gestructureerde benadering gewenst is. 
Hierbij heeft iedere zorgprofessional zijn eigen verantwoordelijkheid, aangaande screening, en 
behandeling van vermoeidheid. Om dit werkelijk te maken is verder onderzoek nodig waarbij 
de nadruk ligt op het ontwikkelen van interventies of strategieën waarmee vermoeidheid 
aangepakt kan worden. Voor het screenen op vermoeidheid bij patiënten en mantelzorgers 
lijkt de oncologieverpleegkundige de professional bij uitstek. Het is belangrijk deze screening 
zowel voorafgaand aan een behandeling als ook op gezette tijden gedurende de behandeling 
te doen. Ook het verder exploreren bij de patiënt welke psychosociale factoren mogelijk een rol 
spelen bij vermoeidheid is belangrijk. Voor de naasten lijkt het van belang met hen in gesprek te 
blijven of zij zich nog voldoende bekwaam en toegerust achten voor de aan hun toebedeelde 
taken. Door hier regelmatig met beiden bij stil te staan, wordt een eerste stap gezet naar het 
nog optimaler begeleiden en ondersteunen tijdens het palliatieve traject van hen die ernstige 
vermoeidheid ervaren, ongeacht of het de patiënt of de mantelzorger betreft.

DANKWOORD
D
FATIGUE  in  METASTATIC CANCER
136
DANKWOORD
Op de eerder door mij aangehaalde quote ‘Het leven is wat je gebeurt, terwijl je andere 
plannen maakt’, vormt de achterliggende promotieperiode geen uitzondering. Hoe bizar kan 
het lopen dat je zelf geconfronteerd wordt met de diagnose kanker, terwijl je onderzoek doet 
naar vermoeidheid tijdens behandeling voor kanker. Door al het vertrouwen en de steun die 
ik met name in de minder goede periodes van zoveel mensen om mij heen heb gehad, mag ik 
nu toch dit proefschrift verdedigen. Toch is het proefschrift uiteraard geen soloproduct. Velen 
hebben hier aan bijgedragen en hen wil ik erg graag vanaf deze plek bedanken. In de lijn van 
mijn onderzoek heb ik hiervoor een aangepast model van uitlokkende en instandhoudende 
factoren gemaakt.
Figuur 1 Uitlokkende en instandhoudende factoren
Proefschrift
Werkomgeving
Vooropleiding /
werkervaring
Gezondheid
Patiënten 
en hun 
mantelzorgers
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DE UITLOKKENDE FACTOREN
De werkomgeving
Om in een promotietraject te stappen is vertrouwen en geloof in je kunnen van je werkom-
geving onontbeerlijk. In mijn geval stond daar het zogenaamde ‘begeleidend comité’, met de 
promotoren Winette en Gijs en de copromotoren Stans en Martine. Zij zagen, eerder dan ik zelf, 
de potentie in mij tot het doen van eigen onderzoek met bijbehorend promotietraject. Dank 
voor dit vertrouwen en ook dank dat jullie belangrijke instandhoudende factoren bleken te zijn. 
Dit door gedurende het gehele traject mij ter zijde te staan middels tijd en ruimte te maken 
voor overleg (ondanks een overvolle agenda), alle conceptversies kritisch te lezen (zelfs bij de 
McDonald’s – met WiFi – in Frankrijk), alle cijfertjes telkens opnieuw te controleren (en er regel-
matig toch weer oneffenheden uit te halen!) en uitgebreid telefonisch te sparren over hoe de 
bevindingen nog sterker neer te zetten (en gelijk ook weer even bij te kletsen).
 Eveneens wil ik hierbij het Paul Speth fonds noemen dat het financieel mogelijk heeft gemaakt 
dat dit onderzoek heeft kunnen plaatsvinden. Dit voelde heel speciaal, omdat ik tijdens mijn 
opleiding tot verpleegkundige jaren les heb gehad van Paul.
Vooropleiding / werkervaring
De door mij doorlopen opleidingen hebben mij de kennis en kunde gegeven waardoor ik 
in staat bleek de onderzoeksresultaten te analyseren en te interpreteren. Mijn eerdere werk-
ervaring met name als research verpleegkundige is waardevol gebleken doordat ik inmiddels 
bekend was met onderzoek in de praktijk neer te zetten. De vele contacten uit die tijd bleken 
ook zeer behulpzaam bij de praktische uitvoer van het onderzoek zoals het benaderen van 
kandidaten voor het onderzoek in het Jeroen Bosch-ziekenhuis.
DE INSTANDHOUDENDE FACTOREN
Patiënten en hun mantelzorgers
Zonder patiënten (en mantelzorgers) is geen onderzoek mogelijk. Ik ben dan ook veel dank 
verschuldigd aan alle patiënten en hun mantelzorgers die meegedaan hebben aan dit onder-
zoek. Heel bijzonder, zeker gezien de fase waarin zij zich ten tijde van het onderzoek bevonden.
Gezondheid
Een goede gezondheid lijkt een open deur, het is echter een factor die we niet in eigen hand 
hebben. Het promotietraject heeft door mijn ziekteperiode zeker vertraging opgelopen maar 
door het ervaren van alle steun vanuit de andere ‘factoren’ heb ik de draad vast kunnen houden 
en langzamerhand weer volledig op kunnen pakken.
FATIGUE  in  METASTATIC CANCER
138
Collega’s
Het belang van collega’s om je heen. Niets is heerlijker dan tijdens het werk je ups en downs direct 
te kunnen delen met de villabewoners, te merken dat collega’s van de afdeling/dagbehandeling 
en polikliniek iedere keer weer belangstelling tonen en enthousiast reageren bij behaalde mijl-
palen. En dan doel ik hierbij niet alleen op het promotietraject. Ik voel mij, ook vanaf de andere 
kant, altijd veilig en in goede handen bij jullie!. Ook de verschillende overleggen met collega 
onderzoekers bij het NKCV, Medische Psychologie, PhD-groep Verplegingswetenschappen 
zijn allemaal zeer waardevol gebleken; Het is een vorm van lotgenotencontact dat zijn weerga 
niet kent. En dan heb je altijd mensen met wie het wel heel goed klikt, met wie je wel heel 
veel bespreekt – al of niet tijdens het vrijdagmiddagborreltje, en die als vanzelf heel dicht bij je 
komen te staan.
Ontspanning
Om een traject van jaren vol te kunnen houden zijn ook andere bezigheden uiteraard van 
belang. Met name om je hoofd even helemaal leeg te maken en weer op te kunnen laden. Na 
aanvankelijk graag hard te lopen noopte lichamelijke ongemakken om dit gevoel elders te 
zoeken. Het fietsen met de pedaleurs bleek gedurende een aantal jaren een goed alternatief. 
Maar als je in de Alpen naar boven wilt moet je wel heel veel trainen dus inmiddels fiets ik in 
een rustiger tempo samen met mijn fietsmaatje voort. Het maken van muziek is voor mij een 
andere sublieme manier gebleken om te ontspannen waarbij het promotietraject al snel naar de 
achtergrond verdwijnt. De wekelijkse repetities bij @speranza zijn een vast rustpunt in de week. 
Het oefenen is er de laatste tijd wel erg bij ingeschoten maar ik streef naar beterschap hierin.
Vrienden
Vrienden zijn onmisbaar en ik ben in de gelukkige omstandigheid dat er een trouwe schare 
vrienden is, met wie het wel en wee soms al meer dan veertig jaar gedeeld wordt. Met vaak 
geheel verschillende achtergronden en loopbanen blijft het fantastisch om te zien dat er nog 
steeds een klik is als we elkaar weer treffen. Anderen tref je vaker en wat is er mooier dan samen 
biertjes te proeven, lekker te eten (het koken laat ik graag aan anderen over), uren te kletsen 
met lekkere muziek op de achtergrond, weekendjes weg te gaan, kortom te genieten van de 
geneugten des levens. En ook al wonen sommigen niet naast de deur, als je merkt dat het 
gesprek gewoon verder gaat waar het de vorige keer eindigde, geeft dat een heel rijk gevoel en 
blijkt afstand geen punt.
Familie
Het begint bij je ouders en als de basis goed is, komt er alleen maar bij. Dat is gelukkig het geval. 
Mijn vader kan hier helaas niet meer bij zijn, net zomin als mijn schoonouders. Maar zoals mijn 
moeder afgelopen jaren naar dit moment heeft toegeleefd, hoop ik dat zij nu in viervoud zal 
genieten. Ook mijn broer, schoonzussen, zwagers, neven en nichten hebben dit gehele traject 
van dichtbij meegemaakt en op de voet gevolgd. Deze missie is volbracht, mede dankzij jullie 
support, dus nu is het party-time.
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Gezin
Wat een jaren liggen er achter ons en wat ben ik verschrikkelijk blij met jullie. We hebben veel 
voor de kiezen gehad maar jullie zijn er – onvoorwaardelijk – in voor- en tegenspoed. Hoe trots 
kun je zijn!!
En tot slot my first, my last ( hopelijk  ), my everything. Je vroeg een tijd terug: alles leuk en 
aardig maar wat krijg ik hiervoor? Daar heb ik natuurlijk wel over na zitten denken en ik wil je 
graag de S doorgeven, als zijnde mijn Significante wederhelft. Maar ook de S van Samen op stap 
met ons campertje, Samen blijven genieten van al het mooiS (Fiep), leukS en lekkerS dat het 
leven ons te bieden heeft.
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CURRICULUM VITAE
Marlies Peters werd geboren in het St. Radboudziekenhuis 
te Nijmegen op 10 januari 1959. In 1975 behaalde ze 
haar HAVO-diploma aan de Scholengemeenschap 
Nijmegen-West. Na het afronden van de opleiding 
Activiteitenbegeleiding van het Nederlandse Rode Kruis 
te Epe maakte zij de overstap naar de in-service opleiding 
tot A-verpleegkundige aan het Sint Radboud Ziekenhuis 
te Nijmegen. Haar eerste werkplek als gediplomeerd 
verpleegkundige was de afdeling Medische Oncologie 
/ Radiotherapie / Nefrologie in voornoemd ziekenhuis. 
Vervolgens bracht een verhuizing vanwege werkzaam-
heden van haar echtgenoot haar naar ’s Gravenhage 
waar zij gedurende de jaren 1985–1991 in diverse velden 
(verpleeghuiszorg, wijkzorg, onderwijs) werkzaam is 
geweest. Na een terugkeer richting Nijmegen (en het Academisch Ziekenhuis Sint Radboud) 
combineerde zij het vak verpleegkundige met het volgen van de leraren opleiding verpleeg-
kunde aan de Hogeschool Nijmegen. Na afronding van deze opleiding in 1994 volgde ook 
een terugkeer naar het specialisme Medische Oncologie. Na enkele jaren als verpleeg-
kundige werkzaam te zijn geweest maakte zij in 1997 de overstap naar het klinisch weten-
schap pelijk onderzoek als researchverpleegkundige. Verdere interesse in het uitvoeren van 
wetenschappelijk onderzoek leidde tot het gaan volgen van de Master-opleiding Evidence 
Based Practice – aan de afdeling Epidemiologie en Biostatistiek van de Universiteit van 
Amsterdam. Deze opleiding rondde zij in 2005 af. Uit deze periode stamt ook de samen-
werking met het Nijmeegs Kenniscentrum Chronische Vermoeidheid (NKCV), rondom onder-
zoek naar vermoeidheid en kanker. In 2008 kreeg Marlies de ruimte om als verpleegkundig 
expert de kennis en kunde rondom evidence based werken binnen de verpleegkundige 
discipline van de afdeling medische oncologie te vergroten. Tevens startte zij met het zelf 
uitvoeren van wetenschap pelijk onderzoek. In samenwerking met het NKCV heeft zij onder 
andere onderzoek gedaan naar vermoeidheid bij patiënten met kanker in het palliatieve traject 
en hun mantelzorgers. De resultaten hiervan hebben geleid tot dit proefschrift.
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Sinds 1997 is Marlies zowel binnen het Radboudumc als nationaal en internationaal actief in 
verschillende werkgroepen. Momenteel is zij binnen het Radboudumc lid van de kerngroep van 
de Werkgroep Oncologie Verpleegkundigen. Landelijk heeft zij deel uitgemaakt van meerdere 
werkgroepen van de beroepsvereniging voor oncologieverpleegkundigen, het huidige V&VN-
Oncologie, waar zij momenteel deel uitmaakt van het bestuur. In mei 2015 zal zij haar bestuurs-
periode voortzetten als voorzitter van V&VN-Oncologie. Binnen de European Organisation for 
Research and Treatment of Cancer (EORTC) heeft zij geparticipeerd in de Early Clinical Study 
group for research nurses. Vanuit deze werkgroep was zij gedurende een aantal jaren board 
member van de EORTC Clinical Research Coordinators Group. Op dit moment is Marlies lid van de 
advisory board van de European Oncology Nursing Society (EONS), waarin zij V&VN-Oncologie 
vertegenwoordigd. Daarnaast is Marlies een officiële reviewer van het tijdschrift Cancer Nursing.
Marlies woont samen met haar echtgenoot Nic Windt in Malden. Hun zonen Tim (1983) en Rik 
(1985) wonen inmiddels op zichzelf, samen met respectievelijk Petra en Dorien. Sinds januari 
2015 zijn Marlies en Nic de trotse grootouders van kleindochter Fiep.
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